Inventiva (IVA) 20-F 15 Mar 21 2020 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2020shares
Document and Entity Information [Abstract]
Entity Registrant Name	Inventiva S.A.
Document Type	20-F
Document Period End Date	Dec. 31, 2020
Amendment Flag	false
Entity Central Index Key	0001756594
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding	38,630,261
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Interactive Data Current	Yes
ICFR Auditor Attestation Flag	false

STATEMENTS OF FINANCIAL POSITIO

STATEMENTS OF FINANCIAL POSITION - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Non-current assets
Intangible assets	€ 935	€ 1,228	€ 1,543
Property, plant and equipment	3,282	3,721	4,261
Other non-current assets	1,706	3,135	2,374
Total non-current assets	5,923	8,084	8,178
Current assets
Inventories	320	387	410
Trade receivables	48	4	6
Tax receivables	9,028	9,833	9,434
Other current assets	17,914	2,811	5,092
Cash and cash equivalents	105,687	35,840	56,692
Total current assets	132,997	48,875	71,634
TOTAL ASSETS	138,920	56,960	79,812
Shareholders' equity
Share capital	386	268	223
Premiums related to share capital	139,668	86,012	77,460
Reserves	4,777	(14,670)	16,927
Net loss for the period	(33,619)	(30,218)	(33,014)
Total Shareholders' equity	111,211	41,392	61,596
Non-current liabilities
Long-term debt	10,037	2	74
Long-term provisions	2,377	574	358
Provisions for retirement benefit obligations	1,385	1,127	1,029
Long-term contract liabilities			1,673
Total non-current liabilities	13,800	1,703	3,134
Current liabilities
Short-term debt	18	113	151
Trade payables	6,923	7,491	8,372
Short-term provisions	130	1,264	1,140
Short-term contract liabilities			548
Other current liabilities	6,838	4,998	4,871
Total current liabilities	13,908	13,865	15,082
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	€ 138,920	€ 56,960	€ 79,812

STATEMENTS OF INCOME (LOSS)

STATEMENTS OF INCOME (LOSS) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Revenues and other income
Revenues	€ 372	€ 6,998	€ 3,197
Other income	4,891	4,293	4,182
Total revenues and other income	5,263	11,291	7,379
Research and development expenses	(23,717)	(33,791)	(31,758)
Marketing - Business development expenses	(563)	(249)	(225)
General and administrative expenses	(8,499)	(6,088)	(6,045)
Other operating income (expenses)	(2,202)	(1,475)	(2,255)
Operating profit (loss)	(29,718)	(30,312)	(32,903)
Financial income	2,057	175	142
Financial expenses	(5,959)	(81)	(253)
Financial income (loss)	(3,902)	93	(111)
Income tax
Net loss for the period	€ (33,619)	€ (30,218)	€ (33,014)
Basic / diluted loss per share (euros/share)	€ (0.99)	€ (1.28)	€ (1.61)
Weighted average number of outstanding shares used for computing basic/diluted loss per share	33,874,751	23,519,897	20,540,979

STATEMENTS OF COMPREHENSIVE INC

STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
Net loss for the period	€ (33,619)	€ (30,218)	€ (33,014)
Actuarial gains (losses) on retirement benefit obligations (IAS 19)	(49)	(96)	31
Items that will not be reclassified subsequently to profit or loss	(49)	(96)	31
Other items in the total profit (loss) to be recycled subsequently to the net profit (loss)	0
Total comprehensive loss	€ (33,668)	€ (30,315)	€ (32,983)

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash flows provided by (used in) operating activities
Net loss for the period	€ (33,619)	€ (30,218)	€ (33,014)
Elimination of other non-cash, non-operating income and expenses
Depreciation, amortization and provisions	1,888	1,579	1,295
Tax credits	(7,654)	(4,297)	(4,299)
Cost of net debt	118	(5)	5
Share-based compensation expense	938	1,407	833
Exchange gains / losses	3,039
Fair value variation through profit and loss	(1,791)
Other	41
Cash flows used in operations before tax, interest and changes in working capital	(37,041)	(31,534)	(35,180)
Decrease / (Increase) in operating and other receivables	(459)	1,780	(1,156)
Increase / (Decrease) in operating and other payables	1,271	(2,974)	2,884
Decrease in inventories	68	22	30
Tax credit received	8,424	3,897
Other	(2,853)	403	(785)
Tax, interest and changes in operating working capital	6,451	3,130	973
Net cash flows used in operating activities	(30,590)	(28,404)	(34,207)
Cash flows provided by (used in) investing activities
Purchases of property, plant and equipment and intangible assets	(292)	(136)	(549)
Disposals of property, plant and equipment and intangible assets	0	3
Decrease / (Increase) in short-term deposit accounts	(7,694)
Decrease / (Increase) in other noncurrent financial assets	(571)	(693)	129
Net cash flows used in investing activities	(8,557)	(826)	(420)
Cash flows provided by (used in) financing activities
Capital increase, net of transaction costs	101,782	8,654	32,526
Increase in debt	9,979
Repayment of debt	(61)	(146)	(259)
Repayment of lease debt	(26)	(130)
Net cash flows provided by financing activities	111,674	8,378	32,268
Net increase (decrease) in cash and cash equivalents	72,527	(20,852)	(2,358)
Net cash and cash equivalents at beginning of period	35,840	56,692	59,051
Exchange rate effect on cash in foreign currency	(2,681)
Net cash and cash equivalents at end of period	€ 105,687	€ 35,840	€ 56,692

STATEMENTS OF CHANGES IN SHAREH

STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - EUR (€)	Share capital	Premiums related to share capital	Reserves	Net profit (loss)	Total
Balance at the beginning at Dec. 31, 2017	€ 164,445	€ 44,991,815	€ 35,599,000	€ (19,463,000)	€ 61,292,000
Balance at the beginning (in shares) at Dec. 31, 2017	16,444,477
Net loss for the period				(33,014,000)	(33,014,000)
Other comprehensive income (loss)			31,000		31,000
Total comprehensive loss			31,000	(33,014,000)	(32,983,000)
Appropriation of net loss			(19,463,000)	19,463,000
Issue of ordinary shares	€ 56,000	35,441,000			35,497,000
Issue of ordinary shares (in shares)	5,572,500
Transaction costs		(3,079,000)			(3,079,000)
Exercise of BSAs/BSPCEs and vesting of AGAs	€ 2,000	106,000	(1,000)		108,000
Exercise of BSAs/BSPCEs and vesting of AGAs (in shares)	240,300
Share-based compensation expense			833,000		833,000
Treasury shares			(72,000)		(72,000)
Balance at the end at Dec. 31, 2018	€ 222,573	77,460,125	16,927,000	(33,014,000)	61,596,000
Balance at the end (in shares) at Dec. 31, 2018	22,257,277
Net loss for the period				(30,218,000)	(30,218,000)
Other comprehensive income (loss)			(96,000)		(96,000)
Total comprehensive loss			(96,000)	(30,218,000)	(30,315,000)
Appropriation of net loss			(33,014,000)	33,014,000
Issue of ordinary shares	€ 45,000	8,858,000			8,903,000
Issue of ordinary shares (in shares)	4,473,935
Transaction costs		(324,000)			(324,000)
Exercise of BSAs/BSPCEs and vesting of AGAs	€ 1,000	18,000	(1,000)		18,000
Exercise of BSAs/BSPCEs and vesting of AGAs (in shares)	114,900
BSA share warrants subscription premium			57,000		57,000
Share-based compensation expense			1,407,000		1,407,000
Treasury shares			50,000		50,000
Balance at the end at Dec. 31, 2019	€ 268,461	86,011,893	(14,670,000)	(30,218,000)	41,392,000
Balance at the end (in shares) at Dec. 31, 2019	26,846,112
Net loss for the period				(33,619,000)	(33,619,000)
Other comprehensive income (loss)			(49,000)		(49,000)
Total comprehensive loss			(49,000)	(33,619,000)	(33,668,000)
Appropriation of net loss			(30,218,000)	30,218,000
Issue of ordinary shares	€ 113,000	108,986,000			109,099,000
Issue of ordinary shares (in shares)	11,256,599,000
Transaction costs		(7,397,000)			(7,397,000)
Exercise of BSAs/BSPCEs and vesting of AGAs	€ 5,000	67,000	(5,000)		67,000
Exercise of BSAs/BSPCEs and vesting of AGAs (in shares)	527,550,000
BSA share warrants subscription premium			13,000		13,000
Share-based compensation expense			938,000		938,000
Appropriation of the issue premium		(48,000,000)	48,000,000
Treasury shares			768,000		768,000
Balance at the end at Dec. 31, 2020	€ 386,302	€ 139,667,603	€ 4,777,000	€ (33,619,000)	€ 111,211,000
Balance at the end (in shares) at Dec. 31, 2020	38,630,261				38,630,261

Company Information

Company Information	12 Months Ended
	Dec. 31, 2020
Company Information
Company Information	Note 1. Company Information 1.1. Inventiva S.A. (“Inventiva” or the “Company”) is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, mucopolysaccharidoses, or MPS, and other diseases with significant unmet medical need. The Company is developing its most advanced product candidate, lanifibranor, for the treatment of patients with NASH, a disease for which there are currently no approved therapies. Inventiva conducted a Phase IIb clinical trial of lanifibranor in patients with NASH, for which it published positive results on June 15, 2020. On October 12, 2020, we announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to lanifibranor for the treatment of NASH. The Breakthrough Therapy designation by the FDA is intended to expedite the development and review of drug candidates for serious or life-threatening conditions. Following the positive feedback from the FDA received on November 10, 2020 to start the pivotal Phase III, the Company announced, on January 5, 2021, that it seeks to obtain accelerated approval in the U.S. and conditional approval in the European Union for lanifibranor based on a 72-week histology analysis and confirmed the planned initiation of its pivotal Phase III clinical study in the first half of 2021. The Company is also developing a second clinical-stage asset, odiparcil, for the treatment of patients with subtypes of MPS. In December 2019, the Company announced positive results from a Phase IIa clinical trial of odiparcil for the treatment of adult patients with the MPS VI subtype. On October 19, 2020, the Company announced that the U.S. FDA has granted Fast Track designation to odiparcil for the treatment of MPS type VI (MPS VI). Based on positive feedback from the FDA to advance its lead drug candidate lanifibranor, the Company has decided to focus its clinical efforts on the development of lanifibranor in NASH and will suspend all MPS-related R&D activities. As a consequence, the Phase I/II SAFE-KIDDS clinical trial evaluating odiparcil in MPS VI children and the Phase IIa extension clinical trial with odiparcil in MPS VI patients who completed the prior iMProveS Phase IIa clinical trial will not be initiated in the first half of 2021 as initially planned. The Company will review all available options to optimize the development of its second clinical-stage asset odiparcil for the treatment of MPS VI. Other pre-clinical programs are also in development, including for the treatment of certain autoimmune diseases in collaboration with AbbVie Inc. (AbbVie). AbbVie is currently evaluating ABBV-157, a drug candidate that Inventiva and AbbVie jointly discovered, in a Phase I clinical trial for the treatment of autoimmune diseases under the terms of a multi-year drug discovery partnership. Inventiva’s ordinary shares have been listed on the Euronext Paris regulated market since February 2017 and Inventiva's American Depositary Shares (ADSs), each representing one ordinary share, have been listed on the Nasdaq Global Market since July 2020. 1.2. Business Positive results for clinical trial with Native On June 15, 2020, the Company announced positive results for the Phase IIb clinical trial of lanifibranor. FDA confirmed that a single Phase III clinical trial – planned for the first half of 2021 – may be adequate for submitting U.S. marketing authorization application See note 1.1 Company information Based on positive feedback from the FDA, the Company has decided to focus its clinical efforts on the development of lanifibranor in NASH This strategic reorientation has no impact on the financial statements for the fiscal year ended December 31, 2020. See note 1.1 Company information Capital increases Capital increase of €14.7 million reserved for a category of investors in February 2020 On February 7, 2020, Inventiva completed a capital increase with cancellation of shareholders’ preferential subscription rights subscribed by BVF Partners L.P., Novo A/S, New Enterprise Associates 17, L.P. and Sofinnova Partners, existing shareholders of the Company. A total of 3,778,338 new shares were issued at a per share price of €3.97 (par value of €0.01 plus an issue premium of €3.96), resulting in net proceeds to the Company of €14.7 million. The settlement-delivery of the new shares took place on February 7, 2020 in a total gross amount of €15.0 million. The new shares were admitted to trading on Euronext Paris on the same date. USD 107.7 million initial public offering on the Nasdaq Global Market On July 15, 2020, Inventiva closed its initial public offering (IPO) on the Nasdaq Global Market of a total of 7,478,261 ordinary new shares in the form of ADSs, at an offering price of USD 14.40 per share (the Offering). The aggregate gross proceeds of the Offering, before deducting underwriting commissions and estimated expenses payable by the Company, were approximately USD 107.7 million (€94.1 million, based on exchange rate on July 15, 2020, date of receipt of funds). The net proceeds from the Offering will mostly be used to complete the preparatory stages and launch a Phase III clinical trial for lanifibranor in the treatment of NASH, and to continue with the development of odiparcil. The capital increase enables the Company to continue to finance its activities through the fourth quarter of 2022. Following settlement-delivery on July 15, 2020, Inventiva’s share capital amounted to €383,930.11 divided into 38,393,011 shares. The ordinary shares are fungible with the existing shares of the Company and have been admitted to trading on the regulated market of Euronext Paris under the symbol “IVA”. The ADSs are listed on the Nasdaq Global Market under the symbol “IVA” and began trading on July 10, 2020. Following the Offering on the Nasdaq Global Market, the Company entered into two new insurances for a total amount of 3.6 million: · "Public Offering of Securities Insurance" to cover the risks related to the Offering, amounting to €1.6 million · "Directors and Officers Liability Insurance", directors' and officers' liability insurance, to protect the economic damage of the two executive directors of the Company resulting from breaches of their obligations, amounting to €2.0 million Both contracts cover the period of one year from the Offering. As of December 31, 2020, the Company recorded prepaid expenses of €1.8 million (See note 8.2, “Other current assets and receivables”). Consequently, the impact on the statement of income (loss) in 2020 is an additional expense of €1.8 million, including €0.8 million related to the Offering, recorded under "Other operating income (expenses) (See note 19, “Other operating income (expenses)”. Vesting of 517,550 bonus share awards (‘AGA') On January 26, 2020, the Chairman and Chief Executive Officer recorded a capital increase arising from the vesting of AGA 2018-2 bonus share awards in an amount of €633 through the issue of 63,300 new ordinary shares with a par value of €0.01 each. On June 28, 2020, the Chairman and Chief Executive Officer placed on record a capital increase arising from the vesting of AGA 2019-2 bonus share awards in an amount of €2,270 through the issue of 227,000 new ordinary shares with a par value of €0.01 each. On December 14, 2020, the Chairman and Chief Executive Officer placed on record a capital increase arising from the vesting of AGA 2018-3 bonus share awards in an amount of €2,272.5 through the issue of 227,250 new ordinary shares with a par value of €0.01 each. Characteristics of the new plans, movements in granted AGA bonus share awards as well as the accounting impact of share-based payments are described in Note 10.4, "Bonus share award plans". New share warrant plans (“BSA”) in 2020 On March 9, 2020, the Company’s Board of Directors granted 46,000 share warrants , to Company consultants as follows: · 10,000 share warrants (BSA 2019 bis) to Jérémy Goldberg, a member of JPG Healthcare LLC, a service provider to the Company; · 36,000 share warrants (BSA 2019 ter) to David Nikodem, a member of Sapidus Consulting Group LLC, a service provider to the Company; Characteristics of the new plans, movements in granted BSA share warrants as well as the accounting impact of share-based payments are described in Note 10.3, “Share warrants plans”. Ongoing tax disputes Tax audit on payroll tax In 2019, our payroll taxes for the 2016, 2017 and 2018 taxable years were audited by the French tax authorities and the Company received a proposed tax adjustment of €1.7 million (including penalties and late payment interest) in December 2019. On June 16, 2020, the Company received a response from the French tax authorities, granting it a concession with respect to the disputed payroll taxes for fiscal year 2018, i.e. €0.5 million. On October 30, 2020, the Company received the Notice of Recovery (AMR) related to the payroll taxes for the taxable year 2016 and 2017 requesting the payment of €1.2 million (mark-up and delays interests as of December 31, 2019 included). A contentious claim with a request for a suspension of payment was sent by Inventiva on December 8, 2020. The tax authorities responded favorably to the request subject to the constitution of a guarantee in the amount of €1.2 million. A description of the audits performed and their impacts on the financial statements is provided in Note 12, “Provisions”. Surety provided to the French tax authorities On February 1, 2019, as part of its application for a suspension of payment on the CIR and payroll taxes, the Company offered the French tax authorities a surety in the form of a €3.4 million bank guarantee with Crédit Agricole bank. Two pledges over cash, for a total amount of €1.7 million, were granted by the Company, including : · one pledge over cash of €0.7 million was granted by the Company on February 1, 2019, equivalent to 50% of the sum not covered by the indemnity to be received from the Abbott group under the Additional Agreement , and · in accordance with the initial undertaking, an additional pledge over cash of €1.0 million was granted by the Company on June 30, 2020, as the dispute to which the guarantee pertains remains unresolved. Tax audit on research tax credit Following the tax audit, for fiscal years 2013 to 2015, on August 1, 2017, the Company received a collection notice on August 17, 2018 for an amount of €1.9 million, including penalties and late payment interest. Under the ongoing procedures, the Company initiated mediation on January 7, 2020 and received the mediator's response on January 28, 2021, who waived €0.3 million corresponding to the part of the dispute related to the subcontracting expenses in consideration of the recent changes in the jurisprudence and the last decision of the Council of State in July 2020 on the eligibility of subcontracting expenses in the evaluation of the research tax credit. A description of the tax audits performed and their impacts on the financial statements are provided in Note 12, “Provisions". Bank financing and treasury Research tax credit (credit d'impôt recherche, or "CIR") received The Company received the entire amount of the 2018 CIR, totaling €4.2 million, in January 2020. The company received the full amount of its 2019 CIR, namely €4.3 million, following the acceptance by the French tax authorities of the full adjustment claimed by the Company. As a consequence, in 2020, the company received a total of €8.4 million related to the 2018 and 2019 CIR. Non-dilutive financing of €10 million guaranteed by the French State in the context of the Covid-19 pandemic In May 2020, the Company obtained financing for a total amount of €10.0 million from a syndicate of French banks, in the form of three loans guaranteed by the French State. The Company has the option of extending maturity dates up to four additional years. As of the date of these financial statements, the Company has notified the banks of its intention to extend the maturity until May 2022. Their impacts on the financial statements are provided in Note 11, “Debt”. Completion of foreign currency forward contracts for USD 60 million In September 2020, the Company completed two future currency contracts for a total amount of USD 40 million to protect its activities against EUR-USD exchange rate fluctuations in accordance with its investment policy. In October 2020, the Company completed a third currency contract for a total amount of USD 20 million for the same purpose. Those contracts mature in May 2021. Reinvestment of short-term USD deposits for an amount of USD 9 million In November 2020, the Company chose to replace the two short-term deposits of USD 9 million, ended at September and October. The two new short-term deposits will end at February 2021. Their impacts on the financial statements are provided in Note 8.2, "Other Current Assets". 1.3. Capital increase The capital increases occurred in 2018 and 2019 are detailed in the note 10.1., “Share capital”. Revenue received in connection with the collaboration agreements with AbbVie and Boehringer Ingelheim The main events related with the collaboration agreements and impacting the revenue in 2018 and 2019 are detailed in the note 17., “Revenue and other income”. New share warrants plans (“BSA”) and new bonus share award plans (“AGA”) in 2018 and 2019 Characteristics of the new plans, movements in granted BSA share warrants as well as the accounting impact of share-based payments are described in notes 10.3, “Share warrants plans” and 10.4., “Bonus share award plans”. Tax audit A description of the tax audits performed and their impacts on the financial statements in 2018 and 2019 are provided in Note 12, “Provisions”. 1.4. As of the date of issuance of these financial statements, the Covid-19 pandemic did not impact significantly the Company’s business activities, financial position and operating results. Following the updated recommendations of domestic public health authorities and a continuous risk assessment of the Covid-19 pandemic situation, the Company has implemented a series of measures to address and minimize the impact of Covid-19 on its employees, customers and business and to protect their health and safety, while ensuring the ongoing development of its research programs, such as: · Work-from-home policies for all employees, whose are now able to come back in the Company’s offices through a phased, principles-based approach that involved adapting its premises, with a focus on ensuring employee safety and an optimal work environment. · Close work with its employees and subcontractors to manage its supply chain and mitigate potential disruptions to its product supplies as a result of Covid-19. The Company has already experience and may continue to experience disruptions and delays in pre-clinical programs and clinical trials, without any impacts on the 2020 financial statements. For example: · clinical site initiation and patient recruitment may be delayed due to the prioritization of essential resources for hospitals in the fight against Covid-19; and, · due to Covid-19, the screening and recruitment of new patients has been suspended at the University of Florida where Professor Kenneth Cusi’s Phase II NAFLD study is currently ongoing, and therefore results from this trial could be delayed. Some patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. With respect to regulatory activities, the Company did not experience delays in the timing of the Company’s interactions with the regulatory authorities to date. However, the global pandemic of Covid-19 continues to rapidly evolve and its ultimate impact remains highly uncertain and subject to change. The Company cannot predict the full extent of potential delays or potential impact on its business or clinical trials. Inventiva continues to monitor the Covid-19 situation closely as, if the pandemic persists for an extended period, the impacts on the Company’s operations could be material. for instance: · the essential distribution systems may be impacted and the Company may experience disruptions in the supply chain and its operations; · the Company may experience difficulties in recruiting and retaining patients and principal investigators and site staff due to fear of exposure to Covid-19, which could have a significant adverse impact on its clinical trials; · the Company may be impacted delays due to the absence of the regulatory authorities’ employees, an inability to conduct the necessary physical inspections for regulatory approval or the refocusing of regulatory efforts and attention on the approval of other therapeutic products and other activities to combat Covid-19. · At the present date, the major potential impacts on the lanifibranor development plans pertain to the pivotal Phase III in NASH. The Covid-19 crisis may: · Delay the start of the pivotal Phase III due to delays in the review of clinical trial submission dossiers by the Competent Authorities (including Ethics Committees) and in investigational site openings due to lack of availability of clinical staff. · Impede the conduct of the studies due to the lack of availability of clinical staff at investigational sites and, if lock-down resumes, patients can no longer access investigational centers or investigational centers cannot be not supplied with treatment units in due time. Overall, any delays in the pivotal Phase III will affect the registration of lanifibranor in NASH. At the date of issuance of these financial statements, the Company was not aware of any specific events or circumstances that would require it to update its estimates, assumptions and judgments or to revise the carrying amounts of its assets and liabilities. Such estimates may be adjusted as new events occur and additional information is obtained. The adjustments will be recognized in the interim financial statements as soon as the Company becomes aware of the new events or the additional information. Actual results may differ from the estimates and any differences may be material for the financial statements.

Statement of Compliance

Statement of Compliance	12 Months Ended
	Dec. 31, 2020
Statement of Compliance
Statement of Compliance	Note 2. Statement of Compliance These individual financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standard Board (“IASB”). They were approved by the Company’s Board of Directors on March 2, 2021. Standards, amendments to existing standards and interpretations published by the IASB whose application has been mandatory since January 1, 2020 The application of standards, amendments to existing standards and interpretations published by the IASB whose application has been mandatory since January 1, 2020 had no significant impact on the Company’s financial statements as of December 31, 2020. They primarily concern: - Amendments to IAS 1 and IAS 8 related to definition of materiality - Amendments to IFRS 9, IAS 39 and IFRS 7 related to interest rate benchmark reform - Phase 1 - Amendment to IFRS 3 related to business combinations and - Amendment to IFRS 16 on rent relief related to Covid-19 Standards, amendments to existing standards and interpretations published by the IASB whose application is not yet mandatory No standards, amendments to existing standards or interpretations had been published but were not yet applicable as of December 31, 2020, that may have significant impact on the Company’s financial statements. 2.1. Impact of the first time adoption of IFRS 16 since January 1, 2019 IFRS 16 - Leases has been mandatory since January 1, 2019. In accordance with the standard, the Company recognizes: · an asset, representing its right to use the leased asset during the lease term (right-of-use asset); · a liability, representing the value of the outstanding lease payments (lease liability). For the first-time adoption of IFRS 16, the Company used the simplified retrospective method by applying the practical expedients provided in the standard. Consequently and in accordance with IFRS 16, comparative data have not been restated. Following an analysis, the Company identified two types of leases that meet the IFRS 16 criteria and whose accounting treatment must be restated in accordance with the new standard: two vehicles and research equipment (10 fibroscan machines). For each asset, the discount rate used to calculate the lease liability is determined based on the incremental borrowing rate at the date of signature of the lease. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment. The incremental borrowing rate applied to leases at January 1, 2019 is 1.57%. The Company has not restated its other leases because they are covered by the exemptions permitted under the standard (short-time leases and low-value leases). They include: · leases that expire within 12 months of the date of first-time adoption (January 1, 2019); · 12-month leases with automatic renewal, where it is not reasonably certain at the date of first-time application that the leases will be renewed; and · leases for which the underlying asset is less than €5,000. Rental expenses for short-term and low-value leases continue to be recognized in operating expenses in the Company'sincome statement. Impact on the Company's financial statements The impact of the first-time adoption of IFRS 16 at January 1, 2019 included a €0.2 million increase in debt and a €0.3 million increase in net property, plant and equipment (including the reclassification of a prepaid expense in the amount of €0.1 million). The carrying amount of net property, plant and equipment and of debt at December 31, 2019 increased by €49 thousand and €37 thousand respectively. In 2019, the net impact on the Company's statement of income (loss) was €12 thousand.

Accounting Principles

Accounting Principles	12 Months Ended
	Dec. 31, 2020
Accounting Principles
Accounting Principles	Note 3. Accounting Principles The principal accounting policies applied in the preparation of the financial statements are described below. Unless otherwise stated, the same policies have been consistently applied for all periods presented. 3.1. In accordance with IAS 38 — Intangible Assets , research costs are recognized in the statement of income (loss) in the period during which they are incurred. An internally generated intangible asset arising from a research program is recognized if, and only if, the Company can demonstrate all of the following: · The technical feasibility necessary to complete the research program. · Its intention to complete the intangible asset and use or sell it. · Its ability to use or sell the intangible asset. · How the intangible asset will generate probable future economic benefits. · The availability of adequate technical, financial and other resources to complete the research program. · The ability to measure reliably the expenditure attributable to the intangible asset during its development. Given the risks and uncertainties involved in regulatory approval and in the process of research and development, the Company considers that the six criteria set out in IAS 38 are met only upon obtaining market authorization for a product candidate. Consequently, all development costs are charged directly to expenses. Intangible assets comprise: · The cost of acquiring software licenses, which are written down over a period of between one and five years based on their expected useful life. · The library of compounds acquired pursuant the APA together with additional chemical components, which are written down over a 13‑year period corresponding to their estimated useful lives. 3.2. Property, plant and equipment are stated at cost. Depreciation and amortization are calculated based on the estimated useful life of assets using the straight‑line method. A complete review of the useful lives of acquired non‑current assets is performed on an annual basis. Any material adjustments are reflected prospectively in the depreciation schedule. The principal useful lives applied are as follows: · Buildings: 20 to 25 years · Fixtures and fittings: 10 years · Technical facilities: 6 to 10 years · Equipment and tooling: 6 to 10 years · General facilities, miscellaneous fixtures and fittings: 10 years · Office equipment: 5 years · IT equipment: 5 years · Furniture: 10 years 3.3.Lease contracts Lease contracts are recognized in accordance with the standard IFRS 16 - Leases as follows : · an asset, representing its right to use the leased asset during the lease term (right‑of‑use asset); · a liability, representing the value of the outstanding lease payments (lease liability). For each asset, the discount rate used to calculate the lease liability is determined based on the incremental borrowing rate at the date of signature of the lease. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right‑of‑use asset in a similar economic environment. Exemptions The Company has not restated its other leases because they are covered by the exemptions permitted under the standard (short‑time leases and low‑value leases). They include: · leases that expire within 12 months of the date of first‑time adoption (January 1, 2019); · 12‑month leases with automatic renewal, where it is not reasonably certain at the date of first‑time application that the leases will be renewed; and · leases for which the underlying asset is less than €5,000. Rental expenses for short‑term and low‑value leases continue to be recognized in operating expenses in the Company’s statement of income (loss). 3.4. Other non‑current assets include: - long‑term deposit accounts that do not qualify as cash equivalents within the meaning of IAS 7 — Statement of Cash Flows and whose maturity is more than one year on the present closing date; - Security deposits - Accrued income with a maturity greater than one year on the present closing date 3.5. IAS 36 — Impairment of Assets requires that depreciated and amortized assets be tested for impairment whenever specific events or circumstances indicate that their carrying amount may exceed their recoverable amount. The excess of the carrying amount of the asset over the recoverable amount is recognized as an impairment. The recoverable amount of an asset is the higher of its value in use and its fair value less costs to sell. Impaired non‑financial assets are examined at each year‑end or half‑year closing date for a possible impairment reversal. 3.6. In accordance with IAS 2 — Inventories , inventories are measured at the lower of cost (determined using the weighted average cost method) and net realizable value. In case of impairment, any write‑down is recognized as an expense in other operating income (loss). 3.7. Trade receivables are measured at nominal value, which generally equate with the fair value of the consideration to be received, net of impairment. The Company recognizes loss allowances for expected credit losses ("ECL"), which, for trade receivables and contract assets, are measured at an amount equal to lifetime ECLs that result from all possible default events over their expected life. Loss allowances are deducted from the gross amounts of the assets. 3.8. Currency term accounts are classified as other current assets, their main characteristics don't meet the definition of "Cash equivalents" within the meaning of IAS 7. 3.9. Derivatives The Company uses derivative financial instruments to hedge its exposure to exchange rate risks (Currency forward sales). The Company has not opted for hedge accounting in accordance with IFRS 9. Derivatives are measured at their fair value in the statement of financial position. The change in fair value of derivative instruments is accounted as an offsetting entry in the financial income (loss) in the statement of income (loss). The fair values of derivatives are estimated on the basis of commonly used valuation models considering data from active markets. The net gains and losses of instruments at fair value through the statement of income (loss) correspond to the flows exchanged and the change in value of the instrument. 3.10. Cash and cash equivalents include cash on hand and demand deposits, as well as other short‑term highly liquid investments with maturities of three months or less , convertible at a known amount,and subject to an insignificant risk of changes in value. Monetary Undertakings for Collective Investments in Transferable Securities (UCITS) may be recognized as cash equivalents when they: · have an original maturity of three months or less; · are readily convertible to a known cash amount; and · are subject to an insignificant risk of decrease in value. Bank overdrafts are recorded in liabilities in the statement of financial position under short‑term debt. 3.11. Share capital Ordinary shares are classified in shareholders’ equity. Transaction costs Costs directly attributable to the issue of ordinary shares or share options are recognized as a reduction in the share premium. Costs related to multiple operations (Initial public offering and capital increase) are distinctly recorded. Concerning the IPO, the part related to the new shares is recognized in deduction of the premiums related to share capital and the part related to existing shares in expenses as transaction costs. 3.12. At the Company’s inception, the Company put in place a compensation plan settled in equity instruments in the form of share warrants awarded to employees ( Bons de souscription de parts de créateur d’entreprise , BSPCE or BSPCE share warrants) and to a non‑employee ( Bons de souscription d’actions , BSA or BSA share warrants), and bonus share award to employees ( Attribution gratuite d’actions , AGA or AGA bonus share award). In accordance with IFRS 2 — Share‑based Payment , the cost of transactions settled in equity instruments is recognized in expenses, offset by increases in equity, in the period in which the benefit is granted to the employee or non‑employee. Before the admission of the Company on the Euronext listing, the value of the share warrants has been determined with the assistance of an independent expert using a combination of the following valuation methods: · The market approach which indicates the value of a business by comparing it to companies whose market price is available and/or recent market transactions involving comparable companies or assets. · The income approach which indicates the value of a business by discounting the expected future cash flows of the business to present value. This approach necessitates the use of the discounted cash flow method. Since the Company is a listed company on Euronext, the value of the share warrants has been determined with the assistance of an independent expert using the Black & Scholes model based on the value of the underlying asset at grant date (stock price), the volatility observed in a sample of comparable listed companies and the economic life of the related share warrant. No new plan has been issued by the Company since its listing on the Nasdaq Global Market. The measurement of the fair value of options incorporates the vesting conditions as described in Notes 1.2. “Significant events”, 10.3 “Share award plans” and 10.4 “Bonus share award plans”. In 2020, two BSA share warrant plans were allocated to some service providers of the Company. Details of these plans are provided in Note 10, "Shareholders' equity". 3.13. Bank loans are initially recognized at fair value, i.e., the issue proceeds (fair value of the consideration received) net of transaction costs incurred. Borrowings are subsequently measured at amortized cost, calculated using the effective interest rate method. Any difference between initial fair value and repayment value is recognized in the statement of income (loss) over the life of the loan using the effective interest rate method. The effective interest rate is the discount rate at which the present value of all future cash flows (including transaction costs) over the expected life of the loan, or where appropriate, over a shorter period of time, is equal to the loan’s initial carrying amount. 3.14. Trade payables and other current liabilities are initially recognized at fair value and subsequently measured at amortized cost, calculated using the effective interest rate method. Given the due date, the amortized cost is equal to the initial fair value. 3.15. Tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to the French tax authorities, using tax rates and tax laws enacted or substantively enacted at the end of the reporting period. The income tax charge for the period comprises current tax due and the deferred tax charge. The tax expense is recognized in the statement of income (loss) unless it relates to items recorded in other comprehensive income and expense or directly in equity, in which case the tax is also recorded in other comprehensive income and expense or directly in equity. Current taxes The current tax expense is calculated based on taxable profit for the period, using tax rates enacted or substantively enacted at the statement of financial position date. Considering the level of tax loss of the Company, no current tax expense is recognized. Deferred taxes Deferred taxes are recognized when there are temporary differences between the carrying amount of assets and liabilities in the Company’s financial statements and the corresponding tax basis used to calculate taxable profit. Deferred taxes are not recognized if they arise from the initial recognition of an asset or liability in a transaction other than a business combination which, at the time of the transaction, does not affect either the accounting or the taxable profit (tax loss). Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, based on tax rates and tax laws enacted or substantively enacted by the end of the reporting period. Deferred tax assets and liabilities are not discounted. Deferred tax assets and liabilities are offset when a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes concern the same entity and the same tax authority. Deferred tax assets Deferred tax assets are recognized for all deductible temporary differences, unused tax losses and unused tax credits to the extent that it is probable that the temporary difference will reverse in the foreseeable future and that taxable profit will be available against which the deductible temporary difference, unused tax losses or unused tax credits can be utilized. The recoverable amount of deferred tax assets is reviewed at the end of each reporting period and their carrying amount is reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow the benefit of part or all of the deferred tax assets to be utilized. Unrecognized deferred tax assets are reassessed at the end of each reporting period and are recognized when it becomes probable that future taxable profit will be available to offset the temporary differences. Deferred tax liabilities Deferred tax liabilities are recognized for all taxable temporary differences, except when the Company is able to control the timing of the reversal of the difference and it is probable that the reversal will not occur in the foreseeable future. 3.16. Retirement benefit obligations The Company operates a defined benefit pension plan. Its obligations in respect of the plan are limited to the lump sum payments upon retirements, which are expensed in the period in which the employees provide the corresponding service. The liability recorded in the statement of financial position in respect of defined benefit pension plans and other post‑retirement benefits is the present value of the defined benefit obligation at the statement of financial position date. The defined benefit obligation is calculated annually by independent actuaries using the projected unit credit method. The present value of the defined benefit obligation is determined by discounting estimated future cash outflows, using the interest rate of high‑quality corporate bonds of a currency and term consistent with the currency and term of the pension obligation concerned. Actuarial gains and losses arise from the effect of changes in assumptions and experience adjustments (i.e., differences between the assumptions used and actual data). These actuarial gains and losses are recognized wholly and immediately in other comprehensive income and expense and are not subsequently reclassified to the statement of income (loss). The net expense in respect of defined benefit obligations recognized in the statement of income (loss) for the period corresponds to: · The service cost for the period (acquisition of additional rights). · The interest cost. · The past service cost. · The impact of any plan settlements, amendments and curtailments The effect of unwinding the obligation is recognized in net financial income and expenses. Termination benefits Termination benefits are payable when a company terminates an employee’s employment contract before the normal retirement age or when an employee accepts compensation as part of a voluntary redundancy. In the case of termination benefits, the event that gives rise to an obligation is the termination of employment. In the case of an offer made to encourage voluntary redundancy, termination benefits are measured based on the number of employees expected to accept the offer. Profit‑sharing and bonus plans The Company recognizes a liability and an expense for profit‑sharing and bonus plans based on a formula that takes into account the Company’s performance. 3.17. In accordance with IAS 37 — Provisions, Contingent Liabilities and Contingent Assets , a provision should be recognized when: (i) an entity has a present legal or constructive obligation as a result of a past event; (ii) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation; and (iii) a reliable estimate can be made of the amount of the obligation. Provisions for restructuring include termination benefits. No provisions are recognized for future operating losses. Where there are a number of similar obligations, the probability that an outflow will be required in settlement is determined by considering the class of obligations as a whole. Although the likelihood of outflow for any one item may be small, it may well be probable that some outflow of resources will be needed to settle the class of obligations as a whole. If that is the case, a provision is recognized. The provision represents the best estimate of the amount required to settle the present obligation at the end of the reporting period. Where the effect of the time value of money is material, the amount of a provision corresponds to the present value of the expected costs that the Company considers necessary to settle the obligation. The pre‑tax discount rate used reflects current market assessments of the time value of money and specific risks related to the liability. The effect of unwinding discounts on provisions due to the time value of money is recognized in net financial income and expenses. 3.18. Revenue is recognized in accordance with IFRS 15 — Revenue from Contracts with Customers, which is mandatorily applicable for reporting periods beginning on or after January 1, 2018. Collaboration agreements The contracts are analyzed as research and development services contracts. Any licenses that result from the collaborations are therefore not deemed to be separate performance obligations. The performance obligations contained in the contracts are deemed to be satisfied as and when the Company expends efforts (e.g., incurs costs or spends time). In return for the efforts expended, the Company receives fixed payments (such as lump‑sum payments) and variable payments (such as milestone payments or royalties on sales of any future approved products). Fixed payments for research and development expenditures, which primarily consist of rebilled payroll expenditure, are recognized over time based on the Company’s efforts or inputs to the satisfaction of a performance obligation (costs incurred or hours expended). Milestone payments obtained following the achievement of specific milestones (e.g., scientific results or regulatory or commercial approvals) are deemed to be variable payments and are included in the contract price as soon as their receipt is highly probable, resulting in an upward revision of the contract price and a cumulative adjustment to income in the statement of income (loss). Revenue from royalties corresponds to Inventiva’s contractual entitlement to receive a percentage of the future product sales achieved by its counterparties. Such royalties will be recognized if and when sales are made. Rendering of services The Company provides short term research services to various clients. Such services are recognized to revenue over time based on time incurred. 3.19. Research tax credit The research tax credit ( crédit d’impôt recherche , or “CIR”) granted by the French tax authorities to encourage technical and scientific research by French companies is recorded in the “Tax receivables” line of the statement of financial position. Companies demonstrating that they have expenses that meet the required criteria, including research expenses located in France or certain other European countries, receive a tax credit that can be used against the payment of the corporate tax due the fiscal year in which the expenses were incurred and during the next three fiscal years; provided, that companies may receive cash reimbursement for any excess portion. Only those companies meeting the EU definition of a small or medium-sized entity (“SME”) are eligible for payment in cash of their CIR (to the extent not used to offset corporate taxes payable) in the year following the request for reimbursement. Inventiva meets the EU definition of an SME and therefore should continue to be eligible for prepayment. Inventiva has been eligible for CIR since inception. The CIR is recognized in “Other income” during the reporting period in which the eligible expenditure is incurred and recorded in the “Tax receivables” line in the statement of financial position. Subsidies The Company receives subsidies from several public bodies. The subsidies are related to net income and granted to compensate for incurred expenses. They are therefore recognized in net income as other income for the period in which it becomes reasonably certain that they will be received. 3.20. Financial income Financial income includes: - The “Income from cash and cash equivalents”, which includes income from short‑term investments remeasured at fair value at the end of each reporting period. - Fair value variation gains / losses on cash equivalents which are revalued at each closing. - Foreign exchange gains. - Gains from unwinding discounting. - Other financial income. Financial expenses Financial expenses primarily include: - Interest cost. - Fair value variation gains / losses on cash equivalents which are revalued at each closing. - Foreign exchange losses. - Losses from unwinding discounting. - Other financial expenses. 3.21. Other operating income and expenses Other operating income and expenses are disclosed separately on the face of the statement of income (loss). This line item is set aside for unusual events that may arise during the period whose presentation within other items (relating to ordinary activities) could be misleading for users of the financial statements in their understanding of the Company’s performance. This item therefore includes income and expenses that are rare that represent material amounts and that the Company discloses separately on the face of the statement of income (loss) to facilitate understanding of operating performance (see Note 18, “Other operating income (expenses)”). Disposals of non‑current assets Income from the disposal of non‑current assets during the period is recognized in “Other operating income (expenses)”. 3.22. In the table below, financial instruments are measured at fair value according to a hierarchy comprising three levels of valuation inputs: · Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date. · Level 2: Inputs other than quoted market prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. · Level 3: Unobservable inputs for the asset or liability. The table below presents the financial assets and liabilities of the Company measured at fair value at December 31, 2020: At December 31, 2020 (in thousands of euros) Level 1 Level 2 Level 3 Assets Financial assets at fair value through profit or loss Foreign currency forwards (1) — 1,791 — Total assets — 1,791 — Foreign currency forwards — — — Total liabilities — — — (1) The valuation of the instrument is estimated based on observable market parameters. The instrument is not directly listed on a market. As of December 31, 2018 and 2019, no financial asset or liability was measured at fair value. 3.23. Functional and presentation currency The Company’s financial statements are presented in euros, which is also the Company’s functional currency. All amounts presented in these notes to the financial statements are denominated in euros unless otherwise stated. Translation of foreign currency transactions As of December 31, 2020, foreign currency transactions include bank accounts and term deposits in U.S. dollars implemented after the IPO on the Nasdaq Global Market in July 2020. Certain purchasing transactions are carried out in foreign currencies for our studies and clinical trials conducted in the United States, the United Kingdom, Switzerland, Australia, Canada and Sweden. In 2020, these foreign currency expenses amounted to approximately €2.5 million, or approximately 7% of our operating expenses. These transactions are translated into euros at the rate prevailing at the date of each transaction. Purchasing transactions in foreign currencies are presented in operating income as they relate to the Company's ordinary activities. Foreign exchange gains and losses relating to short-term investments and bank accounts in U.S. dollars are presented in financial income (loss). 3.24. The assessment of the entity’s performance and the decisions about resources to be allocated are made by the chief operating decision maker, based on the management reporting system of the entity. Only one operating segment arises from the management reporting system: service delivery and clinical stage research, notably into potential therapies in the areas of fibrosis, lysosomal storage disorders and oncology. Thus, the entity’s performance is assessed at the Company level. All the Company’s operations, assets, liabilities and losses are located in France. 3.25. The preparation of financial statements in accordance with IFRS requires: · Management to make judgments when selecting appropriate assumptions for accounting estimates, which consequently involve a certain degree of uncertainty. · Management to make estimates and apply assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as well as information presented for the period. The estimates and judgments, which are updated on an ongoing basis, are based on past experience and other factors, in particular assumptions of future events, deemed reasonable in light of circumstances. The Company makes estimates and assumptions concerning the future. The resulting accounting estimates, by definition, often differ from actual reported values. Estimates and assumptions that could lead to a significant risk of a material adjustment in the carrying amount of assets and liabilities in the subsequent period are analyzed below. Revenue · Allocation of transaction price to performance obligations — A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. To determine the proper revenue recognition method, the Company evaluates whether the contract should be accounted for as more than one performance obligation. This evaluation requires significant judgment; some of the Company’s contracts have a single performance obligation as the promise to transfer the individual goods or services is not separately identifiable from other promises in the contracts and, therefore, not distinct. For contracts with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract. · Variable consideration — Due to the nature of the work required to be performed on many of the Company’s performance obligations, the estimation of total revenue and cost at completion is complex, subject to many variables and requires significant judgment. It is common for the collaboration agreements to contain variable consideration that can increase the transaction price. Variability in the transaction price arises primarily due to milestone payments obtained following the achievement of specific milestones (e.g., scientific results or regulatory or commercial approvals). The Company includes the related amounts in the transaction price as soon as their receipt is highly probable. The effect of the increase of the transaction price due to milestones payments is recognized as an adjustment to revenue on a cumulative catch‑up basis. · Revenue recognized over time and input method — The Company’s performance obligations are satisfied over time as work progresses or at a point in time. For the collaboration agreements, because services are rendered over time, revenue is recognized based on the extent of progress towards completion of the performance obligation, using an input measure of progress as it best depicts the transfer of control to the customers. Under the Company’s input measure of progress, the extent of progress towards completion is measured based on the ratio of days expended to date to the total estimated days at completion of the performance obligation. Provision for tax audit The Company calculated the provision for the tax audits to which the Company has been subject based on an estimate of the related risk. The provision represents the best estimate of the amount required to settle any amounts owed to the French tax authorities at the end of the reporting period (see Note 12, “Provisions”). CIR The amount of the CIR is determined based on the Company’s internal and external expenditure in the reporting period. Only eligible research costs may be included when calculating the CIR. Valuation of share warrants and bonus share award Fair value measurements of share warrants and bonus share award granted to employees are based on actuarial models which require the Company to factor certain assumptions into its calculations (see Notes 10.3, "Share warrants plans" and 10.4, "Bonus share award plans"). Measurement of retirement benefit obligations The Company operates a defined benefit pension plan. Its defined benefit plan obligations are measured in accordance with actuarial calculations based on assumptions such as discount rates, the rate of future salary increases, employee turnover, mortality tables and expected increases in medical costs. The assumptions used are generally reviewed and updated annually. The main assumptions used and the methods chosen to determine them are set out in Notes 3.16, "Provisions for retirement benefit obligations" and 13, “Provisions for retirement benefit obligations”. The Company considers that the actuarial assumptions used are appropriate and justified in light of current circumstances. Nevertheless, retirement benefit obligations are likely to change in the event that actuarial assumptions are revised. Derivatives The Company uses derivative financial instruments to hedge its exposure to exchange rate risks (Currency forward sales). The Company has not opted for hedge accounting in accordance with IFRS 9. Derivatives are measured at their fair value in the statement of financial position. The fair values of derivatives are estimated on the basis of commonly used valuation models considering data from active markets.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2020
Intangible Assets
Intangible Assets	Note 4. Intangible Assets (in thousands of euros) January 1, 2018 Increases Decreases December 31, 2018 Library of compounds 2,142 — — 2,142 Software 1,398 106 — 1,504 Intangible assets, gross 3,540 106 — 3,646 Amortization of library of compounds (828) (165) — (993) Amortization of software (906) (204) — (1,110) Amortization (1,733) (369) — (2,103) Intangible assets, net 1,806 (264) — 1,543 (in thousands of euros) January 1, 2019 Increases Decreases December 31, 2019 Library of compounds 2,142 — — 2,142 Software 1,504 29 — 1,533 Intangible assets, gross 3,646 29 — 3,674 Amortization of library of compounds (993) (165) — (1,157) Amortization of software (1,110) (179) — (1,289) Amortization (2,103) (343) — (2,446) Intangible assets, net 1,543 (314) — 1,228 (in thousands of euros) January 1, 2020 Increases Decreases December 31, 2020 Library of compounds 2,142 — — 2,142 Software 1,533 — 1,533 Intangible assets, gross 3,674 — 3,674 Amortization of library of compounds (1,157) (165) — (1,322) Amortization of software (1,289) (129) — (1,417) Amortization (2,446) (293) — (2,739) Intangible assets, net 1,228 (293) — 935 Changes during the periods mainly correspond to amortization charges of €0.3 million by year. In the absence of any indication of a loss of value, no impairment tests have been performed on amortizable intangible assets in the years ended December 31, 2018, 2019 and 2020.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment
Property, Plant and Equipment	Note 5. Property, Plant and Equipment January 1, December 31, (in thousands of euros) 2018 Increases Decreases Reclassifications 2018 Land 172 — — — 172 Buildings 3,407 — — — 3,407 Technical facilities, equipment and tooling 4,267 334 — 75 4,677 Other property, plant and equipment 1,023 58 — — 1,081 Property, plant and equipment in progress 67 51 — (75) 43 Property, plant and equipment, gross 8,937 443 — — 9,380 Depreciation of buildings (1,144) (202) — — (1,346) Depreciation of technical facilities, equipment and tooling (2,608) (391) — — (2,999) Depreciation of other property, plant and equipment (668) (105) — — (774) Depreciation (4,421) (698) — — (5,119) Property, plant and equipment, net 4,516 (255) — — 4,261 January 1, December 31, (in thousands of euros) 2019 Increases Decreases Reclassifications 2019 Land 172 — — — 172 Buildings 3,407 — — — 3,407 Technical facilities, equipment and tooling 4,677 74 (2) — 4,748 Other property, plant and equipment 1,081 33 — 43 1,157 Property, plant and equipment in progress 43 — — (43) — Right of use (1) 252 — — — 252 Property, plant and equipment, gross 9,632 107 (2) — 9,736 Depreciation of buildings (1,346) (196) — — (1,542) Depreciation of technical facilities, equipment and tooling (2,999) (398) 1 — (3,396) Depreciation of other property, plant and equipment (774) (100) — — (874) Depreciation of right of use (1) — (203) — — (203) Depreciation (5,119) (897) 1 — (6,015) Property, plant and equipment, net 4,513 (790) (2) — 3,721 (1) At January 1, 2019, in application of IFRS 16 — Leases, an asset representing the right to use the leased assets (see Note 2.1, "Impact of the first-time application of IFRS 16"). Changes during the period 2020 mainly correspond to depreciation charges of €0.9 million. January 1, December 31, (in thousands of euros) 2020 Increases Decreases Others (1) 2020 Land 172 — — — 172 Buildings 3,407 — — — 3,407 Technical facilities, equipment and tooling 4,748 108 — 4,856 Other property, plant and equipment 1,157 46 — 1,203 Property, plant and equipment in progress — 137 — — 137 Right of use (1) 252 — — (218) 34 Property, plant and equipment, gross 9,736 292 (218) 9,810 Depreciation and impairment of buildings (1,542) (196) — — (1,737) Depreciation and impairment of technical facilities, equipment and tooling (3,396) (386) — — (3,782) Depreciation and impairment of other property, plant and equipment (874) (102) — — (976) Depreciation and impairment of right of use (203) (32) — 202 (33) Depreciation and impairment (6,015) (716) — 202 (6,528) Property, plant and equipment, net 3,721 (424) (16) 3,282 (1) Others during the period corresponding to the retirement of the net value of the right of use related to the fibroscan lease contract following its early termination. Changes during the period 2020 mainly correspond to depreciation charges of €0.7 million. In the absence of any indication of a loss of value, no impairment tests have been performed on amortizable tangible assets and right of use in the years ended December 31, 2018, 2019 and 2020.

Other Non-Current Assets

Other Non-Current Assets	12 Months Ended
	Dec. 31, 2020
Other Non-Current Assets
Other Non-Current Assets	Note 6. Other Non‑Current Assets As of December 31, (in thousands of euros) 2018 2019 2020 Accrued income 1,932 2,000 — Long ‑ term deposit accounts 108 792 1,698 Security deposits — 8 8 Tax loss carry back 333 333 — Other non ‑ current assets 2,374 3,135 1,706 As of December 31, 2019, non-current accrued income corresponded entirely to an income receivable from the group Abbott following the tax audit of fiscal years 2013, 2014, 2015, the conclusions of which were received during fiscal year 2018. On February 10, 2021, the Company has requested the payment from Abbott of the €2.0 million corresponding to the maximum amount covered by the indemnity under the Additional Agreement (see notes 8.2, “Other current assets” and 12, “Provisions”), which is expected to be received in the first semester 2021. As a result, this non-current receivable is reclassified to other current assets as at December 31, 2020. Long-term deposit accounts correspond to: - a total amount of €1.7 million of two pledges over cash granted in connection with the surety provided by the Company to the French tax authorities in the form of a €3.4 million bank guarantee with Crédit Agricole (see Note 12, "Provisions"). They break down as follows: o a pledge over cash granted by the Company on February 1, 2019, equal to 50% of the sum not covered by the indemnity to be received from the Abbott group under the Additional Agreement , amounting to €0.7 million, and o in accordance with the initial agreement, an additional pledge over cash granted by the Company on June 30, 2020, as the dispute to which the guarantee pertains remains unresolved, amounting to €1.0 million. - the pledge of a gradual rate deposit account with a balance of €101 thousand as collateral for the €254 thousand loan from Société Générale agreed in July 2015, which is released in 2020. The tax loss carry back corresponds to the tax credit resulting from the tax loss carry back recognized by the Company at December 31, 2017 and recoverable after five years if not used by the Company to pay income tax within that period. As of December 31, 2020, this tax loss carry back receivable is entirely impaired following the reception, on December 15, 2020, of a tax reassessment from tax authorities which rejects the entire deficit carry-back recognized by the Company in 2017 (see Notes 19, "Other Operating Income (expenses)" and 26. "Events After the Reporting Date").

Inventories

Inventories	12 Months Ended
	Dec. 31, 2020
Inventories
Inventories	Note 7. Inventories As of December 31, (in thousands of euros) 2018 2019 2020 Laboratory inventories 443 420 353 Inventories write ‑ down (33) (33) (33) Total inventories 410 387 320 The write‑down presented for the year ended December 31, 2020 is unchanged.

Trade Receivables and Other Cur

Trade Receivables and Other Current Assets and Receivables	12 Months Ended
	Dec. 31, 2020
Trade Receivables and Other Current Assets and Receivables
Trade Receivables and Other Current Assets and Receivables	Note 8. Trade Receivables and Other Current Assets and Receivables 8.1. Trade receivables break down as follows: As of December 31, (in thousands of euros) 2018 2019 2020 3 months or less 6 4 48 Between 3 and 6 months — — — Between 6 and 12 months — — — More than 12 months — — — Trade receivables 6 4 48 The average payment period is 30 days. 8.2. As of December 31, (in thousands of euros) 2018 2019 2020 CIR 9,158 9,818 9,012 CICE tax credit 264 — — Other 12 16 16 Tax receivables 9,434 9,833 9,028 Prepaid expenses 1,184 495 3,313 Short-term deposit accounts — — 7,336 Current accrued income — — 2,000 Foreign currency forwards — — 1,791 Liquidity agreement - Cash account (1) 31 261 1,029 VAT receivable 3,033 1,416 1,625 Other receivables 843 639 821 Other current assets 5,092 2,811 17,914 Other current assets and receivables 14,526 12,644 26,942 (1) Year ended 31 December 2020 As of December 31, 2020, tax receivables mainly correspond to research tax credits receivable for 2020 in an amount of €4.8 million, as well as corrective claims for additional reimbursements of CIR with regard to the years from 2017 to 2019 for a total amount of €2.9 million recorded in 2020, requested following the decision of the Council of State in July 2020 on the eligibility of subcontracting expenses. Short-term deposit accounts of €7.3 million correspond to short-term deposit accounts in U.S. dollars contracted with Société Générale and Crédit Agricole for the amounts of €3.3 million ($4.0 million) and €4.1 million ($5.0 million) respectively. Current accrued income corresponded entirely to an income receivable from the group Abbott following the tax audit of fiscal years 2013, 2014, 2015, the conclusions of which were received during fiscal year 2018. On February 10, 2021, the Company has requested the payment from Abbott of the €2.0 million corresponding to the maximum amount covered by the indemnity under the Additional Agreement (see notes 6, “Other current assets” and 12, “Provisions”), which is expected to be received in the first semester 2021. As a result, this non-current receivable recorded in December 31, 2019 is reclassified to other current assets as at December 31, 2020. Foreign currency forwards correspond to the change in fair value of the three contracts that have been subscribed by the Company with Société Générale and Crédit Agricole to protect the value of investments in dollars against fluctuations in the exchange rate between the euro and the dollar up to $60 million (refer to notes 1.2, "Significant events of 2020" and 22. "Commitments"). The prepaid expenses correspond mainly to deferral of insurance costs in connection with the initial public offering on the Nasdaq Global Market for an amount of €1.8 million (see note 1.2, "Significant events of 2020") and, to a lesser extent, to IT maintenance and research and development equipment costs, patent maintenance fees and insurance contributions in respect of the first quarter of 2021. Year ended 31 December 2019 and 2018 As of December 31, 2019, tax receivables in a total amount of €9,833 thousand correspond mainly to CIR receivables, comprised of the €4,293 thousand receivable for the current year and receivables from previous years not yet received , including €4,171 thousand for 2018 (which is received in 2020), €880 thousand for 2017 and €478 thousand in corrective claims. The CIR receivable relating to 2017 initially amounted to €4,513 thousand (corrective claim included), of which €3,633 thousand (81%) was received in September 2019; the Company is currently disputing the residual amount of €880 thousand withheld by the tax authorities (see. Note 12., "Provisions"). The majority of prepaid expenses amounting to €495 thousand at December 31, 2019 correspond to IT maintenance costs, patent maintenance fees and insurance contributions paid in respect of first quarter 2020. At December 31, 2018, prepaid expenses also included rents relating to fibroscans and certain ad hoc scientific work billed in advance.

Cash and Cash Equivalents

Cash and Cash Equivalents	12 Months Ended
	Dec. 31, 2020
Cash and Cash Equivalents
Cash and Cash Equivalents	Note 9. Cash and Cash Equivalents As of December 31, (in thousands of euros) 2018 2019 2020 Other cash equivalents (1) 41,767 14,004 12,001 Cash at bank and at hand 14,925 21,837 93,686 Cash and cash equivalents 56,692 35,840 105,687 (1) Other cash equivalents correspond to short‑term bank deposits in euros at Société Générale and Crédit Agricole.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2020
Shareholders' Equity
Shareholders' Equity	Note 10. Shareholders’ Equity 10.1. The share capital is set at €386 thousand at December 31, 2020 divided into 38,630,261 fully authorized, subscribed and paid‑up shares with a nominal value of €0.01. Changes in share capital during the years ended December 31, 2018, 2019 and 2020 are as follows: in euros, except number of shares Premiums Share related to Number of Nominal Date Nature of the transactions capital share capital shares value Balance as of January 1 st , 2018 164,445 44,991,815 16,444,477 0.01 01/26/2018 Capital increase by issuance of ordinary shares - Exercise of 1,803 BSPCE by Company employees 1,803 106,384 180,300 0.01 04/17/2018 Capital increase by issuance of ordinary shares – Company’s private placement 55,725 35,441,100 5,572,500 0.01 04/17/2018 Transaction costs related to the Company’s private placement — (3,079,174) — — 04/18/2018 Capital increase by issuance of ordinary shares – Vesting of AGA by Company employees 600 — 60,000 0.01 Balance as of January 1 st , 2019 222,573 77,460,125 22,257,277 0.01 01/23/2019 Capital increase by issuance of ordinary shares — Exercise of 274 BSPCE by Company employees 274 17,693 27,400 0.01 01/26/2019 Capital increase by issuance of ordinary shares — Vesting of AGA by Company employees (AGA 2018 ‑ 1) 100 — 10,000 0.01 04/18/2019 Capital increase by issuance of ordinary shares — Vesting of AGA by Company employees (AGA 2017 ‑ 1) 775 — 77,500 0.01 09/20/2019 Capital increase by issuance of ordinary shares — Company’s private placement 41,600 8,236,798 4,159,999 0.01 09/20/2019 Transaction costs related to the Company’s private placement — (312,294) — — 10/02/2019 Capital increase by issuance of ordinary shares — Company’s private placement 3,139 621,593 313,936 0.01 10/02/2019 Transaction costs related to the Company’s private placement — (12,023) — — Balance as of January 1 st , 2020 268,461 86,011,893 26,846,112 0.01 01/26/2020 Capital increase by issuance of ordinary shares – Vesting of AGA by Company employees (AGA 2018-2) 633 — 63,300 0.01 02/07/2020 Capital increase by issuance of ordinary shares – Company’s private placement 37,783 14,962,218 3,778,338 0.01 02/07/2020 Transaction costs related to the Company’s private placement — (319,564) — — 04/17/2020 Appropriation of the issue premium — (48,000,000) — — 06/28/2020 Capital increase by issuance of ordinary shares – Vesting of AGA by Company employees (AGA 2019-2) 2,270 — 227,000 0.01 07/15/2020 Capital increase by issuance of ordinary shares – Company’s initial public offering 74,783 94,024,272 7,478,261 0.01 07/15/2020 Transaction costs related to the Company’s initial public offering — (7,077,866) — — 11/30/2020 Capital increase by emission of ordinary shares – exercise of 10,000 BSA by Karen Aïach, former administrator (BSA 2017) 100 66,650 10,000 0.01 12/14/2020 Capital increase by issuance of ordinary shares – Vesting of AGA by Company employees (AGA 2018-3) 2,273 — 227,250 0.01 Balance as of December 31, 2020 386,302 139,667,603 38,630,261 During the three periods presented, the main impacts on the share capital relate to the following events: - USD 107.7 million initial public offering on the Nasdaq Global Market in July 2020 See note 1.2 Significant events of 2020 - The reclassification of €48.0 million from debit retained earnings to premiums related to share capital following the decision of the General Meeting on April, 18 2020; - Capital increase of €14.7 million reserved for a category of investors in February 2020 See note 1.2 Significant events of 2020 - Capital increases for a total amount of €8.9 million subscribed by Americans and Europeans investors in September and October 2019 On September 20, 2019 and On October 2, 2019, Inventiva completed two capital increases subscribed by New Enterprise Associates (NEA), as well as BVF Partners L.P., Sofinnova Partners and Novo Holdings A/S, three of the Company's existing shareholders. The settlement-delivery of the new shares took place successfully on September 20, 2019 and on October 2, 2019. The gross proceeds of the transaction were €8.9 million and were mainly dedicated to the research and development activities of the Company, including the development of the Company's product candidates, in particular lanifibranor and odiparcil. The new shares are assimilated to the existing shares of the Company and are admitted to trading on Euronext Paris. As part of the capital increase, the Company incurred transaction costs of €0.3 million in 2019, comprising compensation to financial intermediaries and legal and administrative fees. The costs are recognized as a deduction from additional paid-in capital within equity. - Capital increase of €32.4 million by way of a private placement for a category of investors in April 2018 On April 17, 2018, Inventiva completed a capital increase without pre-emptive subscription rights for a category of beneficiaries. The settlement-delivery of the new shares took place on April 17, 2018. The new shares are assimilated to the existing shares of the Company and are admitted to trading on Euronext Paris. As part of the capital increase, the Company incurred transaction costs of €3.1 million in 2018, comprising compensation to financial intermediaries and legal and administrative fees. The costs are recognized as a deduction from additional paid-in capital within equity. Movements related to BSA share warrants plans and AGA bonus shares award plans are described in Notes 10.3, “Share warrants plans” and 10.4, “Bonus share award plans”. 10.2. On January 19, 2018, the Company entered into a new liquidity agreement with the investment service provider Kepler Cheuvreux, replacing the previous liquidity agreement with Oddo BHF, for a period of 12 months renewable by tacit agreement. Under the terms of the agreement, the investment services provider (ISP) is authorized to buy and sell Inventiva treasury shares without interference from the Company in order to ensure the liquidity of the shares on the Euronext market. At the date of approval of these financial statements, the liquidity agreement with Kepler Chevreux was extended for a new period of 12 months from January 1, 2021. At December 31, 2018, 2019 and 2020, treasury shares purchased and sold by Inventiva through its ISP, as well as the gains or losses resulting from share purchase, sale, issue and cancellation transactions during the period, were accounted for as a deduction from equity. Consequently, these transactions had no impact on the Company’s results. 10.3. Share warrants correspond to: · BSPCE founder share warrants granted to the Company’s employees in 2013 and 2015; · BSA share warrants granted to Company directors in 2017, with a subscription price set at €0.534; · BSA share warrants granted to Company service providers in 2018, with a subscription price set at €0.48; · BSA share warrants granted in 2019 to David Nikodem, a member of Sapidus Consulting Group LLC, a service provider of Inventiva, with a subscription price set at €0.18; and · BSA share warrants granted in 2020 to David Nikodem, a member of Sapidus Consulting Group LLC and to Jeremy Goldberg, a member of PG Heatlhcare LLC, service providers of Inventiva, with a subscription price set at €0.29. Characteristics of BSPCE share warrants plans At December 31, 2020, 88 BSPCE share warrants were outstanding. Each BSPCE share warrant corresponds to 100 shares. They are exercisable until December 31, 2023, after which date they will be forfeited. BSPCE 2013-1 Decision of issuance by the Board of Directors 11/25/2013 Grant date 12/13/2013 Beneficiary Employees Number of BSPCE granted 9,027 Expiration date 12/31/2023 Number of shares per BSPCE 100 BSPCE exercise price (€) 58.50 Characteristics of BSA share warrant plans At January 1, 2020, three BSA share warrant plans were outstanding: BSA 2017, BSA 2018 and BSA 2019. BSA BSA BSA BSA 2017 2018-1 BSA 2019 2019 bis 2019 ter Decision of issuance by the Board of Directors 05/29/2017 12/14/2018 06/28/2019 03/09/2020 03/09/2020 Grant date 05/29/2017 12/14/2018 06/28/2019 03/09/2020 03/09/2020 Beneficiary Directors Service providers Service providers Service providers Service providers Vesting period (year) 3 tranches: 1 year, 2 years and 3 years between 1 and 3 years 1 1 between 1 and 3 years Expiration date 05/29/2027 12/14/2028 06/28/2029 03/09/2030 03/09/2030 Number of BSA granted 195,000 126,000 10,000 10,000 36,000 Number of shares per BSA 1 1 1 1 1 Subscription premium price per share (€) 0.534 0.48 0.18 0.29 0.29 Exercise price per share (€) 6.675 6.067 2.20 3.68 3.68 Performance condition No No No No No Valuation method Black and Scholes Fair value per BSA at grant date (€) 2.47 1.98 0.48 0.90 0.90 Expected volatility 40 % 40 % 40 % 40 % 40 % Average life (years) 6 6 5.5 6 6 Risk free rate 0.22 % 0.30 % 0.33 % 0.0 % 0.0 % Expected dividends — — — — — Movements in BSPCE and BSA share warrants (in number of shares issuable upon exercise) Exercise Outstanding Outstanding Number of price at January 1, at December 31, shares Type Grant date (in euros) 2020 Issued Exercised Forfeited 2020 exercisable BSPCE — 2013 plan December 13, 2013 0.59 8,800 — — — 8,800 8,800 Total BSPCE 8,800 — — — 8,800 8,800 BSA — 2017 plan May 29, 2017 6.68 140,000 — (10,000) — 130,000 130,000 BSA — 2018 plan December 14, 2018 6.07 116,000 — — — 116,000 77,334 BSA — 2019 plan June 28, 2019 2.20 10,000 — — — 10,000 10,000 BSA 2019 Bis March 9, 2020 3.68 — 10,000 — — 10,000 — BSA 2019 Ter March 9, 2020 3.68 — 36,000 — — 36,000 — Total BSA 266,000 46,000 (10,000) — 302,000 217,334 Total 274,800 46,000 (10,000) — 310,800 226,134 The change in BSPCE and BSA share warrants over 2020 can be broken down as follows: · the issue of 10,000 new 2019 Bis BSAs allocated to Jeremy Goldberg, a member of JPG Healthcare LLC, · the issue of 36,000 new 2019 Ter BSAs allocated to David Nikodem, a member of Sapidus Consulting Group LLC, a service provide to the Company. · the exercise of 10,000 BSA 2017 by Karen Aïach (former administrator) At December 31, 2020, a total of 88 BSPCEs (or 8,800 shares) and 302,000 BSAs were outstanding which corresponds to a total of 310,800 shares that can be issued during the exercise. Share-based payments expense totaled €18 thousand at December 31, 2020 (compared to €227 thousand at December 31, 2019 and €184 thousand at December 31, 2018) and were recognized in personnel costs (see Note 18.1, “Personnel costs and headcount”). Exercise Outstanding Outstanding Number of price at January 1, at December 31, shares Type Grant date (in euros) 2019 Issued Exercised Forfeited 2019 exercisable BSPCE — 2015 plan May 25, 2015 0.67 22,800 — (22,800) — — — BSPCE — 2013 plan December 13, 2013 0.59 13,400 — (4,600) — 8,800 8,800 Total BSPCE 36,200 — (27,400) — 8,800 8,800 BSA — 2017 plan May 29, 2017 6.67 175,000 — — (35,000) 140,000 120,000 BSA — 2018 plan December 14, 2018 6.07 126,000 — — (10,000) 116,000 38,667 BSA — 2019 plan June 28, 2019 2.20 — 10,000 — — 10,000 — Total BSA 301,000 10,000 — (45,000) 266,000 158,667 Total stock options 337,200 10,000 (27,400) (45,000) 274,800 167,467 The change in BSPCE and BSA share warrants over 2019 can be broken down as follows: · the exercise of 274 BSPCE share warrants by Company employees on January 23, 2019, whereupon 27,400 new shares were issued; · the cancellation of 35,000 BSA 2017 share warrants allocated to two corporate officers, which were forfeited following the end of their offices at the Annual General Meeting of May 27, 2019; · the cancellation of 10,000 BSA 2018 share warrants allocated to JPG Healthcare, which were forfeited; and · the issue of 10,000 new 2019 BSAs allocated to David Nikodem, a member of Sapidus Consulting Group LLC, a service provide to the Company. As of December 31, 2019, a total of 88 BSPCE (or 8,800 shares) and 266,000 BSA were outstanding. Exercise Outstanding Outstanding Number of price at January 1, at December 31, shares Type Grant date (in euros) 2018 Issued Exercised Forfeited 2018 exercisable BSPCE—2015 plan May 25, 2015 0.67 54,700 — (31,900) — 22,800 22,800 BSPCE—2013 plan December 13, 2013 0.59 161,800 — (148,400) — 13,400 13,400 Total BSPCE 216,500 — 180,300 — 36,200 36,200 BSA—2017 plan May 29, 2017 6.67 195,000 — — (20,000) 175,000 65,000 BSA—2018 plan December 14, 2018 6.067 — 126,000 — — 126,000 — Total BSA 195,000 126,000 — (20,000) 301,000 65,000 Total stock options 411,500 126,000 (180,300) (20,000) 337,200 101,200 The change in BSPCE and BSA share warrants over 2018 can be broken down as follows: - the exercise of 1,803 BSPCE share warrants by Company employees between January 5 and January 20, 2018, whereupon 180,300 new shares were issued; - the cancellation of 20,000 BSA 2017 share warrants allocated to one of the corporate officers which were forfeited following their departure; and - the issue of 126,000 new BSA 2018 share warrants allocated to three of the Company’s external advisers. As of December 31, 2018, a total of 362 BSPCE (or 36,200 shares) and 301,000 BSA were outstanding. 10.4. At January 1, 2020, four AGA free share award plans, two AGA 2018 plans and two AGA 2019 plans were in effect. No bonus share award plan has been attributed in the year ended December 31, 2020. Characteristics of AGA bonus share award plans AGA AGA AGA AGA AGA AGA 2017-1 2018-1 2018-2 2018-3 2019-1 2019-2 Decision of issuance by the Board of Directors 04/18/2017 01/26/2018 01/26/2018 12/14/2018 06/28/2019 06/28/2019 Grant date 04/18/2017 01/26/2018 01/26/2018 12/14/2018 06/28/2019 06/28/2019 Beneficiary Employees Employees Employees Employees Employees Employees Vesting period (year) 2 1 2 2 2 1 Holding period (year) 1 1 1 1 1 1 Service condition Yes Yes Yes Yes Yes Yes Performance condition No No No No No No Number of AGA granted 92,300 10,000 65,700 265,700 37,500 246,000 Number of shares per AGA 1 1 1 1 1 1 Fair value per share at grant date (€) 7.04 5.54 5.54 6.05 1.92 1.92 Bonus share movements (in number of shares issuable upon exercise) Stock price Outstanding Outstanding Number of at grant date at January 1, at December 31, shares Type Grant date (in euros) 2020 Issued vesting Forfeited 2020 exercisable AGA — 2018 ‑ 2 plan January 26, 2018 5.76 63,300 — (63,300) — — — AGA — 2018 ‑ 3 plan December 14, 2018 6.28 227,250 — (227,250) — — — AGA — 2019 ‑ 1 plan June 28, 2019 2.00 37,500 — — (8,400) 29,100 — AGA — 2019 ‑ 2 plan June 28, 2019 2.00 228,000 — (227,000) (1,000) — — Total AGA 556,050 — (517,550) (9,400) 29,100 — During 2020, the change in AGA bonus shares over the period can be broken down as follows: · The definitive vesting of 63,300 AGA 2018-2 , 227,000 AGA 2019-2 and 227,250 AGA 2018-3. As a result, 517,550 new shares were issued; and, · The cancellation of a total of 8,400 AGA 2019-1 AGA and 1,000 AGA 2019-2 that have forfeited following the departure of employees. At December 31, 2020, a total of 29,100 AGA free shares were outstanding. AGA 2019-1 bonus shares are exercisable from June 28, 2021 to no later than June 28, 2022, subject to continued employment. Share-based payments expense totaled €920 thousand at December 31, 2020 (€1,180 thousand at December 31, 2019 and €649 thousand at December 31, 2018) and were recognized in personnel costs (see Note 18.1, “Personnel costs and headcount”). Stock price Outstanding Outstanding Number of at grant date at January 1, at December 31, shares Type Grant date (in euros) 2019 Issued Vesting Forfeited 2019 exercisable AGA — 2017-1 plan April 18, 2017 7.35 77,500 — (77,500) — — — AGA — 2018-1 plan January 26, 2018 5.76 10,000 — (10,000) — — — AGA — 2018-2 plan January 26, 2018 5.76 65,700 — — (2,400) 63,300 — AGA — 2018-3 plan December 14, 2018 6.28 265,700 — — (38,450) 227,250 — AGA — 2019-1 plan June 28, 2019 2.00 — 37,500 — — 37,500 — AGA — 2019-2 plan June 28, 2019 2.00 — 246,000 — (18,000) 228,000 — Total AGA 418,900 283,500 (87,500) (58,850) 556,050 — During 2019, the change in AGA bonus shares over the period can be broken down as follows: · Two new share plans for Company employees involving a total of 283,500 potential new shares. · Final allotment of 10,000 AGA 2018-1 bonus shares on January 26, 2019 and 77,500 AGA 2017-1 bonus shares on April 18, 2019, whereupon 87,500 new shares were issued. · Cancellation of 58,850 AGA bonus shares which were forfeited during the period: 10,850 AGA 2018-3 warrants as part of the redundancy plan for the period, 2,400 AGA 2018-3 bonus shares refused by an employee, and 45,600 AGA bonus shares bonus (of which 2,400 AGA 2018-2 bonus shares, 25,200 AGA 2018-3 bonus shares and 18,000 AGA 2019-2 bonus shares) as a result of voluntary departures. AGA 2019-1 bonus shares are exercisable from June 28, 2021 to no later than June 28, 2022, subject to continued employment. AGA 2019-2 bonus shares are exercisable from June 28, 2020 to no later than June 28, 2021, subject to continued employment. At December 31, 2019, a total of 556,050 AGA bonus shares were outstanding. Stock price Outstanding Outstanding Number of at grant date at January 1, at December 31, shares Type Grant date (in euros) 2018 Issued Vesting Forfeited 2018 exercisable AGA—2017 ‑ 1 plan April 18, 2017 7.35 79,900 — — (2,400) 77,500 — AGA—2017 ‑ 2 plan April 18, 2017 7.35 60,000 — (60,000) — — — AGA—2018 ‑ 1 plan January 26, 2018 5.76 — 10,000 — — 10,000 — AGA—2018 ‑ 2 plan January 26, 2018 5.76 — 65,700 — — 65,700 — AGA—2018 ‑ 3 plan December 14, 2018 6.28 — 265,700 — — 265,700 — Total AGA 139,900 341,400 (60,000) (2,400) 418,900 — At December 31, 2018, a total of 418,900 AGA bonus shares were outstanding.

Debt

Debt	12 Months Ended
	Dec. 31, 2020
Debt
Debt	Note 11. Debt As of December 31, (in thousands of euros) 2018 2019 2020 Bank borrowings 220 74 9,992 Other loans and similar borrowings (1) 5 3 62 Lease liabilities — 37 2 Total debt 225 114 10,055 (1) Consists of accrued interests During 2020 , debt mainly corresponds to three loans taken out from a syndicate of French banks, in the form of the loans guaranteed by the French State for a total amount of €10.0 million. These loans have been taken out in May 2020 and mature in May 2021. In accordance with the provisions put in place by the State in the context of the COVID-19 health crisis, the Company has the option to extend the maturity date for up to an additional four years. As of the date of these financial statements, the Company has notified the banks of its intention to extend the maturity until May 2022. To a lesser extent, this line item also includes the loan taken out from Société Générale in 2015 for a residual amount of €13 thousand. The €0.1 million decrease in 2019 is primarily attributable to: · at December 31, 2019, after repayment of borrowings due in 2019 in a total amount of €0.1 million, the debt relating to bank loans amounted to €0.1 million; and · partly offset by a lease liabilities amounting to €37 thousand which were recognized from January 1, 2019 following the applicable of new accounting standard IFRS 16 — Leases in an initial amount of €167 thousand (see Note 2.1, “Impact of the first‑time adoption of IFRS 16” of this document for more details). In 2019, €0.1 million in repayments were recorded. The breakdown between long‑term and short‑term debt is as follows: December 31, 2018 Less than Between Between More than (in thousands of euros) 1 year 1 and 3 years 3 and 5 years 5 years Bank borrowings 146 74 — — Other loans and similar borrowings 5 — — — Total long ‑ term debt 151 74 — — December 31, 2019 Less than Between Between More than (in thousands of euros) 1 year 1 and 3 years 3 and 5 years 5 years Bank borrowings 74 — — — Other loans and similar borrowings 3 — — — Lease liabilities 35 2 — — Total long ‑ term debt 112 2 — — December 31, 2020 Less than Between Between More than (in thousands of euros) 1 year 1 and 3 years 3 and 5 years 5 years Bank borrowings 13 9,979 — — Other loans and similar borrowings 3 59 — — Lease liabilities 2 — — — Total long ‑ term debt 18 10,037 — — The maturity of long-term debt and of short-term borrowings and debt is determined according to repayment estimates as at December 31, 2018, 2019 and 2020. Change in the period is mainly due to the subscription of a new borrowing in 2020, as follow: (in thousands of euros) January 1, 2018 482 Repayment of bank borrowings (259) Accrued interests 2 December 31, 2018 225 First application of IFRS 16 Leases (1) 167 January 1, 2019 392 Repayment of bank borrowings (146) Repayment of lease liabilities (130) Accrued interests (2) December 31, 2019 114 Subscription of bank borrowings 9,979 Repayment of bank borrowings (61) Repayment of lease liabilities (26) Early termination of lease contracts (2) (9) Capitalized interests 59 Accrued interests (0) December 31, 2020 10,055 (1) see Note 2.1, “Impact of the first‑time application of IFRS 16”. (2) Cancellation of the lease liabilities related to the early termination of the fibroscan lease contract in the first half 2020.

Provisions

Provisions	12 Months Ended
	Dec. 31, 2020
Provisions
Provisions	Note 12. Provisions (in thousands of euros) January 1, 2018 Additions Reversals December 31, 2018 CIR 2013-2015 477 — (119) 358 Long ‑ term provisions 477 — (119) 358 Payroll taxes 2016-2017 — 1,140 — 1,140 Short ‑ term provisions — 1,140 — 1,140 Total Provisions 477 1,140 (119) 1,498 January 1, December 31, (in thousands of euros) 2019 Additions Reversals 2019 CIR 2013-2015 358 — — 358 CIR 2017 — 216 — 216 Long ‑ term provisions 358 216 — 574 Payroll taxes 2016-2018 1,140 123 — 1,264 Short ‑ term provisions 1,140 123 — 1,264 Total Provisions 1,498 339 — 1,837 (in thousands of euros) January 1, 2020 Additions Reclassification December 31, 2020 CIR 2013-2015 358 1,139 — 1,497 CIR 2017 216 665 — 880 Long ‑ term provisions 574 1,804 — 2,377 Payroll taxes 2016-2018 1,264 90 (1,224) 130 Short ‑ term provisions 1,264 90 (1,224) 130 Total Provisions 1,837 1,894 (1,224) 2,507 Provisions booked at December 31, 2018, 2019 and 2020 are related to: - The CIR risk and payroll taxes risk related to the tax audit carried out by the French tax authority in 2016 in respect of the years ended December 31, 2013, 2014 and 2015 (long term for CIR risk and short term for payroll taxes risk), - The CIR risk for the year ended December 31, 2017 in connection with the partial reimbursement received in December 2019 (long term), and - A tax adjustment risk in respect of payroll taxes carried out in September 2019 with regard to the years ended December 31, 2016, 2017 and 2018 (short term). Payroll taxes Context Following the tax audit carried out in July 2016 in respect of the 2013, 2014 and 2015 fiscal years, the Company received a proposed tax adjustment for the three fiscal periods audited relating to the classification of the subsidy granted (subject to conditions) in 2012 by Laboratoire Fournier SA and Fournier Industrie et Santé (now part of the Abbott group) (LFSA and FIS) under the Asset Purchase Agreement ("APA"). A collection notice with respect to payroll taxes was received by Inventiva on August 17, 2018 for an amount of €1.9 million, including penalties and late payment interest. Under the terms and conditions of an additional agreement modifying the APA (the Additional Agreement), LFSA and FIS agreed to indemnify the Company up to a maximum amount of €2.0 million in accordance with the conditions described therein, for any amount claimed by the French tax authorities in relation to the tax treatment of the subsidy paid by LFSA and FIS between 2012 and 2017 (the “Abbott Guarantee”). Following the new tax audit carried out in 2019 and in respect with the payroll tax for the fiscal years 2016, 2017 and 2018, the Company received in December 2019 a proposal of rectification for a total amount of 1.7 million (penalties and late interest included). Year ended December 31, 2018 The Company lodged a claim together with an application for a suspension of payment on October 17, 2018 and, at December 31, 2018, continued to dispute the tax adjustment. Based on the ongoing discussions with the French tax authorities on the one hand and the terms of the Additional Agreement on the other, the Abbott Guarantee may not be sufficient to fully cover the total amount of the tax adjustment and the tax risk. Accordingly, at December 31, 2018: - following receipt of the collection notice and in accordance with the Additional Agreement, accrued expenses and accrued income were recognized in a total amount of €1.9 million for the financial years ended December 31, 2013, 2014 and 2015, which are the subject of the audit and are subject to the Abbott Guarantee (see Notes 6, “Other non‑current assets” and 14.2, “Other current liabilities”); and - the Company has recognized a provision of €1.1 million for the years ended December 31, 2016 and December 31, 2017 (which have not been audited by the French tax authorities at that date and for which the subsidies are still valid). This had no impact on the statements of income (loss) for the year ended December 31, 2018, as these amounts were already recognized at January 1, 2018 Year ended December 31, 2019 The application for suspension of payment lodged on October 17, 2018 was accepted on February 11, 2019 by the French tax authorities following the proposal by the Company to provide a surety in the form of a bank guarantee (see notes 1.2, “Significant events of 2020” and 22, “Commitments”). On September 2, 2019, an application instituting proceedings was filed before the Dijon Administrative Court ( Tribunal Administratif de Dijon). A proposed tax adjustment related to payroll taxes for fiscal years 2016, 2017 and 2018 was received in December 2019. It gave rise to an adjustment of €0.5 million (including penalties and late payment interest) for fiscal year 2018, which the Company was challenging under the ongoing contradictory procedure. Accordingly, at December 31, 2019: - The provision for fiscal years 2016 and 2017 has been increased to €1.3 million (from €1.1 million at December 31, 2018), with the change for the period corresponding to additional late payment interest. - No other provision has been booked for fiscal year 2018 following the proposed adjustment received in December 2019 as the Company assess probable the application of the administrative tolerance for its situation, the subsidy received under the APA having ended in August 2017. This had a €0.1 million impact on the statement of income (loss) for the year ended December 31, 2019. Year ended December 31,2020 In 2020, the Company continues to contest the Notice of Recovery (AMR) with regard to the payroll tax for fiscal years 2016, 2017 and 2018 for an amount of €1.3 million ((including penalties and late payment interest). On June 16, 2020, the Company received a response from the French tax authorities, granting it a concession with respect to the disputed payroll taxes for fiscal year 2018. On October 30, 2020, the Company received the Notice of Recovery (AMR) related to the payroll taxes for the taxable year 2016 and 2017 requesting the payment of €1.2 million (mark-up and delays interests as of December 31, 2019 included). A contentious claim with a request for a suspension of payment was sent by Inventiva on December 8, 2020. The tax authorities responded favorably to the request subject to the constitution of a guarantee in the amount of €1.0 million. On January 25, 2021, the Company received an unfavorable judgement from the Administrative court of Dijon, rejecting the Company’s request, filed on September 2, 2019, on the cancellation of the tax reassessment related to 2013, 2014 and 2015. Thus, as of December 31, 2020, considering the ongoing discussions with both the French tax authorities and Abbott (see Note 26, “Events after the reporting date”): - the €1.2 million provision related to payroll tax for fiscal years 2016 and 2017 is reclassified as an accrued liability, as the consequence of the Notice of Recovery reception (see also note 14.2, “Other current liabilities”). - the accrued expense and related accrued income recognized in 2018 for €2.0 million remained unchanged (see Notes 6, “Other non-current assets” and 14.2, “Other current liabilities”) The net impact on income for fiscal year 2020 amounts to a loss of €0.1 million and corresponds to late payment interest and additional penalties. As of December 31, 2020, only potential additional late interests for the period from the AMR receipt to the 2020 closing date remains as a provision, as these interests are not claimed to date by the tax authorities. CIR CIR for fiscal years 2013 to 2015 (covered by the tax audit) Following the tax audit, for fiscal years 2013 to 2015, on August 1, 2017, the Company received a proposed tax adjustment from the French tax authorities disputing the manner in which some CIR items were calculated over the three fiscal periods audited. Inventiva received a collection notice on August 17, 2018 for an amount of €1.9 million, including penalties and late payment interest. The Company disputed the notice and implementation of the collection procedure pending interlocutory proceedings via a claim lodged on August 29, 2018. This was accompanied by an application for a suspension of payment and an additional claim lodged with the French tax authorities on January 7, 2019. The Company has requested a complete discharge of the amounts claimed in respect of the CIR. At December 31, 2018, based on the ongoing discussions and the ongoing challenge procedures, the Company maintained its assessment of the maximum tax adjustment risk in respect of the CIR to €0.4 million covered by the provision, which was already recorded in the financial statements. As of December 31, 2019, the Company was still awaiting a decision about the ongoing challenge procedures with the French tax authorities, and no additional provision was recorded in 2019. On January 28, 2021, the Company received the mediator's response granting a relief from the tax reassessment of € 0.3 million corresponding to the part of the litigation relating to subcontracting considering that the operations of subcontracting carried out by the Company complied with the conditions set by recent decisions of the Council of State. As such, the Company reassessed the maximum tax adjustment risk related to the CIR to €1.5 million corresponding to the full amount challenged by the French tax authorities. As a consequence, an additional provision was recorded for € 1.1 million. CIR for fiscal year 2017 On 2019, the Company had received 81% of the 2017 CIR, in an amount of €3.6 million relative to the €4.5 million initially requested (see Note 1.2, “Significant events of 2020”). As of December 31, 2019, based on the ongoing discussions and the challenges lodged, the Company assessed the maximum risk in respect of the 2017 CIR at €0.2 million, fully recognized in the financial statements for the year ended December 31, 2019. The Company filed a hierarchical appeal with the Regional Directorate of Public Finances (DRFiP) for the immediate reimbursement of the 2017 CIR part related to sub-contracting expenses, which is still unpaid. As of December 31, 2020, based on the ongoing discussions and the challenges lodged, the Company reassessed the maximum risk in respect of the 2017 CIR at €0.9 million corresponding to the full amount withheld and recorded an additional provision of €0.7 million.

Provisions for Retirement Benef

Provisions for Retirement Benefit Obligations	12 Months Ended
	Dec. 31, 2020
Provisions for Retirement Benefit Obligations
Provisions for Retirement Benefit Obligations	Note 13. Provisions for Retirement Benefit Obligations Retirement benefit obligations are determined based on the rights set forth in the national collective bargaining agreement for the French pharmaceutical industry (IDCC 176/Brochure 3104) and in accordance with IAS 19 — Employee Benefits . These rights depend on the employee’s final salary and seniority within the Company at his/her retirement date. Principal actuarial assumptions The following assumptions were used to measure the obligation: As of December 31, Variables 2018 2019 2020 Retirement age 65 years 65 years 65 years Payroll taxes 41.41 % 41.41 % 41.41 % Salary growth rate 2 % 2 % 2 % Discount rate 1.60 % 0.70 % 0.35 % Mortality table TGH/TGF 05 TGH/TGF 05 TGH/TGF 05 The discount rate corresponds to the rates of Eurozone AA‑rated corporate bonds with maturities of over ten years. Net provision The provision recorded in respect of defined benefit schemes at the end of each reporting period is shown in the table below: As of December 31, (in thousands of euros) 2018 2019 2020 Retirement benefit obligations 1,029 1,127 1,385 Obligation 1,029 1,127 1,385 Given the absence of plan assets at December 31, 2018, 2019 and 2020, the total amount of the provision corresponds to the estimated obligation at those dates. Change in net provision The change in the provision recorded in respect of defined benefit schemes breaks down as follows: Year ended December 31, (in thousands of euros) 2018 2019 2020 Provision at beginning of period (866) (1,029) (1,127) Expense for the period (194) (1) (209) Actuarial gains or losses recognized in other comprehensive income 31 (96) (49) Provision at end of period (1,029) (1,127) (1,385) Breakdown of expense recognized for the period The expense recognized in the statement of income (loss) breaks down as follows: Year ended December 31, (in thousands of euros) 2018 2019 2020 Service cost for the period (192) (195) (202) Interest cost for the period (11) (16) (8) Plan curtailments and modifications — 157 — Benefits for the period 9 53 — Total (194) (1) (209) As of December 31, 2020, the expense related to the retirement benefit obligation increased in comparison to 2019, mainly due to the reversal of the provision related to the redundancy plan implemented in 2019 and the absence of benefits for the period in 2020. Breakdown of actuarial gains and losses recognized in comprehensive income The actuarial gains (losses) can be analyzed as follows: Year ended December 31, (in thousands of euros) 2018 2019 2020 Demographic changes (14) 32 14 Changes in actuarial assumptions 45 (129) (63) Total 31 (96) (49) Demographic differences mainly relate to salary adjustments and to the variations in the workforce. Changes in actuarial assumptions relate to movements in the discount rate (1.60% in 2018 to 0.70% in 2019 and to 0.35% in 2020). Sensitivity analysis A 0.25% change in the discount rate would have had an impact of approximately 3.40% on the obligation amount in 2020, 3.5% in 2019 and around 3.5% in 2018. In thousands December 31, 2018 of euros Benefit obligation at December 31, 2018 at 1.35% 1,067 Benefit obligation at December 31, 2018 at 1.60% 1,029 Benefit obligation at December 31, 2018 at 1.85 % 994 In thousands December 31, 2019 of euros Benefit obligation at December 31, 2019 at 0,45% 1,168 Benefit obligation at December 31, 2019 at 0,70% 1,127 Benefit obligation at December 31, 2019 at 0,95% 1,088 In thousands December 31, 2020 of euros Benefit obligation at December 31, 2020 at 0,10% 1,433 Benefit obligation at December 31, 2020 at 0,35% 1,385 Benefit obligation at December 31, 2020 at 0,60% 1,340

Trade Payables and Other Curren

Trade Payables and Other Current Liabilities	12 Months Ended
	Dec. 31, 2020
Trade Payables and Other Current Liabilities
Trade Payables and Other Current Liabilities	Note 14. Trade Payables and Other Current Liabilities As of December 31, (in thousands of euros) 2018 2019 2020 Trade payables 8,372 7,491 6,923 Other current liabilities 4,871 4,998 6,838 Trade payables and other current liabilities 13,243 12,489 13,761 No calculations have been made to discount trade payables and other current liabilities to present value as payment is due within one year of the end of the reporting period. 14.1. Trade payables break down by payment date as follows: As of December 31, (in thousands of euros) 2018 2019 2020 Due in 30 days 7,966 7,414 6,834 Due in 30 ‑ 60 days 406 77 89 Due in more than 60 days — — — Trade payables 8,372 7,491 6,923 14.2. As of December 31, (in thousands of euros) 2018 2019 2020 Employee ‑ related payables 1,095 1,124 Accrued payroll and other employee ‑ related taxes 1,052 1,041 Sales tax payables 574 668 Other accrued taxes and employee ‑ related expenses 172 177 Other miscellaneous payables 1,978 1,988 Other current liabilities 4,871 4,998 At December 31, 2020, other current liabilities mainly consist of “Other miscellaneous payables”, as well as “Employee-related payables” and “Accrued payroll and other employee-related taxes”. Other miscellaneous payables mainly correspond to: · an accrued expense for an amount of €1.9 million to the French tax authorities recognized in 2018 following receipt of the collection notice with respect to payroll taxes (see Notes 6, "Other non-current assets", 8.2, "Other current assets" and 12, "Provisions"); and, · An accrued expense for an amount of €1.2 million (mark-up and delays interests at December 31, 2019 included) following receipt of the Notice of Recovery, on October 30, 2020, relating to the payroll tax for the taxable years 2016 and 2017 (refer to Note 12, “Provisions”) making the liability certain and, consequently required its reclassification from provision to current liabilities. Accrued payroll and other employee-related taxes mainly relate to payables to social security and employee-benefit organizations such as URSSAF, KLESIA and APGIS for the last quarter of the year. Other accrued taxes and employee-related expenses concern provisions for payroll taxes, such as professional training charges, apprenticeship tax and the employer’s contribution to construction investment in France.

Contract Liabilities

Contract Liabilities	12 Months Ended
	Dec. 31, 2020
Contract Liabilities
Contract Liabilities	Note 15. Contract Liabilities At December 31, 2020, the Company did not provide any services in connection with existing or new contracts with customers. Therefore, the Company did not record any contract assets or liabilities. At December 31, 2019, as all of the services required of the Company in respect of contracts signed with clients had been completed, all liabilities on contracts were reversed in full for the period. Since the Company upheld all its commitments under the collaboration with Boehringer Ingelheim, all the amounts recorded as “contract liabilities” at December 31, 2018, under IFRS 15 — Revenue from Contracts with Customers were reversed over the period, generating a positive impact of €2.1 million on IFRS revenue for fiscal year 2019. December 31, 2018 Enyo (in thousands of euros) BI AbbVie Parma Total Short ‑ term contract liabilities 436 15 97 548 Long ‑ term contract liabilities 1,673 — — 1,673 Total contract liabilities 2,109 15 97 2,221 Revenue to be recognized (1) 7,718 100 97 7,915 (1) The revenue to be recognized corresponds to the remaining highly probable revenue to be recognized on the existing contracts until their completion. Milestones and royalties that are not assessed highly probable are not included. At December 31, 2018, contract liabilities related to the BI Agreement resulted mainly from the exercise of the option in August 2017 which triggered a milestone payment of €2.5 million. This amount was included in transaction price of the BI Agreement, resulting in an upward revision of the contract price. Based on the stage of completion of the BI Agreement, a total amount of €0.7 million of this milestone payment was recognized in revenue, of which €0.2 million in 2018, and the €1.8 million difference was booked to contract liabilities. The remaining contract liabilities related to the BI Agreement (€0.3 million), the agreement with EnyoPharma (€0.1 million) and the AbbVie Collaboration (€15 thousand) corresponded to the difference between payment received and revenue recognized related to the research fees.

Financial Assets and Liabilitie

Financial Assets and Liabilities	12 Months Ended
	Dec. 31, 2020
Financial Assets and Liabilities
Financial Assets and Liabilities	Note 16. Financial Assets and Liabilities At December 31, 2018 Financial Book value assets on the Financial carried at Liabilities statement assets carried fair value carried at of financial at amortized through amortized (in thousands of euros) position cost profit or loss cost Fair value Financial assets Long ‑ term deposit accounts and security deposits 108 108 — — 108 Accrued income 1,932 1,932 — — 1,932 Trade receivables 6 6 — — 6 Other receivables 874 874 — — 874 Cash and cash equivalents 56,692 56,692 — — 56,692 Total assets 59,612 59,612 — — 59,612 Financial liabilities Long ‑ term debt 74 — — 74 74 Short ‑ term debt 151 — — 151 151 Trade payables 8,372 — — 8,372 8,372 Other miscellaneous payables 1,978 — — 1,978 1,978 Total liabilities 10,575 — — 10,575 10,575 At December 31, 2019 Financial Book value assets on the Financial carried at Liabilities statement assets carried fair value carried at of financial at amortized through amortized (in thousands of euros) position cost profit or loss cost Fair value Financial assets Long-term deposit accounts 792 792 — — 792 Long-term security deposits 8 8 — — 8 Accrued income 2,000 2,000 2,000 Trade receivables 4 4 — — 4 Other receivables 900 — — — 900 Cash and cash equivalents 35,840 35,840 — — 35,840 Total assets 39,545 39,545 — — 39,545 Financial liabilities Long-term debt (1) 2 — — 2 2 Short-term debt (1) 113 — — 113 113 Trade payables 7,491 — — 7,491 7,491 Other miscellaneous payables 1,988 — — 1,988 1,988 Total liabilities 9,594 — — 9,594 9,594 (1) including lease liabilities relating to leased assets falling into the scope of IFRS 16 are included in debt as of December 31, 2019 (see Notes 2.1, "Impact of the first-time application of IFRS 16" and 11, "Debt"). At December 31, 2020 Financial Book value assets on the Financial carried at Liabilities statement assets carried fair value carried at of financial at amortized through amortized (in thousands of euros) position cost profit or loss cost Fair value Financial assets Long ‑ term deposit accounts 1,698 1,698 — — 1,698 Long-term security deposits 8 8 — — 8 Current accrued income 2,000 2,000 — — 2,000 Short ‑ term deposit accounts 7,336 7,336 — — 7,336 Trade receivables 48 48 — — 48 Other receivables 1,849 1,849 — — 1,849 Foreign currency forwards 1,791 — 1,791 — 1,791 Cash and cash equivalents 105,687 105,687 — — 105,687 Total assets 120,417 118,626 1,791 — 120,417 Financial liabilities Long ‑ term debt 10,037 — — 10,037 10,037 Short ‑ term debt (1) 18 — — 18 18 Trade payables 6,923 — — 6,923 6,923 Other miscellaneous payables 3,198 — — 3,198 3,198 Total liabilities 20,177 — — 20,177 20,177 (1) including lease liabilities relating to leased assets falling into the scope of IFRS 16 are included in debt as of December 31, 2020 (see Notes 2.1, "Impact of the first-time application of IFRS 16" and 11 "Debt")

Revenues and Other Income

Revenues and Other Income	12 Months Ended
	Dec. 31, 2020
Revenues and Other Income
Revenues and Other Income	Note 17. Revenues and Other Income Year ended December 31, (in thousands of euros) 2018 2019 2020 Sales 3,197 6,998 372 Total revenues 3,197 6,998 372 CIR 4,166 4,293 4,791 Subsidies 16 — — Other — 100 Total other income 4,182 4,293 4,891 Total revenues and other income 7,379 11,291 5,263 Revenues In 2020, revenue amounted to €0.4 million. The decrease in revenue compared to 2019 is mainly explained by (i) no milestone payment triggered according to the collaboration agreement with AbbVie and (ii) the termination of the collaboration agreement with BI in the fourth quarter of 2019. In 2019, revenue amounted to €7.0 million and primarily included: · the €3.5 million milestone payment from AbbVie received in December 2019 following the enrollment of the first patient with psoriasis in the ongoing clinical trial of ABBV-157; · the reversal of all contract liabilities recognized at December 31, 2018 following the termination of all contracts with BI. The reversal amounted to €2.2 million, including €2.1 million following termination of the BI Collaboration in the fourth quarter of 2019 (see Notes 15, “Contract liabilities”). In 2019, revenue from research partnerships with Abbvie and BI represented 51.4% and 36.9% of the Company's revenue, respectively. In 2018, revenue was primarily composed of fees received from AbbVie, BI and, to a lesser extent, other parties in return for research services rendered by the Company, no milestone payment having been received in 2018. In 2018, revenue was primarily composed of fees received from AbbVie, BI and, to a lesser extent, other parties in return for research services rendered by the Company, no milestone payment having been received in 2018. CIR In 2018, 2019 and 2020, the CIR corresponds only to the amount of research tax credit recorded for each period: €4.1 million for 2018, €4.3 million for 2019 and €4.8 million for 2020.

Operating expenses (Other opera

Operating expenses (Other operating income (expenses) excluded)	12 Months Ended
	Dec. 31, 2020
Operating expenses (Other operating income (expenses) excluded)
Operating expenses (Other operating income (expenses) excluded)	Note 18. Operating expenses (Other operating income (expenses) excluded) Research and Marketing — business General and December 31, 2018 development development administrative (in thousands of euros) expenses expenses expenses Total Disposables (2,210) — — (2,210) Energy and liquids (504) — — (504) Patents (401) — — (401) Studies (17,351) — — (17,351) Maintenance (934) — — (934) Fees (98) (1,431) (1,530) IT systems (766) (9) (49) (824) Support costs (including taxes) — — (584) (584) Personnel costs (7,625) (182) (2,266) (10,072) Depreciation, amortization and provisions (890) — (179) (1,069) Other (978) (34) (1,536) (2,549) Total operating expenses (31,758) (225) (6,045) (38,028) Research and Marketing — business General and December 31, 2019 development development administrative (in thousands of euros) expenses expenses expenses Total Disposables (1,560) — — (1,560) Energy and liquids (505) — — (505) Patents (506) — — (506) Studies (19,353) — — (19,353) Maintenance (933) — — (933) Fees (239) — (987) (1,226) IT systems (793) (8) (46) (847) Support costs (including taxes) (568) (568) Personnel costs (8,076) (202) (2,703) (10,981) Depreciation, amortization and provisions (1,060) — (396) (1,456) Other (765) (40) (1,387) (2,192) Total operating expenses (33,790) (250) (6,087) (40,127) Research and Marketing — business General and December 31, 2020 development development administrative (in thousands of euros) expenses expenses expenses Total Disposables (1,243) — — (1,243) Energy and liquids (539) — — (539) Patents (343) — — (343) Studies (10,987) — — (10,987) Maintenance (846) — — (846) Fees (201) (341) (2,005) (2,548) IT systems (597) (8) (46) (651) Support costs (including taxes) — — (722) (722) Personnel costs (7,518) (197) (2,964) (10,680) Depreciation, amortization and provisions (832) — (177) (1,009) Other (608) (16) (2,585) (3,209) Total operating expenses (23,717) (563) (8,499) (32,779) 18.1. Research and Marketing — business General and December 31, 2018 development development administrative (in thousands of euros) expenses expenses expenses Total Wages, salaries and similar costs (5,085) (178) (1,349) (6,613) Payroll taxes (1,981) (3) (576) (2,560) CICE tax credit 103 — 20 124 Provisions for retirement benefit obligations (145) — (45) (190) Share ‑ based compensation expense (516) (1) (316) (833) Total personnel costs (7,625) (182) (2,266) (10,072) Research and Marketing — business General and December 31, 2019 development development administrative (in thousands of euros) expenses expenses expenses Total Wages, salaries and similar costs (4,908) (178) (1,491) (6,577) Payroll taxes (2,206) (1) (634) (2,841) Provisions for retirement benefit obligations (95) — (61) (156) Share ‑ based compensation expense (868) (22) (517) (1,407) Total personnel costs (8,076) (202) (2,703) (10,981) Research and Marketing — business General and December 31, 2020 development development administrative (in thousands of euros) expenses expenses expenses Total Wages, salaries and similar costs (4,590) (183) (1,669) (6,442) Payroll taxes (2,180) 8 (926) (3,098) Provisions for retirement benefit obligations (141) — (60) (202) Share-based compensation expense (607) (22) (309) (938) Total personnel costs (7,518) (197) (2,964) (10,680) The Company had 94 employees at December 31, 2020 compared with 88 employees at December 31, 2019 and 113 employees at December 31, 2018.

Other Operating Income (expense

Other Operating Income (expenses)	12 Months Ended
	Dec. 31, 2020
Other Operating Income (expenses)
Other Operating Income (expenses)	Note 19. Other Operating Income (expenses) Other operating income (expenses) break down as follows: Year ended December 31, (in thousands of euros) 2018 2019 2020 Corrective claims - CIR — — 2,863 Accrued income from Abbott — payroll taxes — 68 — Reversal of restructuring expenses — — 43 Total other operating income — 68 2,905 Provision for risk on payroll taxes — (123) (90) Restructuring expenses — (1,096) — Impairment of tax loss carry back — — (333) CIR provision — — (1,804) IPO costs and follow ‑ on offering (2,221) (323) (2,881) Write ‑ down of inventory (33) — — Total other operating expenses (2,255) (1,541) (5,108) Other operating income (expenses) (2,255) (1,475) (2,202) During 2020, other operating income are mainly composed of corrective claims for additional reimbursements of CIR with regard to the years from 2017 to 2019 for a total amount of €2.9 million, requested following the recent decision of the Council of State in July 2020 on the eligibility of subcontracting expenses. These corrective claims are presented in other operating income, as they resulted from a non-recurring event which is independent from the current activity of the Company. The other operating expenses are mainly composed of: (i) additional provisions with regard to tax risk on CIR (See Note 12,” Provisions”) - an additional provision in the amount of €0.7 million related to the reassessment of the risk on the CIR for 2017 corresponding to the amount contested by the tax authorities at the date of these financial statements, i.e. €0.9 million; - an additional provision in the amount of €1.1 million related to the reassessment of the risk on the CIR for the periods from 2013 to 2015 from €0.4 million to €1.5 million. (ii) Significant events of 2020 ” and 10.1, “ Share capital ”); (iii) Other Non-Current Assets” and 12. “ Provisions” ) During 2019, other operating income and expenses were mainly due to the Approval and implementation of a redundancy plan in the second half of 2019 following the termination of the systemic sclerosis (SSc) program in February 2019. The Company recorded an expense in a total amount of €1.1 million representing the costs incurred by Inventiva over the period. All costs were incurred in 2019.

Financial Income and Expenses

Financial Income and Expenses	12 Months Ended
	Dec. 31, 2020
Financial Income and Expenses
Financial Income and Expenses	Note 20. Financial Income and Expenses Year ended December 31, (in thousands of euros) 2018 2019 2020 Income from cash and cash equivalents 120 157 226 Foreign exchange gains 21 18 40 Fair value variation gains / losses — — 1,791 Total financial income 142 175 2,057 Interest cost (4) (3) (66) Losses on cash and cash equivalents (202) — — Foreign exchange losses (36) (62) (5,884) Other financial expenses (11) (16) (8) Interests costs on discounted liabilities — — (8) Total financial expenses (253) (81) (5,959) Net financial income (loss) (111) 93 (3,902) As of December 31, 2020, financial income mainly relates to the change in the fair value of foreign currency forwards. Foreign exchange losses are mainly due to bank accounts denominated in U.S. dollars for an amount of €2.7 million and short-term deposit accounts in U.S. dollars for an amount of €2.8 million, and are explained by the depreciation of the dollar against the euro since the IPO on the Nasdaq Global Market.

Income Tax

Income Tax	12 Months Ended
	Dec. 31, 2020
Income Tax
Income Tax	Note 21. Income Tax The income tax rate applicable to the Company is the French corporate income tax rate of 31%. Year ended December 31, (in thousands of euros) 2018 2019 2020 Loss before tax (33,014) (30,218) (33,619) Theoretical tax rate 33.33 % 31 % 31 % Tax benefit at theoretical rate 11,004 9,368 10,422 Tax credits 1,435 1,330 2,373 Permanent differences 827 (21) 1,816 Other differences (269) (404) (522) Non recognition of deferred tax assets related to tax losses and temporary differences (12,997) (10,272) (14,089) Actual income tax benefit — — — of which Current taxes — — — Deferred taxes — — — Effective tax rate — — — Tax credits mainly include the CIR, non‑taxable income, classified in other operating income (see Note 17, “Revenues and other income”). The Company faced a tax loss in the years ended December 31, 2020 and 2019. As the recoverability of these tax losses is not considered probable in subsequent periods due to the uncertainties inherent in the Company’s business, no deferred tax assets were recognized in the financial statements as of December 31, 2020 nor as of December 31, 2019 and 2018.

Commitments

Commitments	12 Months Ended
	Dec. 31, 2020
Commitments
Commitments	Note 22. Commitments 22.1 Commitments related to operational activities Commitments given - financial instruments pledged as collateral At December 31, 2020, two pledges over cash, for a total amount of €1.7 million were in place: - one pledge over cash of €0.7 million was granted by the Company on February 1, 2019, equivalent to 50% of the sum not covered by the indemnity to be received from the Abbott group under the Additional Agreement, and - in accordance with the initial undertaking, an additional pledge over cash of €1.0 million was granted by the Company on June 30, 2020, as the dispute to which the guarantee pertains remains unresolved. The pledges were granted as part of the surety provided by the Company to the French tax authorities in connection with its tax disputes, in the form of a €3.4 million bank guarantee from Crédit Agricole (see Note 12, "Provisions " ). Commitments received - Agreements concerning the provision of facilities · Agreement with Novolyze On October 13, 2015, the Company signed a contract to make its premises and facilities available to Novolyze for a 36‑month period beginning October 19, 2015. Pursuant to an amendment signed on October 19, 2016, the monthly rent was increased to €5 thousand as from November 1, 2017, with an annual rate of increase of 2%. Therefore, at December 31, 2020, the total commitment received amounted to €72 thousand and commitments relating to future payments amounted to €58 thousand. · Agreement with Genoway On November 4, 2015, the Company signed a contract to make its premises and facilities available to Genoway for a three‑year period beginning December 1, 2015. On July 1, 2017, the contract was amended and extended through June 30, 2019 and then renewable by tacit agreement for a period of three years, putting the next expiry date at June 30, 2022. The contract is no longer renewable for the period 2022 and will expire in March 2021 according to the Company's estimate. The monthly rent was increased to €15 thousand as from December 1, 2017. Therefore, at December 31, 2020, the total commitment received amounted to €185 thousand and commitments relating to future payments amounted to €46 thousand. · Agreement with Synthecob On March 21, 2016, the Company signed a contract to make its research equipment and services available to the company Synthecob for a two‑year period beginning April 1, 2016. Pursuant to an amendment signed on January 1, 2017, the monthly rent was increased to €2.4 thousand until March 30, 2018 and then to €2.5 thousand. It was increased again to €2.7 thousand as from September 1, 2018. Therefore, at December 31, 2020, the total commitment received amounted to €33 thousand and commitments relating to future payments amounted to €42 thousand. 22. 2 Commitments related to financing activities At December 31, 2020, the Company completed three future currency contracts for a total amount of USD 60 million to protect its activity against exchange rate fluctuations between the euro and the dollar. As of December 31, 2020, the change in fair value of the three forward currency contracts amounting to €1.8 million and was recognized in other current assets on the balance sheet and through profit and loss as a counterparty. Their main characteristics are presented below: in thousands of euros Start date Date of maturity Counterpart Currency Amount Commitments given Forward in U.S. dollars payable 09/03/2020 05/14/2021 Société Générale USD 20,000,000 Forward in U.S. dollars payable 09/08/2020 05/14/2021 Société Générale USD 20,000,000 Forward in U.S. dollars payable 10/30/2020 05/14//2021 Crédit Agricole USD 20,000,000 Commitments received Forward in euros to be received 09/03/2020 05/14/2021 Société Générale EUR 16,794,021 Forward in euros to be received 09/08/2020 05/14/2021 Société Générale EUR 16,794,021 Forward in euros to be received 10/30/2020 05/14//2021 Crédit Agricole EUR 17,001,020

Related-Party Transactions

Related-Party Transactions	12 Months Ended
	Dec. 31, 2020
Related-Party Transactions
Related-Party Transactions	Note 23. Related‑Party Transactions The table below sets out the compensation awarded to the members of the executive team (including the executive and corporate officers) that was recognized in expenses for the years ended December 31, 2018, 2019 and 2020. Year ended December 31, (in thousands of euros) 2018 2019 2020 Wages and salaries 944 1,113 1,369 Benefits in kind 46 47 42 Pension plan expenses 41 66 77 Share ‑ based compensation expense 354 280 259 Attendance fees 200 206 258 Net total 1,585 1,712 2,005 ISLS Consulting, whose Chairman Jean‑Louis Junien was a Company director until May 27, 2019, received €169 thousand, compared to €162 thousand in 2018 within the scope of a consulting service contract. Additionally, on December 14, 2018, the Company’s Board of Directors granted 80,000 share warrants to ISLS Consulting.

Basic and Diluted Loss Per Shar

Basic and Diluted Loss Per Share	12 Months Ended
	Dec. 31, 2020
Basic and Diluted Loss Per Share
Basic and Diluted Loss Per Share	Note 24. Basic and Diluted Loss Per Share Basic earnings (loss) per share are calculated by dividing net income (loss) attributable to owners of the Company by the weighted average number of ordinary shares outstanding during the period. Year ended December 31, (in thousands of euros) 2018 2019 2020 Net loss for the period (33,014) (30,218) (33,619) Weighted average number of outstanding shares used for computing basic/diluted loss per share 20,540,979 23,519,897 33,874,751 Basic/diluted loss per share (in €) (1.61) (1.28) (0.99) As the Company recorded a loss in 2018,2019 and 2020, diluted earnings (loss) per share are identical to basic earnings (loss) per share. Share‑based payment plans (BSAs, BSPCEs and AGAs) are not included as their effects would be anti‑dilutive.

Financial Risk Management

Financial Risk Management	12 Months Ended
	Dec. 31, 2020
Financial Risk Management
Financial Risk Management	Note 25. Financial Risk Management Through its business activities, the Company is exposed to various types of financial risk: foreign exchange risk, credit risk and liquidity risk. Foreign exchange risk On July 15, 2020, the Company closed its initial public offering on the Nasdaq Global Market for aggregate gross proceeds of $107.7 million. The Company decided not to convert the cash obtained through the capital increase into euros, as some of that cash will be used to cover expenses denominated in U.S. dollars over the coming years. Nevertheless, the Company incurs the majority of its expenses in euros and some of its USD cash resources may therefore have to be converted into euros in order to meet its business needs, thereby exposing the Company to foreign exchange risk. At December 31, 2020, some of the U.S. dollar cash resources have been placed in short-term deposit accounts with maturities of less than six months ($9 million). In addition, the Company has taken the appropriate steps to ensure that hedging instruments can be put in place at any time to protect its activities against exchange rate fluctuations, whenever it deems necessary and in accordance with its investment policy. At December 31, 2020, the Company completed three foreign currency forward contracts for a total amount of $60 million. Unfavorable exchange rate fluctuations between the euro and the U.S. dollar, which are difficult to forecast, could affect the Company’s financial position. Foreign currency forwards correspond to the change in fair value of the two contracts that have been entered into by the Company to protect against fluctuations in the exchange rate between the euro and the dollar up to $60 million. Forward currency forwards are recognized as a derivative financial instrument not qualified as a hedge within the meaning of IFRS 9. They are initially recorded on the balance sheet at fair value and upon subsequent recognition, the derivatives are measured at fair value and the resulting variations are recognized in financial income (refer to Note 22 “ Commitments ”). The table below shows, at December 31, 2020, the sensitivity analysis of the Company's assets dominated in U.S. Dollar under the reasonable assumption of a variation of 5% based on the exchange rate at the closing date, to which the Company is exposed: Impact of a 5% Fair Value as of change in (in thousands of euros) December 31, 2020 fair value Cash and cash equivalents dominated in U.S. Dollar 72,429 (3,449) Short-term deposit accounts dominated in U.S. Dollar 7,336 (349) Credit risk Credit risk arises from cash and cash equivalents and deposits with banks and financial institutions, as well as from client exposures. The Company’s exposure to credit risk chiefly relates to trade receivables. The Company has put in place a system to monitor its receivables and their payment and clearance. Generally, the Company is not exposed to a concentration of credit risk given the outstanding trade receivables balance at each reporting date. Liquidity risk Liquidity risk management aims to ensure that the Company disposes of sufficient liquidity and financial resources to be able to meet present and future obligations until the fourth quarter of 2022. The Company prepares short‑term cash forecasts and annual operating cash flow forecasts as part of its budget procedures. Prudent liquidity risk management involves maintaining sufficient liquidity, having access to financial resources through appropriate credit facilities and being able to unwind market positions. The Company’s operations have consumed substantial amounts of cash since inception. Developing pharmaceutical product candidates, including conducting clinical trials, is expensive, lengthy and risky, and the Company expects its research and development expenses to increase substantially in connection with its ongoing activities. Accordingly, the Company will continue to require substantial additional capital to continue its clinical development activities and potentially engage in commercialization activities.

Events After the Reporting Date

Events After the Reporting Date	12 Months Ended
	Dec. 31, 2020
Events After the Reporting Date
Events After the Reporting Date	Note 26. Events After the Reporting Date Guarantee given to the tax authorities On January 6, 2021 following the request for a stay of payment of the payroll tax for fiscal years 2016 and 2017, the Company proposed a guarantee to the tax authorities, in the form of a bank guarantee from Crédit Agricole, in the amount of €1.0 million. At the date of approval of these financial statements, the Company is awaiting the response from the French tax authorities. Tax audit for payroll taxes for fiscal years 2013 to 2015 On January 25, 2021 the Administrative Court of Dijon informed the Company of the dismissal of the contentious claim regarding the amounts claimed for the fiscal years 2013, 2014 and 2015. Abbott leads the defense strategy under the existing agreements. Furthermore, at the date of approval of these financial statements, Abbott has decided not to conduct the appeal procedure with the Administrative Court of Lyon (Tribunal Administratif de Lyon). The Company has two months to conduct the appeal process itself. On February 10, 2021 the Company requested the payment from Abbott of the €2.0 million corresponding to the maximum amount covered by the indemnity under the Additional Agreement. The Company expects to receive this payment by the end of the first semester of 2021. On February 11, 2021, the Company received formal notice to pay the amounts due to the French tax authorities under the AMR issued on August 17, 2018 for an amount of €1.9 million. Provisions for litigation are presented in Note 12. “ Provisions ” of these financial statements. Impairment of tax loss carry back On December 15, 2020, the Company received a tax audit adjustment proposal rejecting 2017 deficits carry-back receivable booked by the Company arguing that the corporate tax due for 2016 was paid by tax reduction and tax credit. At the date of approval of these financial statements, the Company does not intend to engage additional procedures and has accepted the reassessment. As such, the Company impaired the entire tax loss carry back receivable by €0.3 million. As a consequence, the total balance of tax loss carryforwards that the Company may use in the future has been increased. Provisions for litigation are presented in Note 12. “ Provisions ” of these financial statements. Tax audit for CIR On January 7, 2020, the Company initiated mediation on Research Tax Credits 2013 to 2015 reassessment and received the mediator's response, on January 28, 2021, granting a relief from the tax reassessment of € 0.3 million corresponding to the part of the litigation relating to subcontracting considering that the operations of subcontracting carried out by the Company complied with the conditions set by recent decisions of the Council of State. As such, the initial provision has been reassessed from €0.4 million to €1.5 million as of December 31, 2020. Provisions for litigation are presented in Note 12. “ Provisions ” of these financial statements. Creation of Inventiva U.S. subsidiary, Inventiva Inc. Inventiva Inc. was incorporated in the state of New Jersey on January 5, 2021. Inventiva owns 100% of the stock of its U.S. affiliate. Inventiva Inc. will act as service provider for its parent company in the United States, including in connection with the Phase III clinical trial for lanifibranor, which is planned for the first half of 2021. The affiliate will start its operations at the end of the first quarter with the recruitment of its first employees and in particular the CMO. This affiliate will be consolidated starting first quarter 2021.

Accounting Principles (Policies

Accounting Principles (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Principles
Intangible assets	3.1. In accordance with IAS 38 — Intangible Assets , research costs are recognized in the statement of income (loss) in the period during which they are incurred. An internally generated intangible asset arising from a research program is recognized if, and only if, the Company can demonstrate all of the following: · The technical feasibility necessary to complete the research program. · Its intention to complete the intangible asset and use or sell it. · Its ability to use or sell the intangible asset. · How the intangible asset will generate probable future economic benefits. · The availability of adequate technical, financial and other resources to complete the research program. · The ability to measure reliably the expenditure attributable to the intangible asset during its development. Given the risks and uncertainties involved in regulatory approval and in the process of research and development, the Company considers that the six criteria set out in IAS 38 are met only upon obtaining market authorization for a product candidate. Consequently, all development costs are charged directly to expenses. Intangible assets comprise: · The cost of acquiring software licenses, which are written down over a period of between one and five years based on their expected useful life. The library of compounds acquired pursuant the APA together with additional chemical components, which are written down over a 13‑year period corresponding to their estimated useful lives.
Property, plant and equipment	3.2. Property, plant and equipment are stated at cost. Depreciation and amortization are calculated based on the estimated useful life of assets using the straight‑line method. A complete review of the useful lives of acquired non‑current assets is performed on an annual basis. Any material adjustments are reflected prospectively in the depreciation schedule. The principal useful lives applied are as follows: · Buildings: 20 to 25 years · Fixtures and fittings: 10 years · Technical facilities: 6 to 10 years · Equipment and tooling: 6 to 10 years · General facilities, miscellaneous fixtures and fittings: 10 years · Office equipment: 5 years · IT equipment: 5 years · Furniture: 10 years
Lease contracts	3.3.Lease contracts Lease contracts are recognized in accordance with the standard IFRS 16 - Leases as follows : · an asset, representing its right to use the leased asset during the lease term (right‑of‑use asset); · a liability, representing the value of the outstanding lease payments (lease liability). For each asset, the discount rate used to calculate the lease liability is determined based on the incremental borrowing rate at the date of signature of the lease. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right‑of‑use asset in a similar economic environment. Exemptions The Company has not restated its other leases because they are covered by the exemptions permitted under the standard (short‑time leases and low‑value leases). They include: · leases that expire within 12 months of the date of first‑time adoption (January 1, 2019); · 12‑month leases with automatic renewal, where it is not reasonably certain at the date of first‑time application that the leases will be renewed; and · leases for which the underlying asset is less than €5,000. Rental expenses for short‑term and low‑value leases continue to be recognized in operating expenses in the Company’s statement of income (loss).
Other non-current assets	3.4. Other non‑current assets include: - long‑term deposit accounts that do not qualify as cash equivalents within the meaning of IAS 7 — Statement of Cash Flows and whose maturity is more than one year on the present closing date; - Security deposits - Accrued income with a maturity greater than one year on the present closing date
Impairment of non-financial assets	3.5. IAS 36 — Impairment of Assets requires that depreciated and amortized assets be tested for impairment whenever specific events or circumstances indicate that their carrying amount may exceed their recoverable amount. The excess of the carrying amount of the asset over the recoverable amount is recognized as an impairment. The recoverable amount of an asset is the higher of its value in use and its fair value less costs to sell. Impaired non‑financial assets are examined at each year‑end or half‑year closing date for a possible impairment reversal.
Inventories	3.6. In accordance with IAS 2 — Inventories , inventories are measured at the lower of cost (determined using the weighted average cost method) and net realizable value. In case of impairment, any write‑down is recognized as an expense in other operating income (loss).
Trade receivables	3.7. Trade receivables are measured at nominal value, which generally equate with the fair value of the consideration to be received, net of impairment. The Company recognizes loss allowances for expected credit losses ("ECL"), which, for trade receivables and contract assets, are measured at an amount equal to lifetime ECLs that result from all possible default events over their expected life. Loss allowances are deducted from the gross amounts of the assets.
Other current assets	3.8. Currency term accounts are classified as other current assets, their main characteristics don't meet the definition of "Cash equivalents" within the meaning of IAS 7.
Derivatives	3.9. Derivatives The Company uses derivative financial instruments to hedge its exposure to exchange rate risks (Currency forward sales). The Company has not opted for hedge accounting in accordance with IFRS 9. Derivatives are measured at their fair value in the statement of financial position. The change in fair value of derivative instruments is accounted as an offsetting entry in the financial income (loss) in the statement of income (loss). The fair values of derivatives are estimated on the basis of commonly used valuation models considering data from active markets. The net gains and losses of instruments at fair value through the statement of income (loss) correspond to the flows exchanged and the change in value of the instrument.
Cash and cash equivalents	3.10. Cash and cash equivalents include cash on hand and demand deposits, as well as other short‑term highly liquid investments with maturities of three months or less , convertible at a known amount,and subject to an insignificant risk of changes in value. Monetary Undertakings for Collective Investments in Transferable Securities (UCITS) may be recognized as cash equivalents when they: · have an original maturity of three months or less; · are readily convertible to a known cash amount; and · are subject to an insignificant risk of decrease in value. Bank overdrafts are recorded in liabilities in the statement of financial position under short‑term debt.
Share capital	3.11. Share capital Ordinary shares are classified in shareholders’ equity. Transaction costs Costs directly attributable to the issue of ordinary shares or share options are recognized as a reduction in the share premium. Costs related to multiple operations (Initial public offering and capital increase) are distinctly recorded. Concerning the IPO, the part related to the new shares is recognized in deduction of the premiums related to share capital and the part related to existing shares in expenses as transaction costs.
Share-based payments	3.12. At the Company’s inception, the Company put in place a compensation plan settled in equity instruments in the form of share warrants awarded to employees ( Bons de souscription de parts de créateur d’entreprise , BSPCE or BSPCE share warrants) and to a non‑employee ( Bons de souscription d’actions , BSA or BSA share warrants), and bonus share award to employees ( Attribution gratuite d’actions , AGA or AGA bonus share award). In accordance with IFRS 2 — Share‑based Payment , the cost of transactions settled in equity instruments is recognized in expenses, offset by increases in equity, in the period in which the benefit is granted to the employee or non‑employee. Before the admission of the Company on the Euronext listing, the value of the share warrants has been determined with the assistance of an independent expert using a combination of the following valuation methods: · The market approach which indicates the value of a business by comparing it to companies whose market price is available and/or recent market transactions involving comparable companies or assets. · The income approach which indicates the value of a business by discounting the expected future cash flows of the business to present value. This approach necessitates the use of the discounted cash flow method. Since the Company is a listed company on Euronext, the value of the share warrants has been determined with the assistance of an independent expert using the Black & Scholes model based on the value of the underlying asset at grant date (stock price), the volatility observed in a sample of comparable listed companies and the economic life of the related share warrant. No new plan has been issued by the Company since its listing on the Nasdaq Global Market. The measurement of the fair value of options incorporates the vesting conditions as described in Notes 1.2. “Significant events”, 10.3 “Share award plans” and 10.4 “Bonus share award plans”. In 2020, two BSA share warrant plans were allocated to some service providers of the Company. Details of these plans are provided in Note 10, "Shareholders' equity".
Loans and borrowings	3.13. Bank loans are initially recognized at fair value, i.e., the issue proceeds (fair value of the consideration received) net of transaction costs incurred. Borrowings are subsequently measured at amortized cost, calculated using the effective interest rate method. Any difference between initial fair value and repayment value is recognized in the statement of income (loss) over the life of the loan using the effective interest rate method. The effective interest rate is the discount rate at which the present value of all future cash flows (including transaction costs) over the expected life of the loan, or where appropriate, over a shorter period of time, is equal to the loan’s initial carrying amount.
Trade payables and other current liabilities	3.14. Trade payables and other current liabilities are initially recognized at fair value and subsequently measured at amortized cost, calculated using the effective interest rate method. Given the due date, the amortized cost is equal to the initial fair value.
Current and deferred tax	3.15. Tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to the French tax authorities, using tax rates and tax laws enacted or substantively enacted at the end of the reporting period. The income tax charge for the period comprises current tax due and the deferred tax charge. The tax expense is recognized in the statement of income (loss) unless it relates to items recorded in other comprehensive income and expense or directly in equity, in which case the tax is also recorded in other comprehensive income and expense or directly in equity. Current taxes The current tax expense is calculated based on taxable profit for the period, using tax rates enacted or substantively enacted at the statement of financial position date. Considering the level of tax loss of the Company, no current tax expense is recognized. Deferred taxes Deferred taxes are recognized when there are temporary differences between the carrying amount of assets and liabilities in the Company’s financial statements and the corresponding tax basis used to calculate taxable profit. Deferred taxes are not recognized if they arise from the initial recognition of an asset or liability in a transaction other than a business combination which, at the time of the transaction, does not affect either the accounting or the taxable profit (tax loss). Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, based on tax rates and tax laws enacted or substantively enacted by the end of the reporting period. Deferred tax assets and liabilities are not discounted. Deferred tax assets and liabilities are offset when a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes concern the same entity and the same tax authority. Deferred tax assets Deferred tax assets are recognized for all deductible temporary differences, unused tax losses and unused tax credits to the extent that it is probable that the temporary difference will reverse in the foreseeable future and that taxable profit will be available against which the deductible temporary difference, unused tax losses or unused tax credits can be utilized. The recoverable amount of deferred tax assets is reviewed at the end of each reporting period and their carrying amount is reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow the benefit of part or all of the deferred tax assets to be utilized. Unrecognized deferred tax assets are reassessed at the end of each reporting period and are recognized when it becomes probable that future taxable profit will be available to offset the temporary differences. Deferred tax liabilities Deferred tax liabilities are recognized for all taxable temporary differences, except when the Company is able to control the timing of the reversal of the difference and it is probable that the reversal will not occur in the foreseeable future.
Provisions for retirement benefit obligations	3.16. Retirement benefit obligations The Company operates a defined benefit pension plan. Its obligations in respect of the plan are limited to the lump sum payments upon retirements, which are expensed in the period in which the employees provide the corresponding service. The liability recorded in the statement of financial position in respect of defined benefit pension plans and other post‑retirement benefits is the present value of the defined benefit obligation at the statement of financial position date. The defined benefit obligation is calculated annually by independent actuaries using the projected unit credit method. The present value of the defined benefit obligation is determined by discounting estimated future cash outflows, using the interest rate of high‑quality corporate bonds of a currency and term consistent with the currency and term of the pension obligation concerned. Actuarial gains and losses arise from the effect of changes in assumptions and experience adjustments (i.e., differences between the assumptions used and actual data). These actuarial gains and losses are recognized wholly and immediately in other comprehensive income and expense and are not subsequently reclassified to the statement of income (loss). The net expense in respect of defined benefit obligations recognized in the statement of income (loss) for the period corresponds to: · The service cost for the period (acquisition of additional rights). · The interest cost. · The past service cost. · The impact of any plan settlements, amendments and curtailments The effect of unwinding the obligation is recognized in net financial income and expenses. Termination benefits Termination benefits are payable when a company terminates an employee’s employment contract before the normal retirement age or when an employee accepts compensation as part of a voluntary redundancy. In the case of termination benefits, the event that gives rise to an obligation is the termination of employment. In the case of an offer made to encourage voluntary redundancy, termination benefits are measured based on the number of employees expected to accept the offer. Profit‑sharing and bonus plans The Company recognizes a liability and an expense for profit‑sharing and bonus plans based on a formula that takes into account the Company’s performance.
Other provisions	3.17. In accordance with IAS 37 — Provisions, Contingent Liabilities and Contingent Assets , a provision should be recognized when: (i) an entity has a present legal or constructive obligation as a result of a past event; (ii) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation; and (iii) a reliable estimate can be made of the amount of the obligation. Provisions for restructuring include termination benefits. No provisions are recognized for future operating losses. Where there are a number of similar obligations, the probability that an outflow will be required in settlement is determined by considering the class of obligations as a whole. Although the likelihood of outflow for any one item may be small, it may well be probable that some outflow of resources will be needed to settle the class of obligations as a whole. If that is the case, a provision is recognized. The provision represents the best estimate of the amount required to settle the present obligation at the end of the reporting period. Where the effect of the time value of money is material, the amount of a provision corresponds to the present value of the expected costs that the Company considers necessary to settle the obligation. The pre‑tax discount rate used reflects current market assessments of the time value of money and specific risks related to the liability. The effect of unwinding discounts on provisions due to the time value of money is recognized in net financial income and expenses.
Revenue	3.18. Revenue is recognized in accordance with IFRS 15 — Revenue from Contracts with Customers, which is mandatorily applicable for reporting periods beginning on or after January 1, 2018. Collaboration agreements The contracts are analyzed as research and development services contracts. Any licenses that result from the collaborations are therefore not deemed to be separate performance obligations. The performance obligations contained in the contracts are deemed to be satisfied as and when the Company expends efforts (e.g., incurs costs or spends time). In return for the efforts expended, the Company receives fixed payments (such as lump‑sum payments) and variable payments (such as milestone payments or royalties on sales of any future approved products). Fixed payments for research and development expenditures, which primarily consist of rebilled payroll expenditure, are recognized over time based on the Company’s efforts or inputs to the satisfaction of a performance obligation (costs incurred or hours expended). Milestone payments obtained following the achievement of specific milestones (e.g., scientific results or regulatory or commercial approvals) are deemed to be variable payments and are included in the contract price as soon as their receipt is highly probable, resulting in an upward revision of the contract price and a cumulative adjustment to income in the statement of income (loss). Revenue from royalties corresponds to Inventiva’s contractual entitlement to receive a percentage of the future product sales achieved by its counterparties. Such royalties will be recognized if and when sales are made. Rendering of services The Company provides short term research services to various clients. Such services are recognized to revenue over time based on time incurred.
Other income	3.19. Research tax credit The research tax credit ( crédit d’impôt recherche , or “CIR”) granted by the French tax authorities to encourage technical and scientific research by French companies is recorded in the “Tax receivables” line of the statement of financial position. Companies demonstrating that they have expenses that meet the required criteria, including research expenses located in France or certain other European countries, receive a tax credit that can be used against the payment of the corporate tax due the fiscal year in which the expenses were incurred and during the next three fiscal years; provided, that companies may receive cash reimbursement for any excess portion. Only those companies meeting the EU definition of a small or medium-sized entity (“SME”) are eligible for payment in cash of their CIR (to the extent not used to offset corporate taxes payable) in the year following the request for reimbursement. Inventiva meets the EU definition of an SME and therefore should continue to be eligible for prepayment. Inventiva has been eligible for CIR since inception. The CIR is recognized in “Other income” during the reporting period in which the eligible expenditure is incurred and recorded in the “Tax receivables” line in the statement of financial position. Subsidies The Company receives subsidies from several public bodies. The subsidies are related to net income and granted to compensate for incurred expenses. They are therefore recognized in net income as other income for the period in which it becomes reasonably certain that they will be received.
Net financial income	3.20. Financial income Financial income includes: - The “Income from cash and cash equivalents”, which includes income from short‑term investments remeasured at fair value at the end of each reporting period. - Fair value variation gains / losses on cash equivalents which are revalued at each closing. - Foreign exchange gains. - Gains from unwinding discounting. - Other financial income. Financial expenses Financial expenses primarily include: - Interest cost. - Fair value variation gains / losses on cash equivalents which are revalued at each closing. - Foreign exchange losses. - Losses from unwinding discounting. - Other financial expenses.
Other operating income and expenses	3.21. Other operating income and expenses Other operating income and expenses are disclosed separately on the face of the statement of income (loss). This line item is set aside for unusual events that may arise during the period whose presentation within other items (relating to ordinary activities) could be misleading for users of the financial statements in their understanding of the Company’s performance. This item therefore includes income and expenses that are rare that represent material amounts and that the Company discloses separately on the face of the statement of income (loss) to facilitate understanding of operating performance (see Note 18, “Other operating income (expenses)”). Disposals of non‑current assets Income from the disposal of non‑current assets during the period is recognized in “Other operating income (expenses)”.
Fair value measurement	3.22. In the table below, financial instruments are measured at fair value according to a hierarchy comprising three levels of valuation inputs: · Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date. · Level 2: Inputs other than quoted market prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. · Level 3: Unobservable inputs for the asset or liability. The table below presents the financial assets and liabilities of the Company measured at fair value at December 31, 2020: At December 31, 2020 (in thousands of euros) Level 1 Level 2 Level 3 Assets Financial assets at fair value through profit or loss Foreign currency forwards (1) — 1,791 — Total assets — 1,791 — Foreign currency forwards — — — Total liabilities — — — (1) The valuation of the instrument is estimated based on observable market parameters. The instrument is not directly listed on a market. As of December 31, 2018 and 2019, no financial asset or liability was measured at fair value.
Foreign currency transactions	3.23. Functional and presentation currency The Company’s financial statements are presented in euros, which is also the Company’s functional currency. All amounts presented in these notes to the financial statements are denominated in euros unless otherwise stated. Translation of foreign currency transactions As of December 31, 2020, foreign currency transactions include bank accounts and term deposits in U.S. dollars implemented after the IPO on the Nasdaq Global Market in July 2020. Certain purchasing transactions are carried out in foreign currencies for our studies and clinical trials conducted in the United States, the United Kingdom, Switzerland, Australia, Canada and Sweden. In 2020, these foreign currency expenses amounted to approximately €2.5 million, or approximately 7% of our operating expenses. These transactions are translated into euros at the rate prevailing at the date of each transaction. Purchasing transactions in foreign currencies are presented in operating income as they relate to the Company's ordinary activities. Foreign exchange gains and losses relating to short-term investments and bank accounts in U.S. dollars are presented in financial income (loss).
Segment information	3.24. The assessment of the entity’s performance and the decisions about resources to be allocated are made by the chief operating decision maker, based on the management reporting system of the entity. Only one operating segment arises from the management reporting system: service delivery and clinical stage research, notably into potential therapies in the areas of fibrosis, lysosomal storage disorders and oncology. Thus, the entity’s performance is assessed at the Company level. All the Company’s operations, assets, liabilities and losses are located in France.
Use of estimates and judgment	3.25. The preparation of financial statements in accordance with IFRS requires: · Management to make judgments when selecting appropriate assumptions for accounting estimates, which consequently involve a certain degree of uncertainty. · Management to make estimates and apply assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as well as information presented for the period. The estimates and judgments, which are updated on an ongoing basis, are based on past experience and other factors, in particular assumptions of future events, deemed reasonable in light of circumstances. The Company makes estimates and assumptions concerning the future. The resulting accounting estimates, by definition, often differ from actual reported values. Estimates and assumptions that could lead to a significant risk of a material adjustment in the carrying amount of assets and liabilities in the subsequent period are analyzed below. Revenue · Allocation of transaction price to performance obligations — A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. To determine the proper revenue recognition method, the Company evaluates whether the contract should be accounted for as more than one performance obligation. This evaluation requires significant judgment; some of the Company’s contracts have a single performance obligation as the promise to transfer the individual goods or services is not separately identifiable from other promises in the contracts and, therefore, not distinct. For contracts with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract. · Variable consideration — Due to the nature of the work required to be performed on many of the Company’s performance obligations, the estimation of total revenue and cost at completion is complex, subject to many variables and requires significant judgment. It is common for the collaboration agreements to contain variable consideration that can increase the transaction price. Variability in the transaction price arises primarily due to milestone payments obtained following the achievement of specific milestones (e.g., scientific results or regulatory or commercial approvals). The Company includes the related amounts in the transaction price as soon as their receipt is highly probable. The effect of the increase of the transaction price due to milestones payments is recognized as an adjustment to revenue on a cumulative catch‑up basis. · Revenue recognized over time and input method — The Company’s performance obligations are satisfied over time as work progresses or at a point in time. For the collaboration agreements, because services are rendered over time, revenue is recognized based on the extent of progress towards completion of the performance obligation, using an input measure of progress as it best depicts the transfer of control to the customers. Under the Company’s input measure of progress, the extent of progress towards completion is measured based on the ratio of days expended to date to the total estimated days at completion of the performance obligation. Provision for tax audit The Company calculated the provision for the tax audits to which the Company has been subject based on an estimate of the related risk. The provision represents the best estimate of the amount required to settle any amounts owed to the French tax authorities at the end of the reporting period (see Note 12, “Provisions”). CIR The amount of the CIR is determined based on the Company’s internal and external expenditure in the reporting period. Only eligible research costs may be included when calculating the CIR. Valuation of share warrants and bonus share award Fair value measurements of share warrants and bonus share award granted to employees are based on actuarial models which require the Company to factor certain assumptions into its calculations (see Notes 10.3, "Share warrants plans" and 10.4, "Bonus share award plans"). Measurement of retirement benefit obligations The Company operates a defined benefit pension plan. Its defined benefit plan obligations are measured in accordance with actuarial calculations based on assumptions such as discount rates, the rate of future salary increases, employee turnover, mortality tables and expected increases in medical costs. The assumptions used are generally reviewed and updated annually. The main assumptions used and the methods chosen to determine them are set out in Notes 3.16, "Provisions for retirement benefit obligations" and 13, “Provisions for retirement benefit obligations”. The Company considers that the actuarial assumptions used are appropriate and justified in light of current circumstances. Nevertheless, retirement benefit obligations are likely to change in the event that actuarial assumptions are revised. Derivatives The Company uses derivative financial instruments to hedge its exposure to exchange rate risks (Currency forward sales). The Company has not opted for hedge accounting in accordance with IFRS 9. Derivatives are measured at their fair value in the statement of financial position. The fair values of derivatives are estimated on the basis of commonly used valuation models considering data from active markets.

Accounting Principles (Tables)

Accounting Principles (Tables)	12 Months Ended
	Dec. 31, 2020
Accounting Principles
Schedule of financial assets and liabilities measured at fair value	The table below presents the financial assets and liabilities of the Company measured at fair value at December 31, 2020: At December 31, 2020 (in thousands of euros) Level 1 Level 2 Level 3 Assets Financial assets at fair value through profit or loss Foreign currency forwards (1) — 1,791 — Total assets — 1,791 — Foreign currency forwards — — — Total liabilities — — — (1) The valuation of the instrument is estimated based on observable market parameters. The instrument is not directly listed on a market.

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2020
Intangible Assets
Schedule of intangible Assets	(in thousands of euros) January 1, 2018 Increases Decreases December 31, 2018 Library of compounds 2,142 — — 2,142 Software 1,398 106 — 1,504 Intangible assets, gross 3,540 106 — 3,646 Amortization of library of compounds (828) (165) — (993) Amortization of software (906) (204) — (1,110) Amortization (1,733) (369) — (2,103) Intangible assets, net 1,806 (264) — 1,543 (in thousands of euros) January 1, 2019 Increases Decreases December 31, 2019 Library of compounds 2,142 — — 2,142 Software 1,504 29 — 1,533 Intangible assets, gross 3,646 29 — 3,674 Amortization of library of compounds (993) (165) — (1,157) Amortization of software (1,110) (179) — (1,289) Amortization (2,103) (343) — (2,446) Intangible assets, net 1,543 (314) — 1,228 (in thousands of euros) January 1, 2020 Increases Decreases December 31, 2020 Library of compounds 2,142 — — 2,142 Software 1,533 — 1,533 Intangible assets, gross 3,674 — 3,674 Amortization of library of compounds (1,157) (165) — (1,322) Amortization of software (1,289) (129) — (1,417) Amortization (2,446) (293) — (2,739) Intangible assets, net 1,228 (293) — 935

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment
Schedule of property, Plant and Equipment	January 1, December 31, (in thousands of euros) 2018 Increases Decreases Reclassifications 2018 Land 172 — — — 172 Buildings 3,407 — — — 3,407 Technical facilities, equipment and tooling 4,267 334 — 75 4,677 Other property, plant and equipment 1,023 58 — — 1,081 Property, plant and equipment in progress 67 51 — (75) 43 Property, plant and equipment, gross 8,937 443 — — 9,380 Depreciation of buildings (1,144) (202) — — (1,346) Depreciation of technical facilities, equipment and tooling (2,608) (391) — — (2,999) Depreciation of other property, plant and equipment (668) (105) — — (774) Depreciation (4,421) (698) — — (5,119) Property, plant and equipment, net 4,516 (255) — — 4,261 January 1, December 31, (in thousands of euros) 2019 Increases Decreases Reclassifications 2019 Land 172 — — — 172 Buildings 3,407 — — — 3,407 Technical facilities, equipment and tooling 4,677 74 (2) — 4,748 Other property, plant and equipment 1,081 33 — 43 1,157 Property, plant and equipment in progress 43 — — (43) — Right of use (1) 252 — — — 252 Property, plant and equipment, gross 9,632 107 (2) — 9,736 Depreciation of buildings (1,346) (196) — — (1,542) Depreciation of technical facilities, equipment and tooling (2,999) (398) 1 — (3,396) Depreciation of other property, plant and equipment (774) (100) — — (874) Depreciation of right of use (1) — (203) — — (203) Depreciation (5,119) (897) 1 — (6,015) Property, plant and equipment, net 4,513 (790) (2) — 3,721 (1) At January 1, 2019, in application of IFRS 16 — Leases, an asset representing the right to use the leased assets (see Note 2.1, "Impact of the first-time application of IFRS 16"). Changes during the period 2020 mainly correspond to depreciation charges of €0.9 million. January 1, December 31, (in thousands of euros) 2020 Increases Decreases Others (1) 2020 Land 172 — — — 172 Buildings 3,407 — — — 3,407 Technical facilities, equipment and tooling 4,748 108 — 4,856 Other property, plant and equipment 1,157 46 — 1,203 Property, plant and equipment in progress — 137 — — 137 Right of use (1) 252 — — (218) 34 Property, plant and equipment, gross 9,736 292 (218) 9,810 Depreciation and impairment of buildings (1,542) (196) — — (1,737) Depreciation and impairment of technical facilities, equipment and tooling (3,396) (386) — — (3,782) Depreciation and impairment of other property, plant and equipment (874) (102) — — (976) Depreciation and impairment of right of use (203) (32) — 202 (33) Depreciation and impairment (6,015) (716) — 202 (6,528) Property, plant and equipment, net 3,721 (424) (16) 3,282 (1) Others during the period corresponding to the retirement of the net value of the right of use related to the fibroscan lease contract following its early termination.

Other Non-Current Assets (Table

Other Non-Current Assets (Tables)	12 Months Ended
	Dec. 31, 2020
Other Non-Current Assets
Schedule of other non current assets	As of December 31, (in thousands of euros) 2018 2019 2020 Accrued income 1,932 2,000 — Long ‑ term deposit accounts 108 792 1,698 Security deposits — 8 8 Tax loss carry back 333 333 — Other non ‑ current assets 2,374 3,135 1,706

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2020
Inventories
Schedule of inventories	As of December 31, (in thousands of euros) 2018 2019 2020 Laboratory inventories 443 420 353 Inventories write ‑ down (33) (33) (33) Total inventories 410 387 320

Trade Receivables and Other C_2

Trade Receivables and Other Current Assets and Receivables (Tables)	12 Months Ended
	Dec. 31, 2020
Trade Receivables and Other Current Assets and Receivables
Schedule of trade receivables	As of December 31, (in thousands of euros) 2018 2019 2020 3 months or less 6 4 48 Between 3 and 6 months — — — Between 6 and 12 months — — — More than 12 months — — — Trade receivables 6 4 48
Schedule of other current assets and receivables	As of December 31, (in thousands of euros) 2018 2019 2020 CIR 9,158 9,818 9,012 CICE tax credit 264 — — Other 12 16 16 Tax receivables 9,434 9,833 9,028 Prepaid expenses 1,184 495 3,313 Short-term deposit accounts — — 7,336 Current accrued income — — 2,000 Foreign currency forwards — — 1,791 Liquidity agreement - Cash account (1) 31 261 1,029 VAT receivable 3,033 1,416 1,625 Other receivables 843 639 821 Other current assets 5,092 2,811 17,914 Other current assets and receivables 14,526 12,644 26,942 (1)

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	12 Months Ended
	Dec. 31, 2020
Cash and Cash Equivalents
Schedule of Cash and Cash Equivalents	As of December 31, (in thousands of euros) 2018 2019 2020 Other cash equivalents (1) 41,767 14,004 12,001 Cash at bank and at hand 14,925 21,837 93,686 Cash and cash equivalents 56,692 35,840 105,687 (1) Other cash equivalents correspond to short‑term bank deposits in euros at Société Générale and Crédit Agricole.

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of changes in share capital	Premiums Share related to Number of Nominal Date Nature of the transactions capital share capital shares value Balance as of January 1 st , 2018 164,445 44,991,815 16,444,477 0.01 01/26/2018 Capital increase by issuance of ordinary shares - Exercise of 1,803 BSPCE by Company employees 1,803 106,384 180,300 0.01 04/17/2018 Capital increase by issuance of ordinary shares – Company’s private placement 55,725 35,441,100 5,572,500 0.01 04/17/2018 Transaction costs related to the Company’s private placement — (3,079,174) — — 04/18/2018 Capital increase by issuance of ordinary shares – Vesting of AGA by Company employees 600 — 60,000 0.01 Balance as of January 1 st , 2019 222,573 77,460,125 22,257,277 0.01 01/23/2019 Capital increase by issuance of ordinary shares — Exercise of 274 BSPCE by Company employees 274 17,693 27,400 0.01 01/26/2019 Capital increase by issuance of ordinary shares — Vesting of AGA by Company employees (AGA 2018 ‑ 1) 100 — 10,000 0.01 04/18/2019 Capital increase by issuance of ordinary shares — Vesting of AGA by Company employees (AGA 2017 ‑ 1) 775 — 77,500 0.01 09/20/2019 Capital increase by issuance of ordinary shares — Company’s private placement 41,600 8,236,798 4,159,999 0.01 09/20/2019 Transaction costs related to the Company’s private placement — (312,294) — — 10/02/2019 Capital increase by issuance of ordinary shares — Company’s private placement 3,139 621,593 313,936 0.01 10/02/2019 Transaction costs related to the Company’s private placement — (12,023) — — Balance as of January 1 st , 2020 268,461 86,011,893 26,846,112 0.01 01/26/2020 Capital increase by issuance of ordinary shares – Vesting of AGA by Company employees (AGA 2018-2) 633 — 63,300 0.01 02/07/2020 Capital increase by issuance of ordinary shares – Company’s private placement 37,783 14,962,218 3,778,338 0.01 02/07/2020 Transaction costs related to the Company’s private placement — (319,564) — — 04/17/2020 Appropriation of the issue premium — (48,000,000) — — 06/28/2020 Capital increase by issuance of ordinary shares – Vesting of AGA by Company employees (AGA 2019-2) 2,270 — 227,000 0.01 07/15/2020 Capital increase by issuance of ordinary shares – Company’s initial public offering 74,783 94,024,272 7,478,261 0.01 07/15/2020 Transaction costs related to the Company’s initial public offering — (7,077,866) — — 11/30/2020 Capital increase by emission of ordinary shares – exercise of 10,000 BSA by Karen Aïach, former administrator (BSA 2017) 100 66,650 10,000 0.01 12/14/2020 Capital increase by issuance of ordinary shares – Vesting of AGA by Company employees (AGA 2018-3) 2,273 — 227,250 0.01 Balance as of December 31, 2020 386,302 139,667,603 38,630,261
BSPCE and BSA share warrants
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of movements in BSPCE and BSA share warrants and Bonus shares	Exercise Outstanding Outstanding Number of price at January 1, at December 31, shares Type Grant date (in euros) 2020 Issued Exercised Forfeited 2020 exercisable BSPCE — 2013 plan December 13, 2013 0.59 8,800 — — — 8,800 8,800 Total BSPCE 8,800 — — — 8,800 8,800 BSA — 2017 plan May 29, 2017 6.68 140,000 — (10,000) — 130,000 130,000 BSA — 2018 plan December 14, 2018 6.07 116,000 — — — 116,000 77,334 BSA — 2019 plan June 28, 2019 2.20 10,000 — — — 10,000 10,000 BSA 2019 Bis March 9, 2020 3.68 — 10,000 — — 10,000 — BSA 2019 Ter March 9, 2020 3.68 — 36,000 — — 36,000 — Total BSA 266,000 46,000 (10,000) — 302,000 217,334 Total 274,800 46,000 (10,000) — 310,800 226,134 Exercise Outstanding Outstanding Number of price at January 1, at December 31, shares Type Grant date (in euros) 2019 Issued Exercised Forfeited 2019 exercisable BSPCE — 2015 plan May 25, 2015 0.67 22,800 — (22,800) — — — BSPCE — 2013 plan December 13, 2013 0.59 13,400 — (4,600) — 8,800 8,800 Total BSPCE 36,200 — (27,400) — 8,800 8,800 BSA — 2017 plan May 29, 2017 6.67 175,000 — — (35,000) 140,000 120,000 BSA — 2018 plan December 14, 2018 6.07 126,000 — — (10,000) 116,000 38,667 BSA — 2019 plan June 28, 2019 2.20 — 10,000 — — 10,000 — Total BSA 301,000 10,000 — (45,000) 266,000 158,667 Total stock options 337,200 10,000 (27,400) (45,000) 274,800 167,467 Exercise Outstanding Outstanding Number of price at January 1, at December 31, shares Type Grant date (in euros) 2018 Issued Exercised Forfeited 2018 exercisable BSPCE—2015 plan May 25, 2015 0.67 54,700 — (31,900) — 22,800 22,800 BSPCE—2013 plan December 13, 2013 0.59 161,800 — (148,400) — 13,400 13,400 Total BSPCE 216,500 — 180,300 — 36,200 36,200 BSA—2017 plan May 29, 2017 6.67 195,000 — — (20,000) 175,000 65,000 BSA—2018 plan December 14, 2018 6.067 — 126,000 — — 126,000 — Total BSA 195,000 126,000 — (20,000) 301,000 65,000 Total stock options 411,500 126,000 (180,300) (20,000) 337,200 101,200 Stock price Outstanding Outstanding Number of at grant date at January 1, at December 31, shares Type Grant date (in euros) 2020 Issued vesting Forfeited 2020 exercisable AGA — 2018 ‑ 2 plan January 26, 2018 5.76 63,300 — (63,300) — — — AGA — 2018 ‑ 3 plan December 14, 2018 6.28 227,250 — (227,250) — — — AGA — 2019 ‑ 1 plan June 28, 2019 2.00 37,500 — — (8,400) 29,100 — AGA — 2019 ‑ 2 plan June 28, 2019 2.00 228,000 — (227,000) (1,000) — — Total AGA 556,050 — (517,550) (9,400) 29,100 — Stock price Outstanding Outstanding Number of at grant date at January 1, at December 31, shares Type Grant date (in euros) 2019 Issued Vesting Forfeited 2019 exercisable AGA — 2017-1 plan April 18, 2017 7.35 77,500 — (77,500) — — — AGA — 2018-1 plan January 26, 2018 5.76 10,000 — (10,000) — — — AGA — 2018-2 plan January 26, 2018 5.76 65,700 — — (2,400) 63,300 — AGA — 2018-3 plan December 14, 2018 6.28 265,700 — — (38,450) 227,250 — AGA — 2019-1 plan June 28, 2019 2.00 — 37,500 — — 37,500 — AGA — 2019-2 plan June 28, 2019 2.00 — 246,000 — (18,000) 228,000 — Total AGA 418,900 283,500 (87,500) (58,850) 556,050 — Stock price Outstanding Outstanding Number of at grant date at January 1, at December 31, shares Type Grant date (in euros) 2018 Issued Vesting Forfeited 2018 exercisable AGA—2017 ‑ 1 plan April 18, 2017 7.35 79,900 — — (2,400) 77,500 — AGA—2017 ‑ 2 plan April 18, 2017 7.35 60,000 — (60,000) — — — AGA—2018 ‑ 1 plan January 26, 2018 5.76 — 10,000 — — 10,000 — AGA—2018 ‑ 2 plan January 26, 2018 5.76 — 65,700 — — 65,700 — AGA—2018 ‑ 3 plan December 14, 2018 6.28 — 265,700 — — 265,700 — Total AGA 139,900 341,400 (60,000) (2,400) 418,900 —
BSPCE Share Warrants [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of movements in BSPCE and BSA share warrants and Bonus shares	BSPCE 2013-1 Decision of issuance by the Board of Directors 11/25/2013 Grant date 12/13/2013 Beneficiary Employees Number of BSPCE granted 9,027 Expiration date 12/31/2023 Number of shares per BSPCE 100 BSPCE exercise price (€) 58.50
BSA Share warrant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of movements in BSPCE and BSA share warrants and Bonus shares	BSA BSA BSA BSA 2017 2018-1 BSA 2019 2019 bis 2019 ter Decision of issuance by the Board of Directors 05/29/2017 12/14/2018 06/28/2019 03/09/2020 03/09/2020 Grant date 05/29/2017 12/14/2018 06/28/2019 03/09/2020 03/09/2020 Beneficiary Directors Service providers Service providers Service providers Service providers Vesting period (year) 3 tranches: 1 year, 2 years and 3 years between 1 and 3 years 1 1 between 1 and 3 years Expiration date 05/29/2027 12/14/2028 06/28/2029 03/09/2030 03/09/2030 Number of BSA granted 195,000 126,000 10,000 10,000 36,000 Number of shares per BSA 1 1 1 1 1 Subscription premium price per share (€) 0.534 0.48 0.18 0.29 0.29 Exercise price per share (€) 6.675 6.067 2.20 3.68 3.68 Performance condition No No No No No Valuation method Black and Scholes Fair value per BSA at grant date (€) 2.47 1.98 0.48 0.90 0.90 Expected volatility 40 % 40 % 40 % 40 % 40 % Average life (years) 6 6 5.5 6 6 Risk free rate 0.22 % 0.30 % 0.33 % 0.0 % 0.0 % Expected dividends — — — — —
AGA Bonus Share Award Plans Member
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of movements in BSPCE and BSA share warrants and Bonus shares	AGA AGA AGA AGA AGA AGA 2017-1 2018-1 2018-2 2018-3 2019-1 2019-2 Decision of issuance by the Board of Directors 04/18/2017 01/26/2018 01/26/2018 12/14/2018 06/28/2019 06/28/2019 Grant date 04/18/2017 01/26/2018 01/26/2018 12/14/2018 06/28/2019 06/28/2019 Beneficiary Employees Employees Employees Employees Employees Employees Vesting period (year) 2 1 2 2 2 1 Holding period (year) 1 1 1 1 1 1 Service condition Yes Yes Yes Yes Yes Yes Performance condition No No No No No No Number of AGA granted 92,300 10,000 65,700 265,700 37,500 246,000 Number of shares per AGA 1 1 1 1 1 1 Fair value per share at grant date (€) 7.04 5.54 5.54 6.05 1.92 1.92
Bonus share award plans
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of movements in BSPCE and BSA share warrants and Bonus shares	Exercise Outstanding Outstanding Number of price at January 1, at December 31, shares Type Grant date (in euros) 2020 Issued Exercised Forfeited 2020 exercisable BSPCE — 2013 plan December 13, 2013 0.59 8,800 — — — 8,800 8,800 Total BSPCE 8,800 — — — 8,800 8,800 BSA — 2017 plan May 29, 2017 6.68 140,000 — (10,000) — 130,000 130,000 BSA — 2018 plan December 14, 2018 6.07 116,000 — — — 116,000 77,334 BSA — 2019 plan June 28, 2019 2.20 10,000 — — — 10,000 10,000 BSA 2019 Bis March 9, 2020 3.68 — 10,000 — — 10,000 — BSA 2019 Ter March 9, 2020 3.68 — 36,000 — — 36,000 — Total BSA 266,000 46,000 (10,000) — 302,000 217,334 Total 274,800 46,000 (10,000) — 310,800 226,134 Exercise Outstanding Outstanding Number of price at January 1, at December 31, shares Type Grant date (in euros) 2019 Issued Exercised Forfeited 2019 exercisable BSPCE — 2015 plan May 25, 2015 0.67 22,800 — (22,800) — — — BSPCE — 2013 plan December 13, 2013 0.59 13,400 — (4,600) — 8,800 8,800 Total BSPCE 36,200 — (27,400) — 8,800 8,800 BSA — 2017 plan May 29, 2017 6.67 175,000 — — (35,000) 140,000 120,000 BSA — 2018 plan December 14, 2018 6.07 126,000 — — (10,000) 116,000 38,667 BSA — 2019 plan June 28, 2019 2.20 — 10,000 — — 10,000 — Total BSA 301,000 10,000 — (45,000) 266,000 158,667 Total stock options 337,200 10,000 (27,400) (45,000) 274,800 167,467 Exercise Outstanding Outstanding Number of price at January 1, at December 31, shares Type Grant date (in euros) 2018 Issued Exercised Forfeited 2018 exercisable BSPCE—2015 plan May 25, 2015 0.67 54,700 — (31,900) — 22,800 22,800 BSPCE—2013 plan December 13, 2013 0.59 161,800 — (148,400) — 13,400 13,400 Total BSPCE 216,500 — 180,300 — 36,200 36,200 BSA—2017 plan May 29, 2017 6.67 195,000 — — (20,000) 175,000 65,000 BSA—2018 plan December 14, 2018 6.067 — 126,000 — — 126,000 — Total BSA 195,000 126,000 — (20,000) 301,000 65,000 Total stock options 411,500 126,000 (180,300) (20,000) 337,200 101,200 Stock price Outstanding Outstanding Number of at grant date at January 1, at December 31, shares Type Grant date (in euros) 2020 Issued vesting Forfeited 2020 exercisable AGA — 2018 ‑ 2 plan January 26, 2018 5.76 63,300 — (63,300) — — — AGA — 2018 ‑ 3 plan December 14, 2018 6.28 227,250 — (227,250) — — — AGA — 2019 ‑ 1 plan June 28, 2019 2.00 37,500 — — (8,400) 29,100 — AGA — 2019 ‑ 2 plan June 28, 2019 2.00 228,000 — (227,000) (1,000) — — Total AGA 556,050 — (517,550) (9,400) 29,100 — Stock price Outstanding Outstanding Number of at grant date at January 1, at December 31, shares Type Grant date (in euros) 2019 Issued Vesting Forfeited 2019 exercisable AGA — 2017-1 plan April 18, 2017 7.35 77,500 — (77,500) — — — AGA — 2018-1 plan January 26, 2018 5.76 10,000 — (10,000) — — — AGA — 2018-2 plan January 26, 2018 5.76 65,700 — — (2,400) 63,300 — AGA — 2018-3 plan December 14, 2018 6.28 265,700 — — (38,450) 227,250 — AGA — 2019-1 plan June 28, 2019 2.00 — 37,500 — — 37,500 — AGA — 2019-2 plan June 28, 2019 2.00 — 246,000 — (18,000) 228,000 — Total AGA 418,900 283,500 (87,500) (58,850) 556,050 — Stock price Outstanding Outstanding Number of at grant date at January 1, at December 31, shares Type Grant date (in euros) 2018 Issued Vesting Forfeited 2018 exercisable AGA—2017 ‑ 1 plan April 18, 2017 7.35 79,900 — — (2,400) 77,500 — AGA—2017 ‑ 2 plan April 18, 2017 7.35 60,000 — (60,000) — — — AGA—2018 ‑ 1 plan January 26, 2018 5.76 — 10,000 — — 10,000 — AGA—2018 ‑ 2 plan January 26, 2018 5.76 — 65,700 — — 65,700 — AGA—2018 ‑ 3 plan December 14, 2018 6.28 — 265,700 — — 265,700 — Total AGA 139,900 341,400 (60,000) (2,400) 418,900 — Exercise Outstanding Outstanding Number of price at January 1, at December 31, shares Type Grant date (in euros) 2019 Issued Exercised Forfeited 2019 exercisable BSPCE — 2015 plan May 25, 2015 0.67 22,800 — (22,800) — — — BSPCE — 2013 plan December 13, 2013 0.59 13,400 — (4,600) — 8,800 8,800 Total BSPCE 36,200 — (27,400) — 8,800 8,800 BSA — 2017 plan May 29, 2017 6.67 175,000 — — (35,000) 140,000 120,000 BSA — 2018 plan December 14, 2018 6.07 126,000 — — (10,000) 116,000 38,667 BSA — 2019 plan June 28, 2019 2.20 — 10,000 — — 10,000 — Total BSA 301,000 10,000 — (45,000) 266,000 158,667 Total stock options 337,200 10,000 (27,400) (45,000) 274,800 167,467 Exercise Outstanding Outstanding Number of price at January 1, at December 31, shares Type Grant date (in euros) 2018 Issued Exercised Forfeited 2018 exercisable BSPCE—2015 plan May 25, 2015 0.67 54,700 — (31,900) — 22,800 22,800 BSPCE—2013 plan December 13, 2013 0.59 161,800 — (148,400) — 13,400 13,400 Total BSPCE 216,500 — 180,300 — 36,200 36,200 BSA—2017 plan May 29, 2017 6.67 195,000 — — (20,000) 175,000 65,000 BSA—2018 plan December 14, 2018 6.067 — 126,000 — — 126,000 — Total BSA 195,000 126,000 — (20,000) 301,000 65,000 Total stock options 411,500 126,000 (180,300) (20,000) 337,200 101,200 Stock price Outstanding Outstanding Number of at grant date at January 1, at December 31, shares Type Grant date (in euros) 2020 Issued vesting Forfeited 2020 exercisable AGA — 2018 ‑ 2 plan January 26, 2018 5.76 63,300 — (63,300) — — — AGA — 2018 ‑ 3 plan December 14, 2018 6.28 227,250 — (227,250) — — — AGA — 2019 ‑ 1 plan June 28, 2019 2.00 37,500 — — (8,400) 29,100 — AGA — 2019 ‑ 2 plan June 28, 2019 2.00 228,000 — (227,000) (1,000) — — Total AGA 556,050 — (517,550) (9,400) 29,100 — Stock price Outstanding Outstanding Number of at grant date at January 1, at December 31, shares Type Grant date (in euros) 2019 Issued Vesting Forfeited 2019 exercisable AGA — 2017-1 plan April 18, 2017 7.35 77,500 — (77,500) — — — AGA — 2018-1 plan January 26, 2018 5.76 10,000 — (10,000) — — — AGA — 2018-2 plan January 26, 2018 5.76 65,700 — — (2,400) 63,300 — AGA — 2018-3 plan December 14, 2018 6.28 265,700 — — (38,450) 227,250 — AGA — 2019-1 plan June 28, 2019 2.00 — 37,500 — — 37,500 — AGA — 2019-2 plan June 28, 2019 2.00 — 246,000 — (18,000) 228,000 — Total AGA 418,900 283,500 (87,500) (58,850) 556,050 — Stock price Outstanding Outstanding Number of at grant date at January 1, at December 31, shares Type Grant date (in euros) 2018 Issued Vesting Forfeited 2018 exercisable AGA—2017 ‑ 1 plan April 18, 2017 7.35 79,900 — — (2,400) 77,500 — AGA—2017 ‑ 2 plan April 18, 2017 7.35 60,000 — (60,000) — — — AGA—2018 ‑ 1 plan January 26, 2018 5.76 — 10,000 — — 10,000 — AGA—2018 ‑ 2 plan January 26, 2018 5.76 — 65,700 — — 65,700 — AGA—2018 ‑ 3 plan December 14, 2018 6.28 — 265,700 — — 265,700 — Total AGA 139,900 341,400 (60,000) (2,400) 418,900 —

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2020
Debt
Schedule of debt	As of December 31, (in thousands of euros) 2018 2019 2020 Bank borrowings 220 74 9,992 Other loans and similar borrowings (1) 5 3 62 Lease liabilities — 37 2 Total debt 225 114 10,055 (1) Consists of accrued interests
Schedule of maturity of long-term debt and of short-term borrowings	December 31, 2018 Less than Between Between More than (in thousands of euros) 1 year 1 and 3 years 3 and 5 years 5 years Bank borrowings 146 74 — — Other loans and similar borrowings 5 — — — Total long ‑ term debt 151 74 — — December 31, 2019 Less than Between Between More than (in thousands of euros) 1 year 1 and 3 years 3 and 5 years 5 years Bank borrowings 74 — — — Other loans and similar borrowings 3 — — — Lease liabilities 35 2 — — Total long ‑ term debt 112 2 — — December 31, 2020 Less than Between Between More than (in thousands of euros) 1 year 1 and 3 years 3 and 5 years 5 years Bank borrowings 13 9,979 — — Other loans and similar borrowings 3 59 — — Lease liabilities 2 — — — Total long ‑ term debt 18 10,037 — —
Schedule of changes in borrowings	(in thousands of euros) January 1, 2018 482 Repayment of bank borrowings (259) Accrued interests 2 December 31, 2018 225 First application of IFRS 16 Leases (1) 167 January 1, 2019 392 Repayment of bank borrowings (146) Repayment of lease liabilities (130) Accrued interests (2) December 31, 2019 114 Subscription of bank borrowings 9,979 Repayment of bank borrowings (61) Repayment of lease liabilities (26) Early termination of lease contracts (2) (9) Capitalized interests 59 Accrued interests (0) December 31, 2020 10,055 (1) see Note 2.1, “Impact of the first‑time application of IFRS 16”. (2) Cancellation of the lease liabilities related to the early termination of the fibroscan lease contract in the first half 2020.

Provisions (Tables)

Provisions (Tables)	12 Months Ended
	Dec. 31, 2020
Provisions
Schedule of provisions	(in thousands of euros) January 1, 2018 Additions Reversals December 31, 2018 CIR 2013-2015 477 — (119) 358 Long ‑ term provisions 477 — (119) 358 Payroll taxes 2016-2017 — 1,140 — 1,140 Short ‑ term provisions — 1,140 — 1,140 Total Provisions 477 1,140 (119) 1,498 January 1, December 31, (in thousands of euros) 2019 Additions Reversals 2019 CIR 2013-2015 358 — — 358 CIR 2017 — 216 — 216 Long ‑ term provisions 358 216 — 574 Payroll taxes 2016-2018 1,140 123 — 1,264 Short ‑ term provisions 1,140 123 — 1,264 Total Provisions 1,498 339 — 1,837 (in thousands of euros) January 1, 2020 Additions Reclassification December 31, 2020 CIR 2013-2015 358 1,139 — 1,497 CIR 2017 216 665 — 880 Long ‑ term provisions 574 1,804 — 2,377 Payroll taxes 2016-2018 1,264 90 (1,224) 130 Short ‑ term provisions 1,264 90 (1,224) 130 Total Provisions 1,837 1,894 (1,224) 2,507

Provisions for Retirement Ben_2

Provisions for Retirement Benefit Obligations (Tables)	12 Months Ended
	Dec. 31, 2020
Provisions for Retirement Benefit Obligations
Schedule of assumptions used to measure Retirement Benefit Obligations	As of December 31, Variables 2018 2019 2020 Retirement age 65 years 65 years 65 years Payroll taxes 41.41 % 41.41 % 41.41 % Salary growth rate 2 % 2 % 2 % Discount rate 1.60 % 0.70 % 0.35 % Mortality table TGH/TGF 05 TGH/TGF 05 TGH/TGF 05
Schedule of provision recorded in respect of defined benefit schemes at the end of each reporting period	As of December 31, (in thousands of euros) 2018 2019 2020 Retirement benefit obligations 1,029 1,127 1,385 Obligation 1,029 1,127 1,385
Schedule of change in the provision recorded in respect of defined benefit schemes	Year ended December 31, (in thousands of euros) 2018 2019 2020 Provision at beginning of period (866) (1,029) (1,127) Expense for the period (194) (1) (209) Actuarial gains or losses recognized in other comprehensive income 31 (96) (49) Provision at end of period (1,029) (1,127) (1,385)
Schedule of expense recognized in the statement of income (loss)	Year ended December 31, (in thousands of euros) 2018 2019 2020 Service cost for the period (192) (195) (202) Interest cost for the period (11) (16) (8) Plan curtailments and modifications — 157 — Benefits for the period 9 53 — Total (194) (1) (209)
Schedule of actuarial gains and losses recognized in comprehensive income	Year ended December 31, (in thousands of euros) 2018 2019 2020 Demographic changes (14) 32 14 Changes in actuarial assumptions 45 (129) (63) Total 31 (96) (49)
Schedule of sensitivity analysis	In thousands December 31, 2018 of euros Benefit obligation at December 31, 2018 at 1.35% 1,067 Benefit obligation at December 31, 2018 at 1.60% 1,029 Benefit obligation at December 31, 2018 at 1.85 % 994 In thousands December 31, 2019 of euros Benefit obligation at December 31, 2019 at 0,45% 1,168 Benefit obligation at December 31, 2019 at 0,70% 1,127 Benefit obligation at December 31, 2019 at 0,95% 1,088 In thousands December 31, 2020 of euros Benefit obligation at December 31, 2020 at 0,10% 1,433 Benefit obligation at December 31, 2020 at 0,35% 1,385 Benefit obligation at December 31, 2020 at 0,60% 1,340

Trade Payables and Other Curr_2

Trade Payables and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2020
Trade Payables and Other Current Liabilities
Schedule of trade payables and other current liabilities	As of December 31, (in thousands of euros) 2018 2019 2020 Trade payables 8,372 7,491 6,923 Other current liabilities 4,871 4,998 6,838 Trade payables and other current liabilities 13,243 12,489 13,761
Schedule of trade payables break down by payment	Trade payables break down by payment date as follows: As of December 31, (in thousands of euros) 2018 2019 2020 Due in 30 days 7,966 7,414 6,834 Due in 30 ‑ 60 days 406 77 89 Due in more than 60 days — — — Trade payables 8,372 7,491 6,923
Schedule of other current liabilities	As of December 31, (in thousands of euros) 2018 2019 2020 Employee ‑ related payables 1,095 1,124 Accrued payroll and other employee ‑ related taxes 1,052 1,041 Sales tax payables 574 668 Other accrued taxes and employee ‑ related expenses 172 177 Other miscellaneous payables 1,978 1,988 Other current liabilities 4,871 4,998

Contract Liabilities (Tables)

Contract Liabilities (Tables)	12 Months Ended
	Dec. 31, 2020
Contract Liabilities
Schedule of contract liabilities	December 31, 2018 Enyo (in thousands of euros) BI AbbVie Parma Total Short ‑ term contract liabilities 436 15 97 548 Long ‑ term contract liabilities 1,673 — — 1,673 Total contract liabilities 2,109 15 97 2,221 Revenue to be recognized (1) 7,718 100 97 7,915 (1) The revenue to be recognized corresponds to the remaining highly probable revenue to be recognized on the existing contracts until their completion. Milestones and royalties that are not assessed highly probable are not included.

Financial Assets and Liabilit_2

Financial Assets and Liabilities (Tables)	12 Months Ended
	Dec. 31, 2020
Financial Assets and Liabilities
Schedule of financial assets and liabilities	At December 31, 2018 Financial Book value assets on the Financial carried at Liabilities statement assets carried fair value carried at of financial at amortized through amortized (in thousands of euros) position cost profit or loss cost Fair value Financial assets Long ‑ term deposit accounts and security deposits 108 108 — — 108 Accrued income 1,932 1,932 — — 1,932 Trade receivables 6 6 — — 6 Other receivables 874 874 — — 874 Cash and cash equivalents 56,692 56,692 — — 56,692 Total assets 59,612 59,612 — — 59,612 Financial liabilities Long ‑ term debt 74 — — 74 74 Short ‑ term debt 151 — — 151 151 Trade payables 8,372 — — 8,372 8,372 Other miscellaneous payables 1,978 — — 1,978 1,978 Total liabilities 10,575 — — 10,575 10,575 At December 31, 2019 Financial Book value assets on the Financial carried at Liabilities statement assets carried fair value carried at of financial at amortized through amortized (in thousands of euros) position cost profit or loss cost Fair value Financial assets Long-term deposit accounts 792 792 — — 792 Long-term security deposits 8 8 — — 8 Accrued income 2,000 2,000 2,000 Trade receivables 4 4 — — 4 Other receivables 900 — — — 900 Cash and cash equivalents 35,840 35,840 — — 35,840 Total assets 39,545 39,545 — — 39,545 Financial liabilities Long-term debt (1) 2 — — 2 2 Short-term debt (1) 113 — — 113 113 Trade payables 7,491 — — 7,491 7,491 Other miscellaneous payables 1,988 — — 1,988 1,988 Total liabilities 9,594 — — 9,594 9,594 (1) including lease liabilities relating to leased assets falling into the scope of IFRS 16 are included in debt as of December 31, 2019 (see Notes 2.1, "Impact of the first-time application of IFRS 16" and 11, "Debt"). At December 31, 2020 Financial Book value assets on the Financial carried at Liabilities statement assets carried fair value carried at of financial at amortized through amortized (in thousands of euros) position cost profit or loss cost Fair value Financial assets Long ‑ term deposit accounts 1,698 1,698 — — 1,698 Long-term security deposits 8 8 — — 8 Current accrued income 2,000 2,000 — — 2,000 Short ‑ term deposit accounts 7,336 7,336 — — 7,336 Trade receivables 48 48 — — 48 Other receivables 1,849 1,849 — — 1,849 Foreign currency forwards 1,791 — 1,791 — 1,791 Cash and cash equivalents 105,687 105,687 — — 105,687 Total assets 120,417 118,626 1,791 — 120,417 Financial liabilities Long ‑ term debt 10,037 — — 10,037 10,037 Short ‑ term debt (1) 18 — — 18 18 Trade payables 6,923 — — 6,923 6,923 Other miscellaneous payables 3,198 — — 3,198 3,198 Total liabilities 20,177 — — 20,177 20,177 (1) including lease liabilities relating to leased assets falling into the scope of IFRS 16 are included in debt as of December 31, 2020 (see Notes 2.1, "Impact of the first-time application of IFRS 16" and 11 "Debt")

Revenues and Other Income (Tabl

Revenues and Other Income (Tables)	12 Months Ended
	Dec. 31, 2020
Revenues and Other Income
Schedule of revenue and other income	Year ended December 31, (in thousands of euros) 2018 2019 2020 Sales 3,197 6,998 372 Total revenues 3,197 6,998 372 CIR 4,166 4,293 4,791 Subsidies 16 — — Other — 100 Total other income 4,182 4,293 4,891 Total revenues and other income 7,379 11,291 5,263

Operating expenses (Other ope_2

Operating expenses (Other operating income (expenses) excluded) (Tables)	12 Months Ended
	Dec. 31, 2020
Operating expenses (Other operating income (expenses) excluded)
Schedule of Research and Development, Marketing	Research and Marketing — business General and December 31, 2018 development development administrative (in thousands of euros) expenses expenses expenses Total Disposables (2,210) — — (2,210) Energy and liquids (504) — — (504) Patents (401) — — (401) Studies (17,351) — — (17,351) Maintenance (934) — — (934) Fees (98) (1,431) (1,530) IT systems (766) (9) (49) (824) Support costs (including taxes) — — (584) (584) Personnel costs (7,625) (182) (2,266) (10,072) Depreciation, amortization and provisions (890) — (179) (1,069) Other (978) (34) (1,536) (2,549) Total operating expenses (31,758) (225) (6,045) (38,028) Research and Marketing — business General and December 31, 2019 development development administrative (in thousands of euros) expenses expenses expenses Total Disposables (1,560) — — (1,560) Energy and liquids (505) — — (505) Patents (506) — — (506) Studies (19,353) — — (19,353) Maintenance (933) — — (933) Fees (239) — (987) (1,226) IT systems (793) (8) (46) (847) Support costs (including taxes) (568) (568) Personnel costs (8,076) (202) (2,703) (10,981) Depreciation, amortization and provisions (1,060) — (396) (1,456) Other (765) (40) (1,387) (2,192) Total operating expenses (33,790) (250) (6,087) (40,127) Research and Marketing — business General and December 31, 2020 development development administrative (in thousands of euros) expenses expenses expenses Total Disposables (1,243) — — (1,243) Energy and liquids (539) — — (539) Patents (343) — — (343) Studies (10,987) — — (10,987) Maintenance (846) — — (846) Fees (201) (341) (2,005) (2,548) IT systems (597) (8) (46) (651) Support costs (including taxes) — — (722) (722) Personnel costs (7,518) (197) (2,964) (10,680) Depreciation, amortization and provisions (832) — (177) (1,009) Other (608) (16) (2,585) (3,209) Total operating expenses (23,717) (563) (8,499) (32,779)
Schedule of Personnel costs and headcount	Research and Marketing — business General and December 31, 2018 development development administrative (in thousands of euros) expenses expenses expenses Total Wages, salaries and similar costs (5,085) (178) (1,349) (6,613) Payroll taxes (1,981) (3) (576) (2,560) CICE tax credit 103 — 20 124 Provisions for retirement benefit obligations (145) — (45) (190) Share ‑ based compensation expense (516) (1) (316) (833) Total personnel costs (7,625) (182) (2,266) (10,072) Research and Marketing — business General and December 31, 2019 development development administrative (in thousands of euros) expenses expenses expenses Total Wages, salaries and similar costs (4,908) (178) (1,491) (6,577) Payroll taxes (2,206) (1) (634) (2,841) Provisions for retirement benefit obligations (95) — (61) (156) Share ‑ based compensation expense (868) (22) (517) (1,407) Total personnel costs (8,076) (202) (2,703) (10,981) Research and Marketing — business General and December 31, 2020 development development administrative (in thousands of euros) expenses expenses expenses Total Wages, salaries and similar costs (4,590) (183) (1,669) (6,442) Payroll taxes (2,180) 8 (926) (3,098) Provisions for retirement benefit obligations (141) — (60) (202) Share-based compensation expense (607) (22) (309) (938) Total personnel costs (7,518) (197) (2,964) (10,680)

Other Operating Income (expen_2

Other Operating Income (expenses) - (Tables)	12 Months Ended
	Dec. 31, 2020
Other Operating Income (expenses)
Schedule of other operating income (expenses)	Year ended December 31, (in thousands of euros) 2018 2019 2020 Corrective claims - CIR — — 2,863 Accrued income from Abbott — payroll taxes — 68 — Reversal of restructuring expenses — — 43 Total other operating income — 68 2,905 Provision for risk on payroll taxes — (123) (90) Restructuring expenses — (1,096) — Impairment of tax loss carry back — — (333) CIR provision — — (1,804) IPO costs and follow ‑ on offering (2,221) (323) (2,881) Write ‑ down of inventory (33) — — Total other operating expenses (2,255) (1,541) (5,108) Other operating income (expenses) (2,255) (1,475) (2,202)

Financial Income and Expenses (

Financial Income and Expenses (Tables)	12 Months Ended
	Dec. 31, 2020
Financial Income and Expenses
Schedule of financial income and expenses	Year ended December 31, (in thousands of euros) 2018 2019 2020 Income from cash and cash equivalents 120 157 226 Foreign exchange gains 21 18 40 Fair value variation gains / losses — — 1,791 Total financial income 142 175 2,057 Interest cost (4) (3) (66) Losses on cash and cash equivalents (202) — — Foreign exchange losses (36) (62) (5,884) Other financial expenses (11) (16) (8) Interests costs on discounted liabilities — — (8) Total financial expenses (253) (81) (5,959) Net financial income (loss) (111) 93 (3,902)

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax
Schedule of income tax expense	Year ended December 31, (in thousands of euros) 2018 2019 2020 Loss before tax (33,014) (30,218) (33,619) Theoretical tax rate 33.33 % 31 % 31 % Tax benefit at theoretical rate 11,004 9,368 10,422 Tax credits 1,435 1,330 2,373 Permanent differences 827 (21) 1,816 Other differences (269) (404) (522) Non recognition of deferred tax assets related to tax losses and temporary differences (12,997) (10,272) (14,089) Actual income tax benefit — — — of which Current taxes — — — Deferred taxes — — — Effective tax rate — — —

Commitments (Tables)

Commitments (Tables)	12 Months Ended
	Dec. 31, 2020
Commitments
Schedule of commitments	in thousands of euros Start date Date of maturity Counterpart Currency Amount Commitments given Forward in U.S. dollars payable 09/03/2020 05/14/2021 Société Générale USD 20,000,000 Forward in U.S. dollars payable 09/08/2020 05/14/2021 Société Générale USD 20,000,000 Forward in U.S. dollars payable 10/30/2020 05/14//2021 Crédit Agricole USD 20,000,000 Commitments received Forward in euros to be received 09/03/2020 05/14/2021 Société Générale EUR 16,794,021 Forward in euros to be received 09/08/2020 05/14/2021 Société Générale EUR 16,794,021 Forward in euros to be received 10/30/2020 05/14//2021 Crédit Agricole EUR 17,001,020

Related-Party Transactions (Tab

Related-Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2020
Related-Party Transactions
Schedule of transactions with key management personnel	Year ended December 31, (in thousands of euros) 2018 2019 2020 Wages and salaries 944 1,113 1,369 Benefits in kind 46 47 42 Pension plan expenses 41 66 77 Share ‑ based compensation expense 354 280 259 Attendance fees 200 206 258 Net total 1,585 1,712 2,005

Basic and Diluted Loss Per Sh_2

Basic and Diluted Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2020
Basic and Diluted Loss Per Share
Schedule of basic earnings (loss) per share	Year ended December 31, (in thousands of euros) 2018 2019 2020 Net loss for the period (33,014) (30,218) (33,619) Weighted average number of outstanding shares used for computing basic/diluted loss per share 20,540,979 23,519,897 33,874,751 Basic/diluted loss per share (in €) (1.61) (1.28) (0.99)

Financial Risk Management (Tabl

Financial Risk Management (Tables)	12 Months Ended
	Dec. 31, 2020
Financial Risk Management
Schedule of sensitivity analysis of the company's assets.	Impact of a 5% Fair Value as of change in (in thousands of euros) December 31, 2020 fair value Cash and cash equivalents dominated in U.S. Dollar 72,429 (3,449) Short-term deposit accounts dominated in U.S. Dollar 7,336 (349)

Company Information - Capital i

Company Information - Capital increase of 14.7 million (Details) - EUR (€) € / shares in Units, € in Thousands	Feb. 07, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of classes of share capital [line items]
Par value per share		€ 0.01
Net proceeds from issuance of shares		€ 101,782	€ 8,654	€ 32,526
Issue of ordinary shares		€ 109,099	€ 8,903	€ 35,497
BVF Partners L.P., Novo A/S, New Enterprise Associates 17, L.P. and Sofinnova Partners
Disclosure of classes of share capital [line items]
Number of shares issued during the period	3,778,338
Price per share	€ 3.97
Par value per share	0.01
Issue premium per share	€ 3.96
Net proceeds from issuance of shares	€ 14,700
Issue of ordinary shares	€ 15,000

Company Information - USD 107.7

Company Information - USD 107.7 million initial public offering (Details) $ / shares in Units, $ in Millions	Jul. 15, 2020USD ($)directorcontract$ / sharesshares	Jul. 15, 2020EUR (€)directorcontractshares	Jul. 31, 2020USD ($)	Feb. 29, 2020EUR (€)	Oct. 31, 2019EUR (€)	Dec. 31, 2020EUR (€)	Dec. 31, 2019EUR (€)	Dec. 31, 2018EUR (€)	Jul. 15, 2020EUR (€)shares
Disclosure of classes of share capital [line items]
Gross proceeds from Initial Public Offering	$ 107.7		$ 107.7	€ 14,700,000	€ 8,900,000
Share capital						€ 386,000	€ 268,000	€ 223,000
Number of new insurances entered | contract	2	2
Insurance amount | $	$ 3.6
Contracts coverage period						1 year
Prepaid expenses						€ 3,313,000	495,000	1,184,000
Offering expense						7,397,000	€ 324,000	€ 3,079,000
Other Operating Income (Expenses)
Disclosure of classes of share capital [line items]
Additional expense including offering expense						1,800,000
Offering expense						800,000
Other Current Assets and Receivables
Disclosure of classes of share capital [line items]
Prepaid expenses						€ 1,800,000
American Depositary Shares
Disclosure of classes of share capital [line items]
Issue of ordinary shares (in shares) | shares	7,478,261	7,478,261
Price per share | $ / shares	$ 14.40
Gross proceeds from Initial Public Offering	$ 107.7	€ 94,100,000
Share capital									€ 383,930.11
Number of shares issued | shares	38,393,011								38,393,011
Public Offering of Securities Insurance
Disclosure of classes of share capital [line items]
Insurance amount									€ 1,600,000
Directors and Officers Liability Insurance
Disclosure of classes of share capital [line items]
Insurance amount									€ 2,000,000
Number of executive directors under directors' and officers' liability insurance | director	2	2

Company Information - Bonus sha

Company Information - Bonus share award plans ("AGA") (Details)	Dec. 14, 2020EUR (€)€ / shares	Jun. 28, 2020EUR (€)€ / shares	Jan. 26, 2020EUR (€)€ / shares	Dec. 31, 2020EUR (€)€ / shares	Dec. 31, 2019EUR (€)	Dec. 31, 2018EUR (€)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of bonus shares granted					10,000
Number of bonus shares fully vested					27,400
Capital increase arising from the vesting of bonus share awards | €				€ 938,000	€ 1,407,000	€ 833,000
Par value per share | € / shares				€ 0.01
AGA
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of bonus shares fully vested				517,550
AGA 2018-2
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of bonus shares granted				65,700		65,700
Vesting period				2 years
Number of bonus shares fully vested			63,300	63,300
Capital increase arising from the vesting of bonus share awards | €			€ 633,000
Par value per share | € / shares			€ 0.01
AGA 2019-2
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of bonus shares granted				246,000	246,000
Vesting period				1 year
Number of bonus shares fully vested		227,000		227,000
Capital increase arising from the vesting of bonus share awards | €		€ 2,270
Par value per share | € / shares		€ 0.01
AGA 2018-3
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of bonus shares granted				265,700		265,700
Vesting period				2 years
Number of bonus shares fully vested	227,250			227,250
Capital increase arising from the vesting of bonus share awards | €	€ 2,272,500
Par value per share | € / shares	€ 0.01

Company information - New share

Company information - New share warrant plans ("BSA") (Details)	Mar. 09, 2020item	Dec. 31, 2020item	Dec. 31, 2020	Dec. 31, 2019item
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of other equity instruments granted in share-based payment arrangement				10,000
BSA 2019 bis
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of other equity instruments granted in share-based payment arrangement		10,000	10,000
BSA 2019 bis | Jeremy Goldberg
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share warrants granted	10,000
BSA 2019 ter
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of other equity instruments granted in share-based payment arrangement		36,000	36,000
BSA 2019 ter | David Nikodem
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share warrants granted	36,000		36,000
BSA - 2019 plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of other equity instruments granted in share-based payment arrangement	46,000			10,000
BSA - 2019 plan | David Nikodem
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of other equity instruments granted in share-based payment arrangement				10,000

Company Information - Tax audit

Company Information - Tax audit on payroll tax (Details) - EUR (€) € in Millions	Oct. 30, 2020	Jun. 16, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 08, 2020
Other Non Current Assets [Line Items]
Amount of guarantee				€ 1.7
Payroll Tax Audit, 2016, 2017 and 2018
Other Non Current Assets [Line Items]
Proposed payroll tax adjustment			€ 1.7
Payroll Tax Audit, 2018
Other Non Current Assets [Line Items]
Concession granted on disputed payroll taxes		€ 0.5
Payroll Tax Audit, 2016 and 2017
Other Non Current Assets [Line Items]
Payment of payroll taxes for taxable year	€ 1.2
Amount of guarantee					€ 1.2

Company Information - Surety pr

Company Information - Surety provided to the French tax authorities (Details) € in Thousands	Dec. 31, 2020EUR (€)item	Jun. 30, 2020EUR (€)	Dec. 31, 2019EUR (€)	Feb. 01, 2019EUR (€)item	Dec. 31, 2018EUR (€)
Other Non Current Assets [Line Items]
Amount of guarantee	€ 1,700
Longterm deposit accounts	1,698		€ 792		€ 108
Amount of pledge as a percentage of sum not covered by the indemnity to be received				50.00%
Tax Disputees With French Tax Authorities
Other Non Current Assets [Line Items]
Amount of guarantee	€ 1,700			€ 1,700
Number of pledges over cash | item	2			2
Pledge over cash, one | Tax Disputees With French Tax Authorities
Other Non Current Assets [Line Items]
Amount of guarantee				€ 700
Number of pledges over cash | item				1
Amount of pledge as a percentage of sum not covered by the indemnity to be received				50.00%
Pledge over cash, two
Other Non Current Assets [Line Items]
Amount of guarantee	€ 1,000
Pledge over cash, two | Tax Disputees With French Tax Authorities
Other Non Current Assets [Line Items]
Amount of guarantee		€ 1,000
Crdit Agricole bank
Other Non Current Assets [Line Items]
Number of pledges over cash | item	2
Amount of pledge as a percentage of sum not covered by the indemnity to be received	50.00%
Crdit Agricole bank | If dispute remains unresolved
Other Non Current Assets [Line Items]
Amount of guarantee	€ 3,400
Crdit Agricole bank | Tax Disputees With French Tax Authorities
Other Non Current Assets [Line Items]
Amount of guarantee	3,400			€ 3,400
Crdit Agricole bank | Pledge over cash, one
Other Non Current Assets [Line Items]
Amount of guarantee	€ 700
Number of pledges over cash | item	1

Company Information - Tax aud_2

Company Information - Tax audit on research tax credit (Details) - EUR (€) € in Millions	1 Months Ended	12 Months Ended
	Jan. 31, 2020	Dec. 31, 2020	Aug. 01, 2017
Disclosure of other provisions [line items]
Mediator's waiver amount		€ 0.3
Provision for CIR related to tax audit for years 2013 to 2015
Disclosure of other provisions [line items]
Tax Collection Amount			€ 1.9
Provision for CIR risk related to tax audit for the year ended December 31, 2018
Disclosure of other provisions [line items]
French Research Tax Credit (CIR), payments received	€ 4.2
Provision for CIR risk related to tax audit for the year ended December 31, 2019
Disclosure of other provisions [line items]
French Research Tax Credit (CIR), payments received	€ 4.3

Company Information - Research

Company Information - Research tax credit (Details) - EUR (€) € in Millions	1 Months Ended	12 Months Ended
	Jan. 31, 2020	Dec. 31, 2020
Provision for CIR risk related to tax audit for the year ended December 31, 2018
Disclosure of other provisions [line items]
French Research Tax Credit (CIR), payments received	€ 4.2
Provision for CIR risk related to tax audit for the year ended December 31, 2019
Disclosure of other provisions [line items]
French Research Tax Credit (CIR), payments received	€ 4.3
Provision for CIR risk related to tax audit for the year ended December 31, 2018 and 2019
Disclosure of other provisions [line items]
French Research Tax Credit (CIR), payments received		€ 8.4

Company Information - Non-dilut

Company Information - Non-dilutive financing of 10 million (Details) € in Thousands	1 Months Ended	12 Months Ended
	May 31, 2020EUR (€)loan	Dec. 31, 2020EUR (€)
Disclosure of detailed information about borrowings [line items]
Loan obtained		€ 9,979
Financing from a syndicate of French banks
Disclosure of detailed information about borrowings [line items]
Loan obtained	€ 10,000
Number of loans obtained guaranteed by the french state | loan	3
Extension of term of debt	4 years	4 years

Company Information - Completio

Company Information - Completion of a future currency contract (Details) $ in Millions	Dec. 31, 2020contract	Oct. 31, 2020USD ($)	Sep. 30, 2020USD ($)item	Oct. 31, 2020USD ($)
Company Information
Number of future currency contracts completed	3		2
Amount of future currency contracts completed		$ 20	$ 40	$ 60

Company Information - Reinvestm

Company Information - Reinvestment of short-term USD deposits (Details) $ in Millions	1 Months Ended	2 Months Ended
	Nov. 30, 2020item	Oct. 31, 2020USD ($)
Company Information
Reinvestment of short-term USD deposits | $		$ 9
Number of short-term deposits | item	2

Statement of Compliance (Detail

Statement of Compliance (Details)	Jan. 01, 2019EUR (€)leaseitem	Dec. 31, 2020EUR (€)	Dec. 31, 2019EUR (€)	Dec. 31, 2018EUR (€)	Dec. 31, 2017EUR (€)
Disclosure of initial application of standards or interpretations [line items]
Number of types of leases that met IFRS 16 criteria | lease	2
Carrying amount of net property, plant and equipment		€ 3,282,000	€ 3,721,000	€ 4,261,000	€ 4,516,000
Net impact on income statement		(33,619,000)	(30,218,000)	(33,014,000)
IFRS 16
Disclosure of initial application of standards or interpretations [line items]
Incremental borrowing rate	1.57%
Underlying assets of leases not restated	€ 5,000	€ 5,000
Increase in net property, plant and equipment			37,000
Carrying amount of net property, plant and equipment			49,000	€ 4,513,000
Net impact on income statement			€ 12,000
IFRS 16 | Vehicles
Disclosure of initial application of standards or interpretations [line items]
Leased assets | item	2
IFRS 16 | Fibroscan machines
Disclosure of initial application of standards or interpretations [line items]
Leased assets | item	10
IFRS 16 | Cumulative Effect, Period of Adoption, Adjustment
Disclosure of initial application of standards or interpretations [line items]
Increase in debt	€ 200,000
Increase in net property, plant and equipment	300,000
Prepaid expense	€ 100,000

Accounting Principles - Intangi

Accounting Principles - Intangible assets (Details)	12 Months Ended
	Dec. 31, 2020
Software licenses | Minimum
Accounting Principles
Expected useful life of intangible assets	1 year
Software licenses | Maximum
Accounting Principles
Expected useful life of intangible assets	5 years
Library of compounds
Accounting Principles
Expected useful life of intangible assets	13 years

Accounting Principles - Propert

Accounting Principles - Property, plant and equipment (Details)	12 Months Ended
	Dec. 31, 2020
Buildings | Minimum
Accounting Principles
Useful lives of property, plant and equipment	20 years
Buildings | Maximum
Accounting Principles
Useful lives of property, plant and equipment	25 years
Fixtures and fittings
Accounting Principles
Useful lives of property, plant and equipment	10 years
Technical facilities | Minimum
Accounting Principles
Useful lives of property, plant and equipment	6 years
Technical facilities | Maximum
Accounting Principles
Useful lives of property, plant and equipment	10 years
Equipment and tooling | Minimum
Accounting Principles
Useful lives of property, plant and equipment	6 years
Equipment and tooling | Maximum
Accounting Principles
Useful lives of property, plant and equipment	10 years
General facilities, miscellaneous fixtures and fittings
Accounting Principles
Useful lives of property, plant and equipment	10 years
Office equipment
Accounting Principles
Useful lives of property, plant and equipment	5 years
IT equipment
Accounting Principles
Useful lives of property, plant and equipment	5 years
Furniture
Accounting Principles
Useful lives of property, plant and equipment	10 years

Accounting Principles - Leases

Accounting Principles - Leases contracts (Details) - EUR (€)	Dec. 31, 2020	Jan. 01, 2019
IFRS 16
Disclosure of initial application of standards or interpretations [line items]
Underlying assets of leases not restated	€ 5,000	€ 5,000

Accounting Principles - Share b

Accounting Principles - Share based payments (Details)	12 Months Ended
	Dec. 31, 2020
Accounting Principles
Number of BSA share warrant plan set up	2

Accounting Principles - Fair va

Accounting Principles - Fair value measurement (Details) - EUR (€)	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Accounting Principles
Financial assets	€ 120,417,000	€ 39,545,000	€ 59,612,000
Financial liabilities	20,177,000	9,594,000	10,575,000
Long term deposit accounts
Accounting Principles
Financial assets	1,698,000	792,000
Financial assets at fair value through profit or loss
Accounting Principles
Financial assets	1,791,000
At fair value
Accounting Principles
Financial assets		0	0
Financial liabilities		€ 0	€ 0
Level 2 | At fair value
Accounting Principles
Financial assets	1,791,000
Level 2 | At fair value | Financial assets at fair value through profit or loss | Foreign currency forwards
Accounting Principles
Financial assets	€ 1,791,000

Accounting Principles - Foreign

Accounting Principles - Foreign currency transactions and Segment information (Details) € in Millions	12 Months Ended
	Dec. 31, 2020EUR (€)
Accounting Principles
Foreign currency expense amount	€ 2.5
Foreign currency expenses as a percentage of operating expenses	7.00%

Accounting Principles - Segment

Accounting Principles - Segment information (Details)	12 Months Ended
	Dec. 31, 2020
Accounting Principles
Number of operating segments	1

Intangible Assets (Details)

Intangible Assets (Details) - EUR (€)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Reconciliation of changes in intangible assets other than goodwill [abstract]
Balance at the beginning	€ 1,228,000	€ 1,543,000	€ 1,806,000
Increases	(293,000)	(314,000)	(264,000)
Balance at the end	935,000	1,228,000	1,543,000
Amortization charges	300,000	300,000	300,000
Gross
Reconciliation of changes in intangible assets other than goodwill [abstract]
Balance at the beginning	3,674,000	3,646,000	3,540,000
Increases	0	29,000	106,000
Balance at the end	3,674,000	3,674,000	3,646,000
Amortization and impairment
Reconciliation of changes in intangible assets other than goodwill [abstract]
Balance at the beginning	(2,446,000)	(2,103,000)	(1,733,000)
Increases	(293,000)	(343,000)	(369,000)
Balance at the end	(2,739,000)	(2,446,000)	(2,103,000)
Library of compounds | Gross
Reconciliation of changes in intangible assets other than goodwill [abstract]
Balance at the beginning	2,142,000	2,142,000	2,142,000
Balance at the end	2,142,000	2,142,000	2,142,000
Library of compounds | Amortization and impairment
Reconciliation of changes in intangible assets other than goodwill [abstract]
Balance at the beginning	(1,157,000)	(993,000)	(828,000)
Increases	(165,000)	(165,000)	(165,000)
Balance at the end	(1,322,000)	(1,157,000)	(993,000)
Software licenses | Gross
Reconciliation of changes in intangible assets other than goodwill [abstract]
Balance at the beginning	1,533,000	1,504,000	1,398,000
Increases	0	29,000	106,000
Balance at the end	1,533,000	1,533,000	1,504,000
Software licenses | Amortization and impairment
Reconciliation of changes in intangible assets other than goodwill [abstract]
Balance at the beginning	(1,289,000)	(1,110,000)	(906,000)
Increases	(129,000)	(179,000)	(204,000)
Balance at the end	€ (1,417,000)	€ (1,289,000)	€ (1,110,000)

Property, Plant and Equipment_2

Property, Plant and Equipment (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Reconciliation of changes in property, plant and equipment [abstract]
Balance at the beginning	€ 3,721	€ 4,261	€ 4,516
Increases	(424)	(790)	(255)
Decreases	0	(2)
Reclassifications	(16)
Balance at the end	3,282	3,721	4,261
Depreciation charges	700	900
IFRS 16
Reconciliation of changes in property, plant and equipment [abstract]
Balance at the beginning	49	4,513
Balance at the end		49	4,513
Gross
Reconciliation of changes in property, plant and equipment [abstract]
Balance at the beginning	9,736	9,380	8,937
Increases	292	107	443
Decreases	0	(2)
Reclassifications	(218)
Balance at the end	9,810	9,736	9,380
Gross | IFRS 16
Reconciliation of changes in property, plant and equipment [abstract]
Balance at the beginning		9,632
Balance at the end			9,632
Amortization and impairment
Reconciliation of changes in property, plant and equipment [abstract]
Balance at the beginning	(6,015)	(5,119)	(4,421)
Increases	(716)	(897)	(698)
Decreases		1
Reclassifications	202
Balance at the end	(6,528)	(6,015)	(5,119)
Land | Gross
Reconciliation of changes in property, plant and equipment [abstract]
Balance at the beginning	172	172	172
Balance at the end	172	172	172
Buildings | Gross
Reconciliation of changes in property, plant and equipment [abstract]
Balance at the beginning	3,407	3,407	3,407
Balance at the end	3,407	3,407	3,407
Buildings | Amortization and impairment
Reconciliation of changes in property, plant and equipment [abstract]
Balance at the beginning	(1,542)	(1,346)	(1,144)
Increases	(196)	(196)	(202)
Balance at the end	(1,737)	(1,542)	(1,346)
Technical facilities, equipment and tooling | Gross
Reconciliation of changes in property, plant and equipment [abstract]
Balance at the beginning	4,748	4,677	4,267
Increases	108	74	334
Decreases	0	(2)
Reclassifications			75
Balance at the end	4,856	4,748	4,677
Technical facilities, equipment and tooling | Amortization and impairment
Reconciliation of changes in property, plant and equipment [abstract]
Balance at the beginning	(3,396)	(2,999)	(2,608)
Increases	(386)	(398)	(391)
Decreases		1
Balance at the end	(3,782)	(3,396)	(2,999)
Other property, plant and equipment | Gross
Reconciliation of changes in property, plant and equipment [abstract]
Balance at the beginning	1,157	1,081	1,023
Increases	46	33	58
Decreases	0
Reclassifications		43
Balance at the end	1,203	1,157	1,081
Other property, plant and equipment | Amortization and impairment
Reconciliation of changes in property, plant and equipment [abstract]
Balance at the beginning	(874)	(774)	(668)
Increases	(102)	(100)	(105)
Balance at the end	(976)	(874)	(774)
Property, plant and equipment in progress | Gross
Reconciliation of changes in property, plant and equipment [abstract]
Balance at the beginning		43	67
Increases	137		51
Reclassifications		(43)	(75)
Balance at the end	137		43
Right of use | Gross
Reconciliation of changes in property, plant and equipment [abstract]
Balance at the beginning	252	252
Reclassifications	(218)
Balance at the end	34	252	€ 252
Right of use | Amortization and impairment
Reconciliation of changes in property, plant and equipment [abstract]
Balance at the beginning	(203)
Increases	(32)	(203)
Reclassifications	202
Balance at the end	€ (33)	€ (203)

Other Non-Current Assets (Detai

Other Non-Current Assets (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Other Non-Current Assets
Accrued income		€ 2,000	€ 1,932
Longterm deposit accounts	€ 1,698	792	108
Security deposits	8	8
Tax loss carry back		333	333
Other noncurrent assets	€ 1,706	€ 3,135	€ 2,374

Other Non-Current Assets - Long

Other Non-Current Assets - Long-term deposit accounts (Details) € in Thousands	12 Months Ended
	Dec. 31, 2020EUR (€)item	Feb. 10, 2021EUR (€)	Jun. 30, 2020EUR (€)	Feb. 01, 2019EUR (€)item
Other Non Current Assets [Line Items]
Maximum indemnification amount		€ 2,000
Bank guarantee and pledge of gradual rate deposit account	€ 1,700
Amount of pledge as a percentage of sum not covered by the indemnity to be received				50.00%
Period for tax credit recoverable if not used by the Company to pay income tax	5 years
Pledge over cash, two
Other Non Current Assets [Line Items]
Bank guarantee and pledge of gradual rate deposit account	€ 1,000
Tax Disputees With French Tax Authorities
Other Non Current Assets [Line Items]
Number of pledges over cash | item	2			2
Bank guarantee and pledge of gradual rate deposit account	€ 1,700			€ 1,700
Tax Disputees With French Tax Authorities | Pledge over cash, one
Other Non Current Assets [Line Items]
Number of pledges over cash | item				1
Bank guarantee and pledge of gradual rate deposit account				€ 700
Amount of pledge as a percentage of sum not covered by the indemnity to be received				50.00%
Tax Disputees With French Tax Authorities | Pledge over cash, two
Other Non Current Assets [Line Items]
Bank guarantee and pledge of gradual rate deposit account			€ 1,000
Crdit Agricole bank
Other Non Current Assets [Line Items]
Number of pledges over cash | item	2
Amount of pledge as a percentage of sum not covered by the indemnity to be received	50.00%
Crdit Agricole bank | If dispute remains unresolved
Other Non Current Assets [Line Items]
Bank guarantee and pledge of gradual rate deposit account	€ 3,400
Crdit Agricole bank | Pledge over cash, one
Other Non Current Assets [Line Items]
Number of pledges over cash | item	1
Bank guarantee and pledge of gradual rate deposit account	€ 700
Crdit Agricole bank | Tax Disputees With French Tax Authorities
Other Non Current Assets [Line Items]
Bank guarantee and pledge of gradual rate deposit account	3,400			€ 3,400
Socit Gnrale
Other Non Current Assets [Line Items]
Bank guarantee and pledge of gradual rate deposit account	101
Loan amount	€ 254

Inventories (Details)

Inventories (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Schedule of Inventory Disclosure [Line Items]
Inventories	€ 320	€ 387	€ 410
Gross
Schedule of Inventory Disclosure [Line Items]
Inventories	353	420	443
Inventories write-down
Schedule of Inventory Disclosure [Line Items]
Inventories	€ (33)	€ (33)	€ (33)

Trade Receivables and Other C_3

Trade Receivables and Other Current Assets and Receivables - Trade Receivables (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Trade Receivables and Other Current Assets and Receivables [Line Items]
Trade receivables	€ 48	€ 4	€ 6
Average payment period for trade receivables	30 days
3 months or less
Trade Receivables and Other Current Assets and Receivables [Line Items]
Trade receivables	€ 48	€ 4	€ 6

Trade Receivables and Other C_4

Trade Receivables and Other Current Assets and Receivables - Other Current Assets and Receivables (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Trade Receivables and Other Current Assets and Receivables
CIR	€ 9,012	€ 9,818	€ 9,158
CICE tax credit			264
Other	16	16	12
Tax receivables	9,028	9,833	9,434
Prepaid expenses	3,313	495	1,184
Short-term deposit accounts	7,336
Current accrued income	2,000
Foreign currency forwards	1,791
Liquidity agreement - Cash account	1,029	261	31
VAT receivable	1,625	1,416	3,033
Other receivables	821	639	843
Other current assets	17,914	2,811	5,092
Other current assets and receivables	€ 26,942	€ 12,644	€ 14,526

Trade Receivables and Other C_5

Trade Receivables and Other Current Assets and Receivables - Additional Information (Details) € in Thousands, $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2019EUR (€)	Dec. 31, 2020EUR (€)contract	Feb. 10, 2021EUR (€)	Dec. 31, 2020USD ($)	Dec. 31, 2020EUR (€)	Dec. 31, 2019EUR (€)	Dec. 31, 2018EUR (€)	Dec. 31, 2017EUR (€)
Trade Receivables and Other Current Assets and Receivables [Line Items]
Research tax credits receivable from current tax year					€ 4,800
Corrective claims for additional reimbursements of CIR, prior years		€ 2,900
Short-term deposit accounts					7,336
Maximum indemnification amount			€ 2,000
Number of contracts under foreign currency forward | contract		3
Amount of foreign currency forward contract | $				$ 60
Deferral of insurance costs					1,800
Tax receivables					9,028	€ 9,833	€ 9,434
Receivable for current year						4,293
Receivables from previous years not yet received							4,171	€ 880
Corrective claims								478
Receivables from previous years not yet received including corrective claim								€ 4,513
Amount received for tax credit	€ 3,633
Percentage of amount received for tax credit	81.00%
Prepaid expenses					3,313	€ 495	€ 1,184
Socit Gnrale
Trade Receivables and Other Current Assets and Receivables [Line Items]
Short-term deposit accounts				4	3,300
Crdit Agricole bank
Trade Receivables and Other Current Assets and Receivables [Line Items]
Short-term deposit accounts				$ 5	€ 4,100

Cash and Cash Equivalents (Deta

Cash and Cash Equivalents (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash and Cash Equivalents
Other cash equivalents	€ 12,001	€ 14,004	€ 41,767
Cash at bank and at hand	93,686	21,837	14,925
Cash and cash equivalents	€ 105,687	€ 35,840	€ 56,692	€ 59,051

Shareholders' Equity (Details)

Shareholders' Equity (Details) - EUR (€) € / shares in Units, € in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Shareholders' Equity
Share capital	€ 386	€ 268	€ 223
Number of fully authorized, subscribed and paid up shares	38,630,261
Nominal value per share	€ 0.01

Shareholders' Equity - Changes

Shareholders' Equity - Changes in share capital (Details) € / shares in Units, $ in Millions	Dec. 14, 2020EUR (€)€ / sharesshares	Nov. 30, 2020EUR (€)€ / sharesshares	Jul. 15, 2020USD ($)shares	Jul. 15, 2020EUR (€)€ / sharesshares	Jun. 28, 2020EUR (€)€ / sharesshares	Apr. 18, 2020EUR (€)	Apr. 17, 2020EUR (€)	Feb. 07, 2020EUR (€)€ / sharesshares	Jan. 26, 2020EUR (€)€ / sharesshares	Oct. 02, 2019EUR (€)item€ / sharesshares	Sep. 20, 2019EUR (€)item€ / sharesshares	Apr. 18, 2019EUR (€)€ / sharesshares	Jan. 26, 2019EUR (€)€ / sharesshares	Jan. 23, 2019EUR (€)€ / sharesshares	Dec. 31, 2018EUR (€)€ / sharesshares	Apr. 18, 2018EUR (€)€ / sharesshares	Apr. 17, 2018EUR (€)€ / sharesshares	Jan. 26, 2018EUR (€)€ / sharesshares	Jul. 31, 2020USD ($)	Feb. 29, 2020EUR (€)	Apr. 30, 2018EUR (€)	Oct. 31, 2019EUR (€)	Dec. 31, 2020EUR (€)€ / sharesshares	Dec. 31, 2019EUR (€)€ / sharesshares	Dec. 31, 2018EUR (€)€ / sharesshares	Dec. 31, 2017EUR (€)€ / sharesshares
Disclosure of classes of share capital [line items]
Balance															€ 61,596,000								€ 111,211,000	€ 41,392,000	€ 61,596,000	€ 61,292,000
Number of shares outstanding | shares																							38,630,261
Nominal value per share | € / shares																							€ 0.01
Issue of ordinary shares																							€ 109,099,000	8,903,000	35,497,000
Gross Proceeds From Issuing Shares			$ 107.7																$ 107.7	€ 14,700,000		€ 8,900,000
Reclassification of debit retained earnings to premium related to share capital						€ 48,000,000
New Enterprise Associates (NEA), as well as BVF Partners L.P., Sofinnova Partners and Novo Holdings A/S
Disclosure of classes of share capital [line items]
Issue of ordinary shares																							8,900,000
Transaction costs																								300,000	3,100,000
Number of capital increases | item										2	2
Share capital
Disclosure of classes of share capital [line items]
Balance															€ 222,573								€ 386,302	€ 268,461	€ 222,573	€ 164,445
Number of shares outstanding | shares															22,257,277								38,630,261	26,846,112	22,257,277	16,444,477
Nominal value per share | € / shares	€ 0.01	€ 0.01		€ 0.01	€ 0.01			€ 0.01	€ 0.01	€ 0.01	€ 0.01	€ 0.01	€ 0.01	€ 0.01	€ 0.01	€ 0.01	€ 0.01	€ 0.01					€ 0.01	€ 0.01	€ 0.01	€ 0.01
Issue of ordinary shares		€ 100		€ 74,783				€ 37,783		€ 3,139	€ 41,600						€ 55,725						€ 113,000	€ 45,000	€ 56,000
Number of shares issued during the period | shares		10,000	7,478,261	7,478,261				3,778,338		313,936	4,159,999				22,257,277		5,572,500						11,256,599,000	4,473,935	5,572,500
Share capital | BSPCE plans
Disclosure of classes of share capital [line items]
Issue of ordinary shares														€ 274				€ 1,803
Number of shares issued during the period | shares														27,400				180,300
Share capital | AGA Bonus Plans
Disclosure of classes of share capital [line items]
Issue of ordinary shares	€ 2,273				€ 2,270				€ 633			€ 775	€ 100			€ 600
Number of shares issued during the period | shares	227,250				227,000				63,300			77,500	10,000			60,000
Premiums related to share capital
Disclosure of classes of share capital [line items]
Balance															€ 77,460,125								€ 139,667,603	€ 86,011,893	€ 77,460,125	€ 44,991,815
Issue of ordinary shares		€ 66,650		€ 94,024,272				€ 14,962,218		€ 621,593	€ 8,236,798						€ 35,441,100				€ 32,400,000		108,986,000	€ 8,858,000	€ 35,441,000
Transaction costs				€ (7,077,866)				€ (319,564)		€ (12,023)	€ (312,294)						€ (3,079,174)
Appropriation of the issue premium							€ (48,000,000)																€ (48,000,000)
Number of existing shareholders | item										3	3
Premiums related to share capital | BSPCE plans
Disclosure of classes of share capital [line items]
Issue of ordinary shares														€ 17,693				€ 106,384

Shareholders' Equity - Liquidit

Shareholders' Equity - Liquidity agreement (Details)	Jan. 19, 2018	Dec. 31, 2020
Shareholders' Equity
Liquidity Agreement Term	12 months	12 months

Shareholders' Equity - Share wa

Shareholders' Equity - Share warrants plans (Details) - Bonus share award plans - € / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Subscription price				€ 0.534
Service Providers
Disclosure of terms and conditions of share-based payment arrangement [line items]
Subscription price			€ 0.48
David Nikodem
Disclosure of terms and conditions of share-based payment arrangement [line items]
Subscription price	€ 0.29	€ 0.18

Shareholders' Equity - Characte

Shareholders' Equity - Characteristics of BSPCE share warrants plans (Details)	1 Months Ended	12 Months Ended
	Jan. 20, 2018item	Dec. 31, 2020€ / sharesshares	Dec. 31, 2019shares	Dec. 31, 2018shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of bonus shares granted			10,000
BSPCE plans
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share warrants outstanding		88	88	362
Number of share per warrant		100
Number of bonus shares granted | item	180,300
BSPCE 2013-1
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share per warrant		100
Number of bonus shares granted		9,027
BSPCE exercise price () | € / shares		€ 58.50

Shareholders' Equity - Charac_2

Shareholders' Equity - Characteristics of BSA share warrant plans (Details)	12 Months Ended
	Dec. 31, 2020EUR (€)€ / sharesshares	Dec. 31, 2020EUR (€)item€ / sharesshares	Dec. 31, 2020EUR (€)€ / sharesshares	Dec. 31, 2019€ / shares	Dec. 31, 2018€ / shares	Jan. 01, 2020item
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued				10,000
BSA share warrants
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of free share award plans | item						3
BSA - 2017 plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued | item		195,000
Number of shares per BSA | shares	1	1	1
Subscription premium price per share ()	€ 0.534	€ 0.534	€ 0.534
Exercise price (in euros)	€ 6.675	€ 6.675	€ 6.675	€ 6.67	€ 6.67
Fair value per BSA at grant date () | €	€ 2.47	€ 2.47	€ 2.47
Expected volatility			40.00%
Average life (years)			6
Risk free rate			0.22%
BSA - 2017 plan | Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period	1 year
BSA - 2017 plan | Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period	2 years
BSA - 2017 plan | Tranche three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period	3 years
BSA - 2018 plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued					126,000
Exercise price (in euros)	€ 6.070	€ 6.070	€ 6.070	€ 6.07	€ 6.067
BSA 2018-1
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued | item		126,000
Number of shares per BSA | shares	1	1	1
Subscription premium price per share ()	€ 0.480	€ 0.480	€ 0.480
Exercise price (in euros)	€ 6.067	€ 6.067	€ 6.067
Fair value per BSA at grant date () | €	€ 1.98	€ 1.98	€ 1.98
Expected volatility			40.00%
Average life (years)			6
Risk free rate			0.30%
BSA 2018-1 | Maximum
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period	3 years
BSA 2018-1 | Minimum
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period	1 year
BSA 2019
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period	1 year
Issued | item		10,000
Number of shares per BSA | shares	1	1	1
Subscription premium price per share ()	€ 0.180	€ 0.180	€ 0.180
Exercise price (in euros)	€ 2.200	€ 2.200	€ 2.200
Fair value per BSA at grant date () | €	€ 0.48	€ 0.48	€ 0.48
Expected volatility			40.00%
Average life (years)			5.5
Risk free rate			0.33%
BSA 2019 bis
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period	1 year
Issued		10,000	10,000
Number of shares per BSA | shares	1	1	1
Subscription premium price per share ()	€ 0.290	€ 0.290	€ 0.290
Exercise price (in euros)	€ 3.680	€ 3.680	€ 3.680
Fair value per BSA at grant date () | €	€ 0.90	€ 0.90	€ 0.90
Expected volatility			40.00%
Average life (years)			6
Risk free rate			0.00%
BSA 2019 ter
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued		36,000	36,000
Number of shares per BSA | shares	1	1	1
Subscription premium price per share ()	€ 0.290	€ 0.290	€ 0.290
Exercise price (in euros)	€ 3.680	€ 3.680	€ 3.680
Fair value per BSA at grant date () | €	€ 0.90	€ 0.90	€ 0.90
Expected volatility			40.00%
Average life (years)			6
Risk free rate			0.00%
BSA 2019 ter | Maximum
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period	3 years
BSA 2019 ter | Minimum
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period	1 year

Shareholders' Equity - Movement

Shareholders' Equity - Movements in BSPCE and BSA share warrants (in number of shares issuable upon exercise) (Details) € / shares in Units, € in Thousands	Mar. 09, 2020item	May 27, 2019item	Jan. 23, 2019shares	Jan. 20, 2018itemshares	Dec. 31, 2020item€ / sharesshares	Dec. 31, 2020€ / sharesshares	Dec. 31, 2020EUR (€)€ / sharesshares	Dec. 31, 2019item€ / sharesshares	Dec. 31, 2019€ / sharesshares	Dec. 31, 2019EUR (€)€ / sharesshares	Dec. 31, 2018EUR (€)item€ / sharesshares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, Beginning balance						274,800			337,200
Issued									10,000
Exercised/Vesting									(27,400)
Forfeited									(45,000)
Outstanding, Ending balance									274,800		337,200
Number of shares exercisable								167,467	167,467	167,467
Share based payment expense | €							€ 920			€ 1,180	€ 649
BSA 2019 bis
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros) | € / shares					€ 3.680	€ 3.680	€ 3.680
Issued					10,000	10,000
Outstanding, Ending balance						10,000
BSA 2019 bis | JPG Healthcare LLC
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of bonus shares granted						10,000
BSA 2019 bis | Jeremy Goldberg
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of bonus shares granted	10,000
BSA 2019 ter
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros) | € / shares					€ 3.680	€ 3.680	€ 3.680
Issued					36,000	36,000
Outstanding, Ending balance						36,000
BSA 2019 ter | David Nikodem
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of bonus shares granted	36,000					36,000
BSPCE and BSA share warrants
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, Beginning balance						274,800			337,200		411,500
Issued						46,000					126,000
Exercised/Vesting						(10,000)					(180,300)
Forfeited											(20,000)
Outstanding, Ending balance						310,800			274,800		337,200
Number of shares exercisable					226,134	226,134	226,134				101,200
Share based payment expense | €							€ 18			€ 227	€ 184
BSPCE plans
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, Beginning balance						8,800			36,200		216,500
Issued				180,300
Exercised/Vesting									(27,400)		180,300
Outstanding, Ending balance						8,800			8,800		36,200
Number of shares exercisable					8,800	8,800	8,800	8,800	8,800	8,800	36,200
Number of warrants exercised | shares			274	1,803
Number of new shares issued upon exercise of warrants | shares			27,400
Number of share warrants outstanding | shares					88	88	88	88	88	88	362
BSPCE - 2015 Plan [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros) | € / shares								€ 0.67	€ 0.67	€ 0.67	€ 0.67
Outstanding, Beginning balance									22,800		54,700
Exercised/Vesting									(22,800)		(31,900)
Outstanding, Ending balance											22,800
Number of shares exercisable											22,800
BSPCE - 2013 Plan [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros) | € / shares					€ 0.59	€ 0.59	€ 0.59	€ 0.59	€ 0.59	€ 0.59	€ 0.59
Outstanding, Beginning balance						8,800			13,400		161,800
Exercised/Vesting									(4,600)		(148,400)
Outstanding, Ending balance						8,800			8,800		13,400
Number of shares exercisable					8,800	8,800	8,800	8,800	8,800	8,800	13,400
BSA plans
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, Beginning balance						266,000			301,000		195,000
Issued						46,000			10,000		126,000
Exercised/Vesting						(10,000)
Forfeited									(45,000)		(20,000)
Outstanding, Ending balance						302,000			266,000		301,000
Number of shares exercisable					217,334	217,334	217,334	158,667	158,667	158,667	65,000
Number of share warrants outstanding | shares					302,000	302,000	302,000	266,000	266,000	266,000
BSA - 2017 plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros) | € / shares					€ 6.675	€ 6.675	€ 6.675	€ 6.67	€ 6.67	€ 6.67	€ 6.67
Outstanding, Beginning balance						140,000			175,000		195,000
Issued					195,000
Exercised/Vesting						(10,000)
Forfeited								35,000	(35,000)		(20,000)
Outstanding, Ending balance						130,000			140,000		175,000
Number of shares exercisable					130,000	130,000	130,000	120,000	120,000	120,000	65,000
Number of corporate officers who cancelled their share warrants		2									1
BSA - 2017 plan | Karen Aach (former administrator)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercised/Vesting						(10,000)
BSA - 2018 plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros) | € / shares					€ 6.070	€ 6.070	€ 6.070	€ 6.07	€ 6.07	€ 6.07	€ 6.067
Outstanding, Beginning balance						116,000			126,000
Issued											126,000
Forfeited									(10,000)
Outstanding, Ending balance						116,000			116,000		126,000
Number of shares exercisable					77,334	77,334	77,334	38,667	38,667	38,667
Number of Company's external advisers to whom share warrants were allocated								3
BSA - 2018 plan | JPG Healthcare LLC
Disclosure of terms and conditions of share-based payment arrangement [line items]
Forfeited								10,000
BSA - 2018 plan | External Advisors [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued											126,000
BSA - 2019 plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros) | € / shares					€ 2.20	€ 2.20	€ 2.20	€ 2.20	€ 2.20	€ 2.20
Outstanding, Beginning balance						10,000
Issued	46,000								10,000
Outstanding, Ending balance						10,000			10,000
Number of shares exercisable					10,000	10,000	10,000
BSA - 2019 plan | David Nikodem
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued								10,000

Shareholders' Equity - Bonus sh

Shareholders' Equity - Bonus share award plans (Details)	12 Months Ended
	Dec. 31, 2020EUR (€)shares	Dec. 31, 2019plan	Dec. 31, 2018	Jan. 01, 2020plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued		10,000
AGA
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of plans outstanding | plan		2		4
Bonus share award plans
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued		283,500	341,400
AGA 2017-1
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period	2 years
Issued	92,300
Holding period (year)	1 year
Number of shares per AGA | shares	1
Fair value per share at grant date () | €	€ 7.04
AGA 2018
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of plans outstanding | plan				2
AGA 2018-1
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period	1 year
Issued	10,000		10,000
Holding period (year)	1 year
Number of shares per AGA | shares	1
Fair value per share at grant date () | €	€ 5.54
AGA 2018-2
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period	2 years
Issued	65,700		65,700
Holding period (year)	1 year
Number of shares per AGA | shares	1
Fair value per share at grant date () | €	€ 5.54
AGA 2018-3
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period	2 years
Issued	265,700		265,700
Holding period (year)	1 year
Number of shares per AGA | shares	1
Fair value per share at grant date () | €	€ 6.05
AGA 2019 plans
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of plans outstanding | plan				2
AGA 2019-1
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period	2 years
Issued	37,500	37,500
Holding period (year)	1 year
Number of shares per AGA | shares	1
Fair value per share at grant date () | €	€ 1.92
AGA 2019-2
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period	1 year
Issued	246,000	246,000
Holding period (year)	1 year
Number of shares per AGA | shares	1
Fair value per share at grant date () | €	€ 1.92

Shareholders' Equity - Bonus _2

Shareholders' Equity - Bonus share movements (in number of shares issuable upon exercise) (Details) € / shares in Units, € in Thousands	Dec. 14, 2020	Jun. 28, 2020	Jan. 26, 2020	Dec. 31, 2020EUR (€)€ / sharesshares	Dec. 31, 2019EUR (€)plan€ / sharesshares	Dec. 31, 2018EUR (€)€ / shares	Jan. 01, 2020plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, Beginning balance				274,800	337,200
Issued					10,000
Exercised/Vesting					(27,400)
Forfeited					(45,000)
Outstanding, Ending balance					274,800	337,200
Number of shares exercisable					167,467
Share based payment expense | €				€ 920	€ 1,180	€ 649
AGA
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercised/Vesting				(517,550)
Number of plans outstanding | plan					2		4
Bonus share award plans
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, Beginning balance				556,050	418,900	139,900
Issued					283,500	341,400
Exercised/Vesting				(517,550)	(87,500)	(60,000)
Forfeited				(9,400)	(58,850)	(2,400)
Outstanding, Ending balance				29,100	556,050	418,900
Number of awards forfeited as a result of voluntary departures | shares				45,600
AGA 2017-1
Disclosure of terms and conditions of share-based payment arrangement [line items]
Stock price at grant date (in euros)					€ 7.35	€ 7.35
Outstanding, Beginning balance					77,500	79,900
Issued				92,300
Exercised/Vesting					(77,500)
Forfeited						(2,400)
Outstanding, Ending balance						77,500
AGA 2017-2
Disclosure of terms and conditions of share-based payment arrangement [line items]
Stock price at grant date (in euros)						€ 7.35
Outstanding, Beginning balance						60,000
Exercised/Vesting						(60,000)
AGA 2018-1
Disclosure of terms and conditions of share-based payment arrangement [line items]
Stock price at grant date (in euros)					€ 5.76	€ 5.76
Outstanding, Beginning balance					10,000
Issued				10,000		10,000
Exercised/Vesting					(10,000)
Outstanding, Ending balance						10,000
AGA 2018-2
Disclosure of terms and conditions of share-based payment arrangement [line items]
Stock price at grant date (in euros)				€ 5.76	€ 5.76	€ 5.76
Outstanding, Beginning balance				63,300	65,700
Issued				65,700		65,700
Exercised/Vesting			(63,300)	(63,300)
Forfeited					(2,400)
Outstanding, Ending balance					63,300	65,700
AGA 2018-3
Disclosure of terms and conditions of share-based payment arrangement [line items]
Stock price at grant date (in euros)				€ 6.28	€ 6.28	€ 6.28
Outstanding, Beginning balance				227,250	265,700
Issued				265,700		265,700
Exercised/Vesting	(227,250)			(227,250)
Forfeited					(38,450)
Outstanding, Ending balance					227,250	265,700
Number of awards forfeited as part of the redundancy plan | shares					10,850
Number of awards forfeited refused by an employee | shares					2,400
Number of awards forfeited as a result of voluntary departures | shares					25,200
AGA 2019-1
Disclosure of terms and conditions of share-based payment arrangement [line items]
Stock price at grant date (in euros)				€ 2	€ 2
Outstanding, Beginning balance				37,500
Issued				37,500	37,500
Forfeited				(8,400)
Outstanding, Ending balance				29,100	37,500
AGA 2019-2
Disclosure of terms and conditions of share-based payment arrangement [line items]
Stock price at grant date (in euros)				€ 2	€ 2
Outstanding, Beginning balance				228,000
Issued				246,000	246,000
Exercised/Vesting		(227,000)		(227,000)
Forfeited				(1,000)	(18,000)
Outstanding, Ending balance					228,000

Debt - Debt and borrowings (Det

Debt - Debt and borrowings (Details) € in Thousands	1 Months Ended	12 Months Ended
	May 31, 2020EUR (€)loan	Dec. 31, 2020EUR (€)	Dec. 31, 2019EUR (€)	Jan. 01, 2019EUR (€)	Dec. 31, 2018EUR (€)	Dec. 31, 2017EUR (€)
Disclosure of detailed information about borrowings [line items]
Bank borrowings		€ 9,992	€ 74		€ 220
Other loans and similar borrowings		62	3		5
Lease liabilities		2	37
Total Debt		10,055	114	€ 392	€ 225	€ 482
Increase (Decrease) in borrowings			100
Loan obtained		9,979
Payments of lease liabilities, classified as financing activities		€ 26	130
Repayments of borrowings			100
Financing from a syndicate of French banks
Disclosure of detailed information about borrowings [line items]
Number of loans obtained | loan	3
Loan obtained	€ 10,000
Extension of term of debt	4 years	4 years
Socit Gnrale
Disclosure of detailed information about borrowings [line items]
Total Debt		€ 13
IFRS 16
Disclosure of detailed information about borrowings [line items]
Lease liabilities			167
Payments of lease liabilities, classified as financing activities			€ 100

Debt - Breakdown between long t

Debt - Breakdown between long term and short term debt (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019	Jan. 01, 2019	Dec. 31, 2018	Dec. 31, 2017
Disclosure of detailed information about borrowings [line items]
Bank borrowings	€ 9,992	€ 74		€ 220
Other loans and similar borrowings	62	3		5
Lease liabilities	2	37
Total debt	10,055	114	€ 392	225	€ 482
Less than 1 year
Disclosure of detailed information about borrowings [line items]
Bank borrowings, short-term	13
Bank borrowings		74		146
Other loans and similar borrowings	3	3		5
Lease liabilities	2	35
Total debt	18	112		151
Between 1 and 3 years
Disclosure of detailed information about borrowings [line items]
Bank borrowings	9,979			74
Other loans and similar borrowings	59
Lease liabilities		2
Total debt	€ 10,037	€ 2		€ 74

Debt - Repayments of borrowings

Debt - Repayments of borrowings and accrual of interests (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of detailed information about borrowings [line items]
Beginning balance	€ 114	€ 225	€ 482
Repayment of bank borrowings	(61)	(146)	(259)
Accrued interests		(2)	2
First application of IFRS 16 Leases	2	37
Increase in debt	9,979
Repayment of lease liabilities	(26)	(130)
Early termination of lease contracts	(9)
Capitalized interests	59
Accrued interests	0
Ending balance	€ 10,055	114	225
IFRS 16
Disclosure of detailed information about borrowings [line items]
First application of IFRS 16 Leases		167
Repayment of lease liabilities		€ (100)
IFRS 16 | Cumulative Effect, Period of Adoption, Adjustment
Disclosure of detailed information about borrowings [line items]
First application of IFRS 16 Leases			€ 167

Provisions (Details)

Provisions (Details) € in Thousands, $ in Millions	Jan. 28, 2021USD ($)	Jan. 28, 2021EUR (€)	Aug. 17, 2018EUR (€)	Dec. 31, 2020USD ($)	Dec. 31, 2020EUR (€)	Dec. 31, 2019USD ($)	Dec. 31, 2019EUR (€)	Dec. 31, 2018EUR (€)	Oct. 30, 2020USD ($)	Oct. 30, 2020EUR (€)
Long term provisions
Beginning balance					€ 574		€ 358	€ 477
Additions					1,804		216
Reversals								(119)
Closing balance					2,377		574	358
Short term provisions
Beginning balance					1,264		1,140
Additions					90		123	1,140
Reclassified					(1,224)
Closing balance					130		1,264	1,140
Total Provisions
Other provisions at beginning of period					1,837		1,498	477
Additions					1,894		339	1,140
Unused provision reversed, other provisions								(119)
Unused provision reclassified, other povisions					(1,224)
Other provisions at end of period					2,507		1,837	1,498
Mediator's waiver amount					300
Additional provisions					1,894		339	1,140
Provision for tax adjustment risk in respect of payroll taxes for the years ended December 31, 2016, 2017 and 2018
Short term provisions
Beginning balance					1,300		1,100
Closing balance							1,300	1,100
Total Provisions
Payroll taxes payable							1,700
Impact on income (loss) statement							100
Proposed tax adjustment | $						$ 0.5
Provision for CIR risk related to tax audit for the years ended December 31, 2013, 2014 and 2015
Long term provisions
Beginning balance					358		358	477
Additions					1,139
Reversals								(119)
Closing balance					1,497		358	358
Total Provisions
Additions		€ 1,100
Payroll taxes payable			€ 1,900					1,900
Proposed tax adjustment			€ 1,900
Potential risk from proposed tax adjustment | $	$ 0.3
Additional provisions		1,100
Maximum tax adjustment risk		€ 1,500						400
Provision for CIR risk related to tax audit for the year ended December 31, 2017
Long term provisions
Beginning balance					216
Additions					665		216
Closing balance					880		€ 216
Total Provisions
Additions | $				$ 0.7
Additional provisions | $				$ 0.7
Percentage of French Research Tax Credit (CIR) received						81.00%	81.00%
French Research Tax Credit (CIR), payments received							€ 3,600
French Research Tax Credit (CIR), amounts receivable							4,500
Maximum tax adjustment risk					900		200
Provision related to tax audit for the years ended 2013, 2014 and 2015
Total Provisions
Maximum indemnification amount (the "Abbott Guarantee")								2,000
Accrued expenses recognized					2,000			1,900
Accrued income recognized					2,000			1,900
Impact on income (loss) statement					100
Provision related to tax audit for the years ended 2013, 2014 and 2015 | Other Current Liabilities
Total Provisions
Payroll taxes payable					1,200
Provision for tax audit for the years ended December 31, 2016 and December 31, 2017
Short term provisions
Beginning balance							1,140
Additions								1,140
Closing balance								1,140
Total Provisions
Other provisions at beginning of period							1,100
Other provisions at end of period								1,100
Payroll taxes payable							1,200			€ 1,200
Guarantee as condition to suspend AMR | $									$ 1
Provision for tax audit for the years ended December 31, 2016 - 2018
Short term provisions
Beginning balance					1,264		1,140
Additions					90		123
Reclassified					(1,224)
Closing balance					130		€ 1,264	€ 1,140
Total Provisions
Payroll taxes payable					€ 1,300

Provisions for Retirement Ben_3

Provisions for Retirement Benefit Obligations - Principal actuarial assumptions (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Provisions for Retirement Benefit Obligations
Retirement age	65 years	65 years	65 years
Payroll taxes	41.41%	41.41%	41.41%
Salary growth rate	2.00%	2.00%	2.00%
Discount rate	0.35%	0.70%	1.60%
Threshold minimum maturity term for Eurozone AA rated corporate bonds	10 years

Provisions for Retirement Ben_4

Provisions for Retirement Benefit Obligations- Net provision (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Provisions for Retirement Benefit Obligations
Retirement benefit obligations	€ 1,385	€ 1,127	€ 1,029	€ 866

Provisions for Retirement Ben_5

Provisions for Retirement Benefit Obligations - Change in net provision (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Provisions for Retirement Benefit Obligations
Provision at beginning of period	€ (1,127)	€ (1,029)	€ (866)
Expense for the period	(209)	(1)	(194)
Actuarial gains or losses recognized in other comprehensive income	(49)	(96)	31
Provision at end of period	€ (1,385)	€ (1,127)	€ (1,029)

Provisions for Retirement Ben_6

Provisions for Retirement Benefit Obligations - Breakdown of expense recognized for the period (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Provisions for Retirement Benefit Obligations
Expense for the period	€ 209	€ 1	€ 194
Service cost for the period	(202)	(195)	(192)
Interest cost for the period	(8)	(16)	(11)
Plan curtailments and modifications		157
Benefits for the period		53	9
Total	€ (209)	€ (1)	€ (194)

Provisions for Retirement Ben_7

Provisions for Retirement Benefit Obligations - Breakdown of actuarial gains and losses recognized in comprehensive income (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of defined benefit plans [line items]
Demographic changes	€ 14	€ 32	€ (14)
Changes in actuarial assumptions	(63)	(129)	45
Total	€ (49)	€ (96)	€ 31
Discount rate	0.35%	0.70%	1.60%
Maximum
Disclosure of defined benefit plans [line items]
Discount rate			1.60%

Provisions for Retirement Ben_8

Provisions for Retirement Benefit Obligations - Sensitivity analysis (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Discount rate
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Percentage of reasonably possible increase in actuarial assumption	0.25%
Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption (as a percent)	3.40%	3.50%	3.50%
Discount rate at 0.45%
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Benefit Obligation Percentage		0.45%
Benefit obligation at December 31		€ 1,168
Discount rate at 0.70%
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Benefit Obligation Percentage		0.70%
Benefit obligation at December 31		€ 1,127
Discount rate at 0.95%
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Benefit Obligation Percentage		0.95%
Benefit obligation at December 31		€ 1,088
Discount rate at 1.35%
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Benefit Obligation Percentage			1.35%
Benefit obligation at December 31			€ 1,067
Discount rate at 1.60%
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Benefit Obligation Percentage			1.60%
Benefit obligation at December 31			€ 1,029
Discount rate at 1.85%
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Benefit Obligation Percentage			1.85%
Benefit obligation at December 31			€ 994
Discount rate at 0.10%
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Benefit Obligation Percentage	0.10%
Benefit obligation at December 31	€ 1,433
Discount rate at 0.35%
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Benefit Obligation Percentage	0.35%
Benefit obligation at December 31	€ 1,385
Discount rate at 0.60%
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Benefit Obligation Percentage	0.60%
Benefit obligation at December 31	€ 1,340

Trade Payables and Other Curr_3

Trade Payables and Other Current Liabilities (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Trade Payables and Other Current Liabilities
Trade payables	€ 6,923	€ 7,491	€ 8,372
Other current liabilities	6,838	4,998	4,871
Trade payables and other current liabilities	€ 13,761	€ 12,489	€ 13,243

Trade Payables and Other Curr_4

Trade Payables and Other Current Liabilities - Summary of Trade Payables Break Down By Payment Date (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
TradePayablesAndOtherCurrentLiabilities [line items]
Trade payables	€ 6,923	€ 7,491	€ 8,372
Due in 30 days
TradePayablesAndOtherCurrentLiabilities [line items]
Trade payables	6,834	7,414	7,966
Due in 30 60 days
TradePayablesAndOtherCurrentLiabilities [line items]
Trade payables	€ 89	€ 77	€ 406

Trade Payables and Other Curr_5

Trade Payables and Other Current Liabilities - Summary of Other Current Liabilities (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Trade Payables and Other Current Liabilities
Employee-related payables	€ 1,405	€ 1,124	€ 1,095
Accrued payroll and other employeerelated taxes	1,375	1,041	1,052
Sales tax payables	753	668	574
Other accrued taxes and employeerelated expenses	106	177	172
Other miscellaneous payables	3,198	1,988	1,978
Other current liabilities	€ 6,838	€ 4,998	€ 4,871

Trade Payables and Other Curr_6

Trade Payables and Other Current Liabilities - Additional information (Details) - EUR (€) € in Millions	Oct. 30, 2020	Dec. 31, 2019	Dec. 31, 2018	Aug. 17, 2018
Provision for CIR risk related to tax audit for the years ended December 31, 2013, 2014 and 2015
TradePayablesAndOtherCurrentLiabilities [line items]
Payables For Payroll Taxes			€ 1.9	€ 1.9
Provision for tax audit for the years ended December 31, 2016 and December 31, 2017
TradePayablesAndOtherCurrentLiabilities [line items]
Payables For Payroll Taxes	€ 1.2	€ 1.2

Contract Liabilities (Details)

Contract Liabilities (Details) - EUR (€) € in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2020
Disclosure of disaggregation of revenue from contracts with customers [line items]
Shortterm contract liabilities			€ 548
Longterm contract liabilities			1,673
Total contract liabilities			2,221
Revenue to be recognized			7,915
Milestone payment			0
BI
Disclosure of disaggregation of revenue from contracts with customers [line items]
Shortterm contract liabilities			436
Longterm contract liabilities			1,673
Total contract liabilities			2,109
Revenue to be recognized			7,718
Contract liabilities reversed	€ 2,100	€ 2,200
Milestone payment			2,500
Milestone payment recognized in revenue		€ 700	200
Contract liabilities booked			1,800
Contract liabilities related to research fees			300
AbbVie
Disclosure of disaggregation of revenue from contracts with customers [line items]
Shortterm contract liabilities			15
Total contract liabilities			15
Revenue to be recognized			100
Milestone payment				€ 0
Contract liabilities related to research fees			15
EnyoParma
Disclosure of disaggregation of revenue from contracts with customers [line items]
Shortterm contract liabilities			97
Total contract liabilities			97
Revenue to be recognized			97
Contract liabilities related to research fees			€ 100

Financial Assets and Liabilit_3

Financial Assets and Liabilities (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of detailed information about financial instruments [line items]
Financial assets	€ 120,417	€ 39,545	€ 59,612
Financial liabilities	20,177	9,594	10,575
Financial assets, at fair value	120,417	39,545	59,612
Financial liabilities, at fair value	20,177	9,594	10,575
Liabilities carried at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	20,177	9,594	10,575
Long-term debt
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	10,037	2	74
Financial liabilities, at fair value	10,037	2	74
Long-term debt | Liabilities carried at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	10,037	2	74
Short-term debt
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	18	113	151
Financial liabilities, at fair value	18	113	151
Short-term debt | Liabilities carried at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	18	113	151
Trade payables
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	6,923	7,491	8,372
Financial liabilities, at fair value	6,923	7,491	8,372
Trade payables | Liabilities carried at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	6,923	7,491	8,372
Other miscellaneous payables
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	3,198	1,988	1,978
Financial liabilities, at fair value	3,198	1,988	1,978
Other miscellaneous payables | Liabilities carried at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	3,198	1,988	1,978
Financial assets carried at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial assets	118,626	39,545	59,612
Financial assets at fair value through profit or loss
Disclosure of detailed information about financial instruments [line items]
Financial assets	1,791
Long-term deposit accounts and security deposits
Disclosure of detailed information about financial instruments [line items]
Financial assets			108
Financial assets, at fair value			108
Long-term deposit accounts and security deposits | Financial assets carried at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial assets			108
Long term deposit accounts
Disclosure of detailed information about financial instruments [line items]
Financial assets	1,698	792
Financial assets, at fair value	1,698	792
Long term deposit accounts | Financial assets carried at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial assets	1,698	792
Long-term security deposits
Disclosure of detailed information about financial instruments [line items]
Financial assets	8	8
Financial assets, at fair value	8	8
Long-term security deposits | Financial assets carried at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial assets	8	8
Short-term deposit accounts
Disclosure of detailed information about financial instruments [line items]
Financial assets	7,336
Financial assets, at fair value	7,336
Short-term deposit accounts | Financial assets carried at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial assets	7,336
Accrued income
Disclosure of detailed information about financial instruments [line items]
Financial assets	2,000	2,000	1,932
Financial assets, at fair value	2,000	2,000	1,932
Accrued income | Financial assets carried at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial assets	2,000	2,000	1,932
Trade receivables
Disclosure of detailed information about financial instruments [line items]
Financial assets	48	4	6
Financial assets, at fair value	48	4	6
Trade receivables | Financial assets carried at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial assets	48	4	6
Other receivables
Disclosure of detailed information about financial instruments [line items]
Financial assets	1,849	900	874
Financial assets, at fair value	1,849	900	874
Other receivables | Financial assets carried at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial assets	1,849		874
Foreign currency forwards
Disclosure of detailed information about financial instruments [line items]
Financial assets	1,791
Financial assets, at fair value	1,791
Foreign currency forwards | Financial assets at fair value through profit or loss
Disclosure of detailed information about financial instruments [line items]
Financial assets	1,791
Cash and cash equivalents
Disclosure of detailed information about financial instruments [line items]
Financial assets	105,687	35,840	56,692
Financial assets, at fair value	105,687	35,840	56,692
Cash and cash equivalents | Financial assets carried at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial assets	€ 105,687	€ 35,840	€ 56,692

Revenues and Other Income (Deta

Revenues and Other Income (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Revenues and Other Income
Sales	€ 372	€ 6,998	€ 3,197
Total revenues	372	6,998	3,197
CIR	4,791	4,293	4,166
Subsidies			16
Other	100	0
Total other income	4,891	4,293	4,182
Total revenues and other income	€ 5,263	€ 11,291	€ 7,379

Revenues and Other Income - Add

Revenues and Other Income - Additional information (Details) - EUR (€) € in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2018
Ifrs Collaborative Arrangement And Arrangement Other Than Collaborative Line items
Milestone payments received				€ 0
AbbVie
Ifrs Collaborative Arrangement And Arrangement Other Than Collaborative Line items
Milestone payments received following the enrollment of first patient		€ 3.5
Milestone payments received			€ 0
Contribution to Company's revenue (as a percent)		51.40%
BI
Ifrs Collaborative Arrangement And Arrangement Other Than Collaborative Line items
Milestone payments received				€ 2.5
Contribution to Company's revenue (as a percent)		36.90%
Reversal of contract liabilities	€ 2.1	€ 2.2

Operating expenses (Other ope_3

Operating expenses (Other operating income (expenses) excluded) (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of attribution of expenses by nature to their function [Line Items]
Disposables	€ (1,243)	€ (1,560)	€ (2,210)
Energy and liquids	(539)	(505)	(504)
Patents	(343)	(506)	(401)
Studies	(10,987)	(19,353)	(17,351)
Maintenance	(846)	(933)	(934)
Fees	(2,548)	(1,226)	(1,530)
IT Systems	(651)	(847)	(824)
Support costs (including taxes)	(722)	(568)	(584)
Personnel costs	(10,680)	(10,981)	(10,072)
Depreciation, amortization and provisions	(1,009)	(1,456)	(1,069)
Other operating expenses	(3,209)	(2,192)	(2,549)
Total operating expenses	(32,779)	(40,127)	(38,028)
Research and development expense
Disclosure of attribution of expenses by nature to their function [Line Items]
Disposables	(1,243)	(1,560)	(2,210)
Energy and liquids	(539)	(505)	(504)
Patents	(343)	(506)	(401)
Studies	(10,987)	(19,353)	(17,351)
Maintenance	(846)	(933)	(934)
Fees	(201)	(239)	(98)
IT Systems	(597)	(793)	(766)
Personnel costs	(7,518)	(8,076)	(7,625)
Depreciation, amortization and provisions	(832)	(1,060)	(890)
Other operating expenses	(608)	(765)	(978)
Total operating expenses	(23,717)	(33,790)	(31,758)
Marketing - business development expenses
Disclosure of attribution of expenses by nature to their function [Line Items]
Fees	(341)		0
IT Systems	(8)	(8)	(9)
Personnel costs	(197)	(202)	(182)
Other operating expenses	(16)	(40)	(34)
Total operating expenses	(563)	(250)	(225)
General and administrative expense
Disclosure of attribution of expenses by nature to their function [Line Items]
Fees	(2,005)	(987)	(1,431)
IT Systems	(46)	(46)	(49)
Support costs (including taxes)	(722)	(568)	(584)
Personnel costs	(2,964)	(2,703)	(2,266)
Depreciation, amortization and provisions	(177)	(396)	(179)
Other operating expenses	(2,585)	(1,387)	(1,536)
Total operating expenses	€ (8,499)	€ (6,087)	€ (6,045)

Operating expenses (Other ope_4

Operating expenses (Other operating income (expenses) excluded) - Personnel costs and headcount (Details) € in Thousands	12 Months Ended
	Dec. 31, 2020EUR (€)employee	Dec. 31, 2019EUR (€)employee	Dec. 31, 2018EUR (€)employee
Disclosure of attribution of expenses by nature to their function [Line Items]
Number of employees | employee	94	88	113
Wages, salaries and similar costs	€ (6,442)	€ (6,577)	€ (6,613)
Payroll taxes	(3,098)	(2,841)	(2,560)
CICE tax credit			124
Provisions for retirement benefit obligations	(202)	(156)	(190)
Share-based compensation expense	(938)	(1,407)	(833)
Total employee benefits expense	(10,680)	(10,981)	(10,072)
Research and development expense
Disclosure of attribution of expenses by nature to their function [Line Items]
Wages, salaries and similar costs	(4,590)	(4,908)	(5,085)
Payroll taxes	(2,180)	(2,206)	(1,981)
CICE tax credit			103
Provisions for retirement benefit obligations	(141)	(95)	(145)
Share-based compensation expense	(607)	(868)	(516)
Total employee benefits expense	(7,518)	(8,076)	(7,625)
Marketing - business development expenses
Disclosure of attribution of expenses by nature to their function [Line Items]
Wages, salaries and similar costs	(183)	(178)	(178)
Payroll taxes	8	(1)	(3)
Share-based compensation expense	(22)	(22)	(1)
Total employee benefits expense	(197)	(202)	(182)
General and administrative expense
Disclosure of attribution of expenses by nature to their function [Line Items]
Wages, salaries and similar costs	(1,669)	(1,491)	(1,349)
Payroll taxes	(926)	(634)	(576)
CICE tax credit			20
Provisions for retirement benefit obligations	(60)	(61)	(45)
Share-based compensation expense	(309)	(517)	(316)
Total employee benefits expense	€ (2,964)	€ (2,703)	€ (2,266)

Other Operating Income (expen_3

Other Operating Income (expenses) - (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Other Operating Income (expenses)
Corrective claims - CIR	€ 2,863
Accrued income from Abbott - payroll taxes		€ 68
Reversal of restructuring expenses	43
Total other operating income	2,905	68
Provision for risk on payroll taxes	(90)	(123)
Restructuring expenses		(1,096)
Impairment of tax loss carry back	(333)
CIR provision	(1,804)
IPO costs and follow-on offering	(2,881)	(323)	€ (2,221)
Write-down of inventory			(33)
Total other operating expenses	(5,108)	(1,541)	(2,255)
Other operating income (expenses)	€ (2,202)	€ (1,475)	€ (2,255)

Other Operating Income (expen_4

Other Operating Income (expenses) - Additional Information (Details) € in Thousands	12 Months Ended
	Dec. 31, 2020EUR (€)
Other Operating Income (Expense) [Line Items]
Corrective Claims French Research Tax Credit, Revenue	€ 2,863
CIR provision	1,804
Provision for CIR risk related to tax audit for the year ended December 31, 2017
Other Operating Income (Expense) [Line Items]
CIR provision	700
Initial provision	900
Provision for CIR risk related to tax audit for the years ended December 31, 2013, 2014 and 2015
Other Operating Income (Expense) [Line Items]
CIR provision	1,100
Provision for CIR risk related to tax audit for the years ended December 31, 2013, 2014 and 2015 | Minimum
Other Operating Income (Expense) [Line Items]
Initial provision	400
Provision for CIR risk related to tax audit for the years ended December 31, 2013, 2014 and 2015 | Maximum
Other Operating Income (Expense) [Line Items]
Initial provision	€ 1,500

Financial Income and Expenses_2

Financial Income and Expenses (Details) € in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2020EUR (€)	Dec. 31, 2019EUR (€)	Dec. 31, 2018EUR (€)	Dec. 31, 2020USD ($)	Dec. 31, 2020EUR (€)
Financial income and expenses
Income from cash and cash equivalents	€ 226	€ 157	€ 120
Foreign exchange gains	40	18	21
Fair value variation gains / losses	1,791
Total financial income	2,057	175	142
Interest cost	(66)	(3)	(4)
Losses on cash and cash equivalents			(202)
Foreign exchange losses	(5,884)	(62)	(36)
Other financial expenses	(8)	(16)	(11)
Interests costs on discounted liabilities	(8)
Total financial expenses	(5,959)	(81)	(253)
Financial income (loss)	€ (3,902)	93	(111)
Short-term deposits		€ 14,004	€ 41,767		€ 12,001
USD
Financial income and expenses
Bank accounts					2,700
Short-term deposits				$ 9	€ 2,800

Income Tax (Details)

Income Tax (Details) - EUR (€) € in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax
Income tax rate		31.00%	31.00%	33.33%
Loss before tax		€ (33,619)	€ (30,218)	€ (33,014)
Theoretical tax rate		31.00%	31.00%	33.33%
Tax benefit at theoretical rate		€ 10,422	€ 9,368	€ 11,004
Tax credits		2,373	1,330	1,435
Tax credits	€ 3,633
Permanent differences		1,816	(21)	827
Other differences		(522)	(404)	(269)
Non recognition of deferred tax assets related to tax losses and temporary differences		(14,089)	(10,272)	(12,997)
Actual income tax benefit
Deferred tax assets		€ 0

Commitments (Details)

Commitments (Details) € in Thousands	Dec. 31, 2020EUR (€)item	Feb. 01, 2019
Disclosure of detailed information about financial instruments [line items]
Bank guarantee and pledge of gradual rate deposit account	€ 1,700
Amount of pledge as a percentage of sum not covered by the indemnity to be received		50.00%
Financial assets pledged as collateral for liabilities or contingent liabilities	1,700
Pledge over cash, two
Disclosure of detailed information about financial instruments [line items]
Bank guarantee and pledge of gradual rate deposit account	1,000
Financial assets pledged as collateral for liabilities or contingent liabilities	1,000
Socit Gnrale
Disclosure of detailed information about financial instruments [line items]
Loan amount	254
Bank guarantee and pledge of gradual rate deposit account	101
Financial assets pledged as collateral for liabilities or contingent liabilities	€ 101
Crdit Agricole bank
Disclosure of detailed information about financial instruments [line items]
Amount of pledge as a percentage of sum not covered by the indemnity to be received	50.00%
Number of pledges over cash | item	2
Crdit Agricole bank | Pledge over cash, one
Disclosure of detailed information about financial instruments [line items]
Bank guarantee and pledge of gradual rate deposit account	€ 700
Number of pledges over cash | item	1
Financial assets pledged as collateral for liabilities or contingent liabilities	€ 700
Crdit Agricole bank | If dispute remains unresolved
Disclosure of detailed information about financial instruments [line items]
Bank guarantee and pledge of gradual rate deposit account	3,400
Financial assets pledged as collateral for liabilities or contingent liabilities	€ 3,400

Commitments - Commitments Recei

Commitments - Commitments Received (Details) - EUR (€)	Jul. 01, 2017	Mar. 21, 2016	Nov. 04, 2015	Oct. 13, 2015	Dec. 31, 2020	Sep. 01, 2018	Mar. 30, 2018	Dec. 01, 2017	Nov. 01, 2017	Jan. 01, 2017
Agreement with Novolyze | Premises and facilities
Ifrs Collaborative Arrangement And Arrangement Other Than Collaborative Line items
Rental period				36 months
Amount of increase in monthly rent									€ 5,000
Annual increase of rent in percentage									2.00%
Amount of commitment received					€ 72,000
Commitments Related to Future Payments					58,000
Agreement with Genoway | Premises and facilities
Ifrs Collaborative Arrangement And Arrangement Other Than Collaborative Line items
Rental period			3 years
Renewable Period	3 years
Amount of increase in monthly rent								€ 15,000
Amount of commitment received					185,000
Commitments Related to Future Payments					46,000
Agreement with Synthecob | Research equipment and services
Ifrs Collaborative Arrangement And Arrangement Other Than Collaborative Line items
Rental period		2 years
Amount of increase in monthly rent						€ 2,700	€ 2,500			€ 2,400
Amount of commitment received					33,000
Commitments Related to Future Payments					€ 42,000

Commitments - Commitments relat

Commitments - Commitments related to financing activities (Details) € in Thousands, $ in Thousands	Dec. 31, 2020USD ($)contract	Sep. 30, 2020item	Dec. 31, 2020EUR (€)
Disclosure of detailed information about financial instruments [line items]
Number Of Derivative Contracts Completed	3	2
Notional amount	$ 60,000
Change in fair value of future currency contracts	$ 60,000
Foreign currency forwards
Disclosure of detailed information about financial instruments [line items]
Number Of Derivative Contracts Completed | contract	3
Notional amount	$ 60,000
Change in fair value of future currency contracts | €			€ 1,800
Socit Gnrale | Forward in U.S. dollars payable
Disclosure of detailed information about financial instruments [line items]
Notional amount	20,000,000
Socit Gnrale | Forward in U.S. dollars payable
Disclosure of detailed information about financial instruments [line items]
Notional amount	20,000,000
Socit Gnrale | Forward in euros to be received
Disclosure of detailed information about financial instruments [line items]
Notional amount | €			16,794,021
Socit Gnrale | Forward in euros to be received
Disclosure of detailed information about financial instruments [line items]
Notional amount | €			16,794,021
Crdit Agricole bank | Forward in U.S. dollars payable
Disclosure of detailed information about financial instruments [line items]
Notional amount	$ 20,000,000
Crdit Agricole bank | Forward in euros to be received
Disclosure of detailed information about financial instruments [line items]
Notional amount | €			€ 17,001,020

Related-Party Transactions - Su

Related-Party Transactions - Summary of transactions with key management personnel (Details) - Executive and corporate officers - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of transactions between related parties [line items]
Wages and salaries	€ 1,369	€ 1,113	€ 944
Benefits in kind	42	47	46
Pension plan expenses	77	66	41
Share-based compensation expense	259	280	354
Attendance fees	258	206	200
Net total	€ 2,005	€ 1,712	€ 1,585

Related-Party Transactions (Det

Related-Party Transactions (Details) - ISLS Consulting - EUR (€) € in Thousands	Dec. 14, 2018	Dec. 31, 2019	Dec. 31, 2018
Disclosure of transactions between related parties [line items]
Consulting fees		€ 169	€ 162
Number of share warrants granted	80,000

Basic and Diluted Loss Per Sh_3

Basic and Diluted Loss Per Share (Details) - EUR (€) € / shares in Units, € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Basic and Diluted Loss Per Share
Net loss for the period	€ (33,619)	€ (30,218)	€ (33,014)
Weighted average number of outstanding shares used for computing basic/diluted loss per share	33,874,751	23,519,897	20,540,979
Basic/diluted loss per share (in )	€ (0.99)	€ (1.28)	€ (1.61)

Financial Risk management - Exp

Financial Risk management - Exposure to foreign exchange risk (Details) € in Thousands, $ in Millions	Dec. 31, 2020USD ($)contract	Jul. 15, 2020USD ($)	Sep. 30, 2020item	Jul. 31, 2020USD ($)	Feb. 29, 2020EUR (€)	Oct. 31, 2019EUR (€)	Dec. 31, 2020USD ($)contract	Dec. 31, 2020EUR (€)	Dec. 31, 2019EUR (€)	Dec. 31, 2018EUR (€)
Disclosure of nature and extent of risks arising from financial instruments [line items]
Gross proceeds from initial public offering		$ 107.7		$ 107.7	€ 14,700	€ 8,900
Short-term deposits | €								€ 12,001	€ 14,004	€ 41,767
Number Of Derivative Contracts Completed	3		2
Notional amount	$ 60						$ 60
Number of forward contracts that had change in fair value. | contract							2
Change in fair value of future currency contracts	$ 60						$ 60
USD
Disclosure of nature and extent of risks arising from financial instruments [line items]
Term of the short-term deposits	6 months
Short-term deposits	$ 9						$ 9	€ 2,800

Financial Risk management - E_2

Financial Risk management - Exposure to foreign exchange risk - Sensitivity Analysis (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of nature and extent of risks arising from financial instruments [line items]
Fair value of financial assets	€ 120,417	€ 39,545	€ 59,612
Exposure to foreign exchange risk | USD
Disclosure of nature and extent of risks arising from financial instruments [line items]
Percentage of reasonably possible increase (decrease) in risk assumption	5.00%
Cash and cash equivalents
Disclosure of nature and extent of risks arising from financial instruments [line items]
Fair value of financial assets	€ 105,687	€ 35,840	€ 56,692
Cash and cash equivalents | Exposure to foreign exchange risk | USD
Disclosure of nature and extent of risks arising from financial instruments [line items]
Fair value of financial assets	72,429
Impact of a 5% change in fair value	(3,449)
Short-term deposit accounts
Disclosure of nature and extent of risks arising from financial instruments [line items]
Fair value of financial assets	7,336
Short-term deposit accounts | Exposure to foreign exchange risk | USD
Disclosure of nature and extent of risks arising from financial instruments [line items]
Fair value of financial assets	7,336
Impact of a 5% change in fair value	€ (349)

Events After the Reporting Da_2

Events After the Reporting Date (Details) - EUR (€) € in Thousands	Feb. 15, 2021	Feb. 11, 2021	Jan. 28, 2021	Jan. 25, 2021	Aug. 17, 2018	Dec. 31, 2020	Feb. 10, 2021	Jan. 06, 2021
Events after the reporting date
Bank guarantee and pledge of gradual rate deposit account						€ 1,700
Impairment of tax loss carry back						€ (333)
Inventiva Inc.
Events after the reporting date
Proportion of ownership interest in subsidiary						100.00%
Provision for CIR risk related to tax audit for the years ended December 31, 2013, 2014 and 2015
Events after the reporting date
Proposed tax adjustment					€ 1,900
Provision for CIR risk related to tax audit for the years ended December 31, 2013, 2014 and 2015 | Minimum
Events after the reporting date
Initial provision						€ 400
Provision for CIR risk related to tax audit for the years ended December 31, 2013, 2014 and 2015 | Maximum
Events after the reporting date
Initial provision						1,500
Guarantee given to the tax authorities | Provision for tax audit for the years ended December 31, 2016 and December 31, 2017
Events after the reporting date
Bank guarantee and pledge of gradual rate deposit account								€ 1,000
Tax audit for payroll taxes | Provision related to tax audit for the years ended 2013, 2014 and 2015
Events after the reporting date
Period to conduct the appeal process				2 months
Settlement of maximum indemnification requested							€ 2,000
Proposed tax adjustment		€ 1,900
Impairment of tax loss carry back
Events after the reporting date
Impairment of tax loss carry back	€ 300
Tax audit for CIR | Provision for CIR risk related to tax audit for the years ended December 31, 2013, 2014 and 2015
Events after the reporting date
Amount of relief from tax assessment			€ 300
Tax audit for CIR | Provision for CIR risk related to tax audit for the years ended December 31, 2013, 2014 and 2015 | Minimum
Events after the reporting date
Initial provision						400
Tax audit for CIR | Provision for CIR risk related to tax audit for the years ended December 31, 2013, 2014 and 2015 | Maximum
Events after the reporting date
Initial provision						€ 1,500